Healthcare seeking behaviour as a link between tuberculosis and socioeconomic factors by Ku, Chu-Chang
Healthcare seeking behaviour as a
link between tuberculosis and
socioeconomic factors
Chu-Chang Ku
A thesis submitted to the University of Sheffield in partial fulfilment of the
requirements for the degree of Doctor of Philosophy





There are many people who have made this thesis possible. kám-siā
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Abstract
Socioeconomic barriers to tuberculosis care-seeking and costs due to care-seeking
lead to unfavourable treatment, epidemiological and economic outcomes. Espe-
cially in the post-2015 era, socioeconomic interventions for tuberculosis control
are receiving increasing attention. In Taiwan, the National Health Insurance pro-
gramme minimises out-of-pocket expenses for patients, but important delays to
tuberculosis treatment still exist.
Based on the population and tuberculosis epidemiology in Taiwan, I develop
an analysis for profiling the efficacy of tuberculosis care provision and patients’
care-seeking pathways. The results highlight that the interrupted tuberculosis
evaluation processes and low diagnostic capacity in small local hospitals stands as
key causes of extended delays to treatment, unfavourable outcomes, and costs. I
analyse socioeconomic status (SES) of employment, vulnerability, and residential
contexts, to identify risk factors for different aspects of care-seeking.
To link the care-seeking pathways to the nationwide tuberculosis epidemiol-
ogy, I develop a data-driven hybrid simulation model. The model integrates the
advantages of agent-based approaches in representing detail, and equation-based
approaches in simplicity and low computational cost. This approach makes fea-
sible Monte-Carlo experiments for robust inferences without over-simplifying the
care-seeking details of interest. By comparing the hybrid model simulations with
a corresponding equation-based comparator, I confirm its validity.
I considered interventions to improve universal health coverage by decentral-
ising tuberculosis diagnostic capacity. I modelled specific interventions increasing
the coverage of tuberculosis diagnostic capacity using various SES-targeted scale-
up strategies. These show potential benefits in terms of reducing dropouts and
reducing the tuberculosis burden, without significant increases in the inequality
of care-seeking costs.
I suggest considering additional SES variables such as education, health illit-
eracy, and social segregation to find other care-seeking barriers. Further investi-
gations of SES-related interventions against tuberculosis, including formal impact
and health economic evaluation, should be pursued in collaboration with policy-
makers able to advise on feasibility and patients able to advise on acceptability.
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Chapter 1
Introduction
Tuberculosis (TB) is the top infectious killer globally, with an estimated 10 mil-
lion new cases and 1.3 million deaths among the HIV negative in 2018 [1]. An
estimated 40% of global incident TB cases were not notified to the authorities,
implying that many of them may not have been diagnosed or treated. Compar-
ing estimates of incidence and prevalence allows a rough estimation of the mean
duration of active disease; using the data presented in the 2018 WHO TB report,
this suggests a mean global duration of over one year. Taken together, the low
case detection ratio and long duration of active disease highlight the importance
of patient care seeking and access to care in improving TB control worldwide.
In 2015, it was highlighted by the global call for ending poverty in the United
Nations Sustainable Development Goals [2, 3] and the End TB Strategy of the
WHO [4] that poverty and its consequences need to be addressed when developing
TB control policies. The End TB Strategy aims for three targets to be met in 2035,
compared with the level of 2015: (1) a 95% reduction in TB mortality, (2) a 90%
reduction in TB incidence, and (3) zero catastrophic costs of TB-affected families
incurred as a result of TB. The third target directly concerns poverty due to TB,
while the first two address the consequences of poverty. To respond to these
targets, related evidence and their policy implications need to be systematically
investigated.
1.1 Tuberculosis and poverty
TB has long been known as a disease of poverty [5]. In terms of observed trends,
the rapid decline in TB epidemic in England and Wales during the first half of the
20th century was associated with social development [6]; the epidemics in Brazil,
the Americas and worldwide from 1900 to 2010 suggest a negative association be-
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tween TB incidence and social inequality [7]. In terms of spatial patterns, studies
in Brazil [8], Ethiopia [9], and Spain [10] have shown an association between re-
gional socioeconomic factors and the risk of TB. Therefore, poverty reduction is
seen as a critical component in delivering the End TB Strategy targets of incidence
and mortality reduction.
TB patients often suffer an enormous financial burden, especially in the ab-
sence of social support. Throughout an active TB episode, a financial burden is
incurred by both TB-affected families and the wider population. This means TB
can drive people into poverty and trap them in poverty. As TB spreads in com-
munities, the poverty caused by TB also spreads. From a macroeconomic point of
view, Grimard and Harling [11] dealt with this relation empirically and suggested
that there was an annual loss of 1.4 to 2.8 billion US dollars correlated with TB
worldwide. A review in low-and middle-income countries indicated that the cost
of TB care (both direct and indirect) consumed 58% of individual income and 39%
of household income [12].
Lönnroth et al. [13] conceptualised the causality of TB and socioeconomic
status (SES) by reviewing related studies. In their model, poverty and low SES are
upstream causes driving various proximal risk factors for TB [14]. These factors
impact TB epidemics in several ways: overcrowding increases TB transmission
rates; malnutrition weakens immunity against TB; severe indoor pollution impairs
respiratory tracts and then increases the risk of TB; limited healthcare accessibility
delays care-seeking; and so on. In the end, the consequences of TB result in a
lower SES and form a reinforcing feedback loop.
However, awareness of the linkage between TB and SES has been rising. SES-
based actions are required worldwide for TB control. These actions either specif-
ically target TB in low SES populations or change the SES of TB patients through
social support. To ensure the effectiveness of an intervention, I need to address
the social determinants of TB and plan the resource allocation with ex-ante mod-
elling. After the intervention, I need to evaluate the policy impacts with ex-post
modelling and then apply the successful experiences.
In the following sections, I deconstruct the relationships between TB and SES
with respect to three aspects: evidence, control strategy, and modelling. For each
aspect, I further locate our discussion at three stages: prior to TB care-seeking
(e.g. transmission and infection), during TB care-seeking (e.g. care-seeking and
diagnosis), and after TB care-seeking (e.g. care, treatment, and death).
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1.2 Evidence on linking SES and TB
1.2.1 Evidence on TB prior to care-seeking
Epidemic features of TB prior to care-seeking include transmission, infection, im-
munity and disease activation. An active TB case can spread the TB pathogen,
Mycobacterium tuberculosis, in the community; people who inhale the pathogen
without immunity against TB can become infected. About ten percent of the peo-
ple infected develope the TB disease over their lifetime (around one half of these
within 2 years). Naturally, during the pre-TB care phase, TB patients are not super-
vised by any health care system, so their data are not normally available prior to
diagnosis. What evidence there is for this phase is therefore based on retrospective
data, often as it is recalled by patients.
Incidence rate is a standard aggregated measurement capturing the overall ef-
fect of the epidemic features mentioned above. It is defined as the number of
new cases per population at risk in a given time period. Since TB incidence is
impossible to measure in the general population, notification rate is often used
to approximate incidence rate with a correction for under-detection. Apart from
the example mentioned in the previous section, Ploubidis et al. [15] analysed TB
incidence in European countries and found the incidence trend was negatively
associated with regional income per capita and positively associated with income
inequality. Similarly, in Zimbabwe, a hospital-based study demonstrated that the
notification rate of TB co-varied with the national business cycle; that is, there were
more TB cases during the recession [16]. Geographical patterns have also been in-
vestigated: Maciel et al. [17] and Figueiredo Mafra Magalhaes and Medronho
[18] utilised indices of the quality of urban municipality, a social deprivation in-
dex and regional variables of illiteracy, loneliness, and low income to investigate
spatial inequalities in TB incidence in Brazil.
The coverage of vaccination with Bacillus Calmette–Guérin (BCG) is an index
of the susceptibility or immunity to TB of children and young adults. Perez-Then
et al. [19] used a school-based census of school children and found that lower
vaccination coverage was associated with both malnutrition and the distance to
city centres. Guthmann et al. [20] conducted a cross-sectional study on adults and
identified that being taken into care during childhood and their educational level
were risk factors for low vaccination coverage.
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1.2.2 Evidence on TB care-seeking
TB care-seeking involves both a patient’s behaviour and the efficiency of the health-
care system. During the period of care-seeking, although healthcare systems can
collect data from TB patients, data availability is still limited. This is mainly be-
cause TB shares many symptoms with other respiratory diseases and is relatively
uncommon among patients with similar symptoms. In practice, it is inefficient
to collect and trace care-seeking pathways of all patients with respiratory symp-
toms to the point that each pathogen has been diagnosed. Therefore, most studies
assessing care-seeking have used retrospective data.
The basic measurement for TB care-seeking is an assessment of the duration
before proper treatment (i.e., delays). The delays for care-seeking include several
stages of TB diagnosis. Machado et al. [21] analysed the patient delay (from
disease onset to first healthcare visit) and system delay (from first healthcare visit
to diagnosis) in Rio de Janeiro, Brazil and found the patient delay was associated
with personal income and employment, while the system delay did not correlate
with their SES of interest. Chen et al. [22] measured the system delay using
longitudinal data based on the National Health Insurance system in Taiwan, and
identified personal income as a risk factor.
As an assessment of healthcare systems, Patient Pathway Analysis (PPA) was
used to understand access to TB diagnostic tools and treatments (see Hanson et
al. [23] and the associated special issue). In their analysis framework, the primary
focus is on patients that can be properly identified and treated in facilities at their
initial care seeking. However, the use of PPA has ignored SES-related issues and
only unlinked aggregate data (as opposed to individual-level data) has been used,
thereby limiting its ability to explore patient and system delays.
1.2.3 Evidence on TB care and outcome
The epidemic features for the period after care-seeking include compliance with
TB treatment, drug reactions and treatment outcomes. At this stage, longitudinal
data on TB patients becomes more available, and TB mortality can be estimated
through death registration. Hence, the evidence in this field is stronger.
There were systematic reviews that explored the risk factors of treatment out-
comes. Di Gennaro et al. [24] reviewed the social determinants of the treatment
failure of TB patients. Their summary of fifty studies emphasised that low income
and low education were significant risk factors in general. Tola et al. [25] focused
on the treatment outcome of loss to follow-up (LTFU), highlighting several SES
factors, such as lack of a job, financial constraints, and lack of education. Munro
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et al. [26] synthesised 44 qualitative studies and highlighted that household, and
community support played critical roles in adherence to TB treatment.
Some observational studies looked at specific SES factors on TB patients and
assessed their effect on treatment outcomes. For example, in Brazil, Ranzani et al.
[27] found that being homeless was associated with low treatment success due to
loss-to-follow-up. In London, Cegolon et al. [28] found that immigrant patients
and patients that are the most deprived had a higher risk of treatment failure.
In Georgia, a prospective cohort study observed that the poor treatment outcome
was associated with low household income, unemployment, and low education
[29]. Similar evidence is seen worldwide.
In addition to the studies that focussed on specific types of outcome, some
studies summarised the quality of life or financial impacts for TB patients under
treatment. Measurements by Aggarwal et al. [30], in north India, indicated that
whether people had a higher quality of life was associated with less unfavourable
consequences. Mauch et al. [31] and Foster et al. [32] assessed the financial
burden of TB patients in Kenya and South Africa respectively. Both described
financial burden as a barrier to completing TB treatment and a medical poverty
trap.
In the international or global scope, Nagavci et al. [33] analysed the historical
data of 11 European countries, and highlighted that populations with lower SES
have higher TB mortalities. A study by Khazaei et al. [34] confirmed this relation-
ship at a global scale with aggregated data. The relationship between the human
development index and TB treatment success rate suggested the importance of
social and environmental factors in policy making.
1.3 TB control actions based on SES
Moving from evidence to action presents challenges. With the available evidence,
finding actionable risk factors to remove and then estimating their public benefit
involves a complicated process.
1.3.1 Interventions on TB incidence and TB prior to care seeking
In the period before care-seeking, people can be classified in three groups: people
who are not TB infected, people with latent TB infection (LTBI), i.e. those that do
not have any symptoms or illness, and TB patients who have not sought care yet.
Uninfected people are potential TB patients if there are infectious TB patients in
their communities to infect them.
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For patients with LTBI and for ill people who have not sought care, systematic
screening is a potential intervention. Active case finding is the strategy to identify
LTBI and TB patients at an early stage. Patients with early diagnosis and treatment
usually benefit from a higher probability of treatment success, and preventive
therapy for LTBI can reduce the chance of TB disease onset. A study, which in-
vestigated mobile radiographic screening of the homeless and drug users, showed
a 45% prevalence decline within four years [35]. In remote areas of Ethiopia, a
close to community/home health provision programme that included TB screen-
ing, demonstrated improvements in case detection and treatment outcome [36].
1.3.2 Interventions on TB care seeking
As for patients who have started care-seeking but have not been identified as TB
patients or received anti-TB drugs yet, shortening the care-seeking process is one
of the targets for interventions. These “missing” and “delayed” patients affect
the epidemiology of TB and increase uncertainty for policy making because they
are in a stage with a high probability of TB transmission. Care-seeking processes
of patients with TB determines the duration of the infectious period and affects
treatment outcomes after being diagnosed. Longer infectious periods lead to a
higher contribution to force of infection in the communities and then generate
more future TB patients. Lack of interventions on the care-seeking process is a
gap to be closed.
Although some links between SES and care-seeking behaviours have been in-
vestigated (e.g. Chen et al. [22] and Machado et al. [21]), the SES-related interven-
tions on the interaction of patients with healthcare systems remain underexplored.
The critical task behind the issue is how to translate the available evidence into
policy.
1.3.3 Interventions on TB care and death
According to the evidence, disadvantaged SES is an obstacle preventing patients
from accessing proper care. Hence, removing this obstacle could be a potential
breakthrough in TB control. The evidence on TB treatment outcomes considering
SES was richer than the care-seeking prior to treatment, so the available examples
of SES-based interventions are focussed on improving treatment process instead
of targeting population with low SES.
Three projects have examined or are examining, on how social support can im-
prove TB treatment, in response to the global awareness of TB and SES. In South
Africa, a cluster randomised controlled trial attempted to increase treatment ad-
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herence by offering food vouchers [37]. This exemplifies how to increase treatment
success with social support. It suggests that only two programmes have been
tried in Latin America. The Bolsa Familia Programme (BFP) in Brazil conducted
a country-level cash transfer to TB patients to improve treatment outcomes [38].
The programme resulted in a declining TB incidence rate and an increased cure
rate. In Peru, Wingfield et al. [39] conducted a household-randomised controlled
trial. This trial is examining the cash transfer for both TB treatment in active TB
patients and preventive treatments for latent TB infection. The study is attempting
to evaluate the exact effect of cash transfers by controlling the external impact of
exogenous variables.
Moreover, many studies have reported that the use of incentives with social
protection for TB control work as feasible interventions. In an ecological study,
Reeves et al. [40] showed general social protection correlated inversely with the
burden of TB epidemics by analysing the data of 21 European countries. de Pee
et al. [41] reviewed the effect of providing food support to encourage adherence
of TB patients, with eight studies in different settings consistently favouring the
intervention.
1.4 Modelling of SES and TB
Models have been used to glue data, knowledge, and theory together to provide
frameworks for inference and projections of interest. Statistical models connect
data and probability theory to explore empirical findings; mathematical models
derive new theories by integrating knowledge; simulation models apply theories,
absorb new evidence, and make projections. Over the past few decades, epidemi-
ologists have been using mathematical and simulation models to overcome the
difficulties such as time cost, ethical issues and limited budget seen in observa-
tional studies [42]. Functionally, these models provide a virtual environment to
conduct policy experiments that are not feasible in reality.
Regarding TB and SES, Pedrazzoli et al. [43] reviewed mathematical models
of TB with social determinants and identified eight studies in total. Four of them
modelled low SES as a risk factor of TB transmission [44–47]. Three studies used
SES as a risk factor for disease progression [48–50] and one study allowed SES to
influence case detection [51]. Apart from these models, Nili et al. [52] modelled the
interaction of TB epidemics and economic growth in the sense of macroeconomics.
The model demonstrated a negative feedback loop trapping the poor with TB.
Most of the simulation modelling studies on SES covered the pre-care stages. In
modelling the epidemic features of pre-TB care, incidence rate is usually affected
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jointly by disease transmission and progression. The main focus of these studies
was to explore the effect of wealth and urbanisation on TB. For example, Andrews
et al. [44] and Rehkopf et al. [53] highlighted the importance of social segregation
while implementing interventions. These models used surrogate variables (i.e.
using low BMI and undernourishment as proxies for low SES) to parametrise SES
in disease progression. However, none of those modelling studies discussed the
roles of SES on the care-seeking processes and the delays to TB treatments.
In addition, to model TB care seeking and treatment outcomes, Reeves et al.
[51] linked case detection and treatment success with macroeconomic fluctuations.
In the other models, all events associated with healthcare such as screening, diag-
nosis, and treatment outcomes, are summarised as constant parameters without
the SES strata. Without parameterising SES in healthcare seeking directly, An-
drews et al. [44] composed a diagnosis improvement intervention favouring the
poor and showed the importance of interventions that consider the aspect of SES.
In addition, van den Boogarrd et al. [54] modelled the socioeconomic barriers that
keep patients from good adherence. The study results recommended an increase
in social support for TB patients.
1.5 Study scope
Following the announcement of the United Nation Sustainable Development Goals
(SDGs) in 2015 TB control programmes have sought innovative SES-related TB in-
terventions and their empirical evaluations [55]. Care-seeking behaviours and TB
services provision are keys to connect SES with TB. There are a large number of
studies related to the adherence to TB treatments. The evidence linking socioe-
conomic factors and treatment outcome is well developed, and a lot of SES-based
interventions have been shown to improve treatment outcomes. However, less
attention has been paid to other types of care-seeking.
The limited availability of data related to care-seeking that precede TB confir-
mation is a challenge. Before TB confirmation, patients with TB are not technically
“TB patients” by definition. Therefore, most of the related studies collected data
after individuals were identified as TB patients and the events before the diagnosis
were based on retrospective assessments.
Routinely collected healthcare utilisation data typically contain details of health-
care provision since the first care-seeking for TB-suggestive symptoms. The cur-
rently available measurements for patient pathways are restricted in delays (e.g.
Sreeramareddy et al. [56] and Chen et al. [22]), dropout cascades (e.g. Subbara-
man et al. [57]), and the patient pathway analysis (PPA [23]). The delays indicate
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the time spent care-seeking and the dropout shows the adherence of patients in
different stages of care-seeking. Both these measurements are good at reflecting
aspects of the care-seeking process. However, they do not consider the capability
of a health system of providing accurate and efficient TB servicesd, which usually
connects to interventions. On the other hand, the PPA extracts the information
for healthcare provision and patient ends but it does not consider temporal in-
formation. Without temporal information, further intervention evaluation will be
limited.
Assuming the details of the care-seeking process including TB-services pro-
vision and needs are available, how to use them to project the population-level
epidemiology of TB is another challenge. As the review of Pedrazzoli et al.
[43] summarised that mathematical modelling by equation-based models (EBMs)
can incorporate socioeconomic determinants into the simulation of TB dynamics
while EBMs aggregate individuals to population-level. Using agent-based mod-
els (ABMs), which can replicate empirical results in the individual level and in-
clude transmission process. However, the computational burden of ABMs in large
scale population is a major drawback. Providing an efficient simulation model to
compactly represent the system while supporting interventions on the individual
care-seeking process are needed.
This thesis is focusing on TB and SES through the care-seeking process. There
are twofold purposes. First, jointly considering the perspectives from both health-
care providers and demands, I aim to identify the obstacles delaying TB diagnos-
tics and inducing unfavourable treatment outcomes using an individual, longitu-
dinal data. Second, given the empirical results in individual-level, I want to build
a simulation model, providing a platform for exploring SES-based interventions.
1.6 Overview
Chapter 2 reviews the evidence of SES and TB with the connections of care-seeking
and empirical impacts of SES-based interventions on TB-related outcomes. The
chapter includes three scoping reviews, aiming to summarise the existing litera-
ture in the field. The reviews identify gaps in evidence and use this to highlight
potential SES-based interventions that are explored later in my thesis.
Chapter 3 reviews the hybrid modelling approach in the context of health. The
review focuses on the transitions between agents and values in equations given
different levels of needed details. Finally, this chapter discusses the suitability of
this approach for my research questions with examples of hybrid modelling and
technical details in the applications.
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Chapter 4 reviews the applications of health behaviour simulation in agent-
based modelling. The chapter investigates how previous models simulate actions
with the influence of personal tracts, social networks, and overall contexture. The
review results provide information on the parameterisation of ABMs from reality
and a guideline for simulating health behaviour.
Chapter 5 introduces the demography and epidemiology of TB in Taiwan by
presenting the statistical summary and modelling. This chapter analyses and fore-
casted the age-specific TB incidence rates using Lee-Carter models and time-series
analysis. The chapter emphasises the impact of population ageing on TB burden
in the future.
Chapter 6 develops a method, the individual patient pathway analysis (IPPA),
for extracting and analysing care-seeking pathways of TB patients and SES. This
analysis uses a health utilisation dataset based on the National Health Insurance
programme in Taiwan.
Chapter 7 uses the results of Chapter 6 to examine the socioeconomic deter-
minants associated with extended care-seeking processes and economic outcomes
caused by TB care-seeking.
Chapter 8 develops a TB hybrid model which can simulate nationwide TB
dynamics of Taiwan. The model has an agent-based submodel and an equation-
based submodel. The agent-based part of this model instantises the patients with
active TB who seek care and are under treating based, while the equation-based
part captures uninfected population and LTBI who are at risk of TB. The method-
ology is supported by results of Chapter 4 and Chapter 3. The model is driven by
empirical results of Chapter 6 and Chapter 7.
Chapter 9 uses the model developed in Chapter 8 to consider the SES-based
intervention. The simulation focuses on increasing the TB diagnostics provision.
This chapter evaluates the intervention responses on the epidemiological and eco-
nomic aspects.
Finally, the last chapter summarises this thesis and discuss the limitations and
future perspectives.
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Chapter 2
Review: socioeconomic status and
TB care-seeking
2.1 Introduction
Socioeconomic status (SES) impacts the transmission, diagnostics, treatment, and
outcome of TB distally. As conceptualised by Lönnroth et al. [1], the influences
of SES can pass down through multiple routes within multiple aspects of TB epi-
demiology. As more and more scientific facts have been revealed, the interest
in controlling TB through structural changes related to SES and targeting TB is-
sues for low socioeconomic groups has increased. Following the announcement
of the United Nation Sustainable Development Goals (SDGs) in 2015, the TB con-
trol programmes have called for innovative SES-related TB interventions and the
attendant empirical evaluations.
In terms of the care-seeking process of TB, SES plays a fairly straightforward
role. From the healthcare provision end, higher level SES communities are able
to support healthcare facilities with higher quality since providing high quality
and sufficient healthcare services requires the requisite human and financial re-
sources. Meanwhile, from the patient end, individuals who have fewer concerns
about seeking care have a better chance of accessing appropriate care when they
are unwell. These concerns can result from income loss, travelling costs, lack of
information, or stigmatisation. Intuitively, if the barriers to accessing appropri-
ate TB services can be ameliorated or removed, and the healthcare systems can
provide appropriate diagnostics and treatments, the TB-related burden could be
alleviated. However, the care-seeking of TB patients is a complex interaction of
decision making by patients and healthcare providers (health system, healthcare
facilities, and clinicians). To ensure the causal pathway is well-connected and SES-
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based interventions are effective, a systematic arrangement of the evidence related
to a number of aspects is required.
This chapter summarises the available studies on the relationship between SES
and TB that involves the mediator of care-seeking dynamics before it goes on to
systematically discuss the state-of-the-art SES-related TB control strategies. The
chapter is divided into a number of sections. Section 2.2 reviews the evidence
that supports SES-based TB control strategies. Section 2.3 investigates the SES-
based TB control actions based on Universal Health Coverage (UHC) and social
protection (SP), which target support deprived TB patients. The last section then
discusses the challenges related to SES-based TB control strategies.
However, before proceeding, I must clarify the terminology I use when refer-
ring to specific individuals. Here, ill people refers to the individuals who have
active TB, patients refers to ill individuals who have initiated their care-seeking,
and TB patients refers to the individuals who have been diagnosed with TB or
who have begun their TB treatment.
2.2 The influence of SES on care-seeking and treatment ad-
herence
The aim of this section is to bring together the evidence that links SES, to care-
seeking, and treatment adherence and examine its the policy implications. To this
end, I conducted a scoping review to explore the evidence that indicates the exis-
tence of these links. Here, I conceptualised the connections between the evidence
and patient behaviour by using the Theory of Planned Behaviour (TPB) [2], which
is a psychological and conceptual model used to investigate an action as a result
of attitudes, subjective norms, and perceived barriers. In this section, the term
“care-seeking” encompasses care-seeking prior to treatment, the adherence to TB
treatment, and the adherence to preventive TB treatments for TB latency.
2.2.1 Searching strategy
The search was conducted using the Web of Science with keywords related to
TB, SES, and care-seeking behaviours. Specifically speaking, I searched “Tuber-
culosis” AND (socioeconomic OR “socio-economic*” OR “social determinant*”
OR “catastrophic cost*” OR “catastrophic health cost*” OR “social develop*”)
AND (“care seeking” OR “delay*” OR “patient pathway*” OR “compliance”
OR “adherence” OR “default”). I included two types of records: the available re-
view articles with synthesised evidence and research articles with new evidence.
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I reviewed the two article types separately.
I curated review articles published before July 2019 and research articles pub-
lished between January 2015 and July 2019 (post-2015 era). I only included stud-
ies published in English and only those that considered any SES factors associ-
ated with care-seeking behaviours. I included qualitative, cross-sectional, obser-
vational, trial, and statistical modelling studies. I excluded any studies based on
SES-based interventions (which will be analysed in the next section). I also ex-
cluded studies involving participants restricted to specific SES groups without a
comparator group and any that involved assessing the TB treatment failures that
were not due to the care-seeking behaviour of the patients. I also excluded any
studies that had previously been collected in review studies in order to prevent
any potential duplication. In terms of review articles, I excluded those studies that
only provided narrative summaries.
A narrative synthesis was undertaken using the TPB to group findings into
three categories. According to the TPB, the intention of action can be affected
by three factorial dimensions: attitude, subjective norms (SN), and perceived
behavioural control (PBC). Here, the attitude toward care-seeking is related to
whether individuals who are experiencing potential TB-suggestive illness think
they need to seek proper healthcare. Risk perceptions related to TB and the aware-
ness of TB are examples of the attitude in the TPB. I also linked education to the
attitude dimension. Meanwhile, the SN generally refers to the influences of peers
or of significant others. I mapped SN to the stigmatisation of TB and to the dis-
crimination toward TB patients. Finally, the PBC relates to whether people believe
that they can access TB-related services and believe that the services could actually
solve their health problems. I referred PBC to various costs of adherence, low SES,
and the capacity of the assessed hospitals.
2.2.2 Results
As Figure 2.1 shows, I retrieved 20 review articles and 105 research articles. The
title and abstract screening resulted in nine review articles and 41 research articles.
Following the subsequent full text review, I retained three review articles and 19
research articles in the final collection. All the reviews were related to treatment
adherence. Among the 19 research articles, six investigated care-seeking prior
to treatment start; two studies for latent TB preventive therapy, ten looked at
treatment adherence, and one of assessed pre-hospital care-seeking and treatment
nonadherence simultaneously.
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Care-seeking before treatment
I identified seven studies that assessed the care-seeking behaviours before the TB













excluded, with reasons (n = 6)
a) Mismatched topic: 3
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excluded, with reasons (n = 22)
a) Mismatched topic: 2
b) No care-seeking outcome: 8
c) No effects of SES: 3
d) Merged treatment failure
and default: 8
c) Intervention-based: 1
Figure 2.1: PRISMA flow diagram: Care-seeking and SES
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approach, and five were quantitative studies. All of them were retrospective stud-
ies with case-control design or case-control nested in a cohort or trial study, and
all surveyed the TB patients about their event history. Before the initial contact
with the hospital was made, the intention of consultation for a cough that had
persisted for more than two weeks in relation to the pre-hospital care-seeking was
investigated [3, 4]. Here, delays between the onset of the symptoms [5] and the
initial care-seeking [6–9] were found to exist.
Attitude Five out of the seven studies considered education level or risk per-
ception [3–7]. However, the direction of the effects was diverse. Christian et al.
[4] found that people with higher education levels were less likely to consult for
coughs lasting for more than two weeks, while Laohasiriwong et al. [5] and West-
erlund et al. [6] found negative correlations between lower education levels and
longer delays, while the other two studies showed null effects [3, 7].
Subjective norms Four out of the seven studies considered stigmatisation and
regional SES. While quantitatively testing the stigmatisation of TB was not men-
tioned in the quantitative studies, Cremers et al. [3] highlighted the concerns
related to stigmatisation through interviewing TB patients in qualitative terms.
Meanwhile, Saqib et al. [8] showed a regional disparity in that living in rural
areas correlated to prolonging treatment delay.
Perceived behavioural control Financial and transportation barriers were ad-
dressed in all seven studies. With the except of Said et al. [7], the researchers
found that the existence of these barriers correlated to longer delays in various
terms.
Adherence to TB preventive treatment
One review article and two research articles investigated the dropout rate during
Isoniazid preventive therapy [10–12]. A retrospective cohort study conducted in
Brazil identified that a low Human Development Index [13] at a regional level
was associated with a higher dropout rate [10]. Meanwhile, the other study, a
prospective cohort study on HIV infected patients in Tanzania, found that the
dropout rate was not associated with either an asset-based SES index or education
levels [11].
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Adherence to TB treatment
I found two review articles and 11 research articles that had investigated TB treat-
ment adherence. Table 2.1 lists the extracted data of the 11 research articles. Here,
I located ecological, cross-sectional, and nested case-control studies related to the
field in question. Of these, three out of the 10studies were qualitative, two used a
mix-methods approach and the remainers were quantitative studies. One ecolog-
ical study [14] used districts as the basic units while the others were based on TB
patients. Table 2.2 lists the identified factors from the 11 studies that related to the
TPB framework.
Table 2.1: Studies for non-adherence to TB treatment.































































































LTFU: loss to follow-up
Chapter 2. Review: SES and care-seeking 23




[15] TB knowledge, motivation emotional
support
self-efficacy, financial support
[16] transport cost, financial cost




[18] witchcraft belief discrimination income loss
[19] subsistence capacity, housing,
granted leave of absence
[14] illiteracy, HDI (education) asset, HDI (income), SDI







[22] health illiteracy household income
[23] illiteracy living shelter house
HDI: Human Development Index, SDI: Social Development Index
Attitude and information I identified that illiteracy, health-related illiteracy, and
education levels were investigated in the selected body of work. According to
the review from Tola et al. [24] the effects of education were diverse, that is,
higher education does not necessarily imply better adherence to TB treatment. In
my selected research articles, I found no instance where higher education was
associated with lower adherence, while a number did suggest that the association
was insignificant. Algeria-Flores et al. [15] used structural equation modelling
to show how the education variables affect the treatment adherence only through
increasing personal skills related to following the treatment, while no direct effects
were found. Meanwhile, in Theron et al. [22], both education level and health-
related illiteracy were investigated. Here, the treatment adherence was found to
be affected by health-related illiteracy but not by education level. The qualitative
study from Diefenbach-Elstob et al. [18] demonstrated an example where the
patient did not accept the results of TB diagnostics nor TB treatment, because she
regarded it is a sin to have TB. This example indicated that the stigma attached to
TB may stop patients from adhering.
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Subjective norm Stigmatisation and emotional support from the family were
commonly found in the field in question. In fact, both review articles [24, 25]
arouse the importance of these aspects. In the selected qualitative studies, stigma-
tisation was a common concern related to TB treatment, while any such associa-
tion was not consistently identified in the quantitative analyses. A mixed-methods
study from Cremers et al. [3] addressed how the stigma of TB was a factor in their
qualitative analysis but not in their quantitative analysis. However, in their co-
variate analysis of suffering from the stigma and non-adherence revealed that this
factor was insignificant. In addition to the stigma of TB, Lohiniva et al. [21] re-
vealed an issue regarding social norms in terms of individuals who are incapable
of working. Being regarded as an “useless” can be a risk factor for non-adherence.
Perceived behavioural control In terms of PBC, I found various measurements
related to the barriers to completing treatments within the selected body of work.
With regard to patient assets, living in shelters and a lack of water supplies were
identified as risk factors. While many measurements based on income were com-
monly assessed, the attendant effects were found to be diverse. In Maciel et al.
[14], higher regional income was correlated with higher adherence. However, at
the individual level, the effect of personal income or employment was rarely iden-
tified. As for the treatment-related barriers, the effects of income loss, granted
income for absence due to treatment compliance, financial costs, and travelling
costs were consistently identified within the selected studies [3, 16, 18–21]. In
terms of the incoming cost and disposable income, Herrero et al. [19] used the ca-
pacity of subsistence to measure the poverty level and found a positive correlation
to treatment adherence. In addition to these measurements, Alegria-Flores et al.
[15] surveyed an index of self-efficacy and concluded that the index affected TB
treatment adherence.
2.3 SES-based TB interventions
The evidence connecting TB to SES through care-seeking is abundant. However,
how to control TB in view of the SES factors remains debatable [26]. Universal
Health Coverage (UHC) and Social Protection (SP) are the two main streams that
echo the call for SES-based interventions [27]. UHC is aimed at ensuring every per-
son with an illness can have access to appropriate healthcare services. The atten-
dant programmes are generally aimed at a general improvement in care-seeking
attempts and healthcare experiences. On the other hand, SP is literally aimed at
protecting TB patients and TB-affected households from financial and health risks
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when the patients are receiving care. To understand the implementation of SES-
based interventions, I carried out two scoping reviews, one for UHC and one for
SP. I restricted the search the Web of Science to the publications released before
July 2019 that were compiled in English. Again, I included both research arti-
cles and review articles. I collected the evaluations of the interventions through
trial-based, ecological, statistical modelling, and mathematical modelling studies.
2.3.1 Universal Health Care, UHC
The outcome of TB can be catastrophic not only in terms of TB fatality but also in
terms of the financial burden, which will affect the survival of an individual or a
household. Therefore, ending TB is firmly included in the roadmap of achieving
UHC. Meanwhile, the implementation of UHC, in turn, encourages people to ac-
cess the healthcare system when they have TB-suggestive illness. However, while
all the measurements on catastrophic costs can inform the demand for UHC, but
whether UHC can substantially empower TB-related care-seeking remains debat-
able.
Searching and screening
I reviewed the implementation of UHC in terms of empirical or modelling eval-
uations of the impacts on TB treatment and on epidemiological or economic out-
comes. Since social health insurance (SHI) and close to community/home health
provision (CTCH) are common practices of UHC, I specified the related terms as
keywords. In view of relating TB and SES with the keywords relate to UHC, I
searched using the following terms, tuberculosis AND (“universal healthcare”
OR “universal health coverage” OR “universal coverage” OR “universal care”
OR “social insurance” OR “social health insurance” OR “compulsory insur-
ance” OR “close to community” OR “close to home”). Following this, I retrieved
59 initial search records published before July 2019 from the Web of Science.
Results: universal health coverage
As Figure 2.2 shows, I retained three studies after applying the following exclusion
criteria: (1) did not highlight the impact of UHC on TB and (2) did not evaluate
the impact of UHC. One of these studies were about SHI and two were related
CTCH.
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Social health insurance
SHI is provided to mitigate the financial burden of underprivileged people when
they are seeking healthcare. SHI is a common approach to achieve UHC and
secure the fundamental human right to good health. Ideally, a fully functioning
SHI should be able to cover all the catastrophic costs related to TB diagnostics
and treatments. However, my search only identified one empirical study that
evaluated the effect of SHI implementation on TB outcomes. The focus of the study
was on how Indonesia extended its social health insurance programme to private
healthcare providers in 2014, which presented a joint SHI and private-public mix
to relieve the financial burden of TB patients. Here, Fuady et al. [28] surveyed TB
patients following the policy implementation and found that the catastrophic costs
of TB diagnostics and treatment were lower for poor people than for the non-poor.
However, the researchers asserted that the SHI with private-public mix could not
ensure zero catastrophic costs.
Close to community/home health
SHI is a passive SES-based intervention because SHI it works when the ill people
have the intention to seek care. However, as a further aspect of UHC, CTCH
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Figure 2.2: PRISMA flow diagram: Universal Health Coverage
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community or homes to identify healthcare the needs or to eliminate the travelling
costs. In fact, CTCH is directed at the areas where people face high travelling
costs in terms of either money or time and where the severity of the illness is often
misjudged. Overall, it provides an additional link between the underprivileged
population and the healthcare system.
In Ethiopia, a CTCH-based, health extension program was launched in 2003.
The health extension workers (HEWs) were deployed to provide essential preven-
tive health services in the community. With this, the TB REACH project attempted
to introduce TB-related services to the routine tasks of the HEWs. Looking at the
provider end, Datiko et al. [29] qualitatively surveyed the reactions to the project
from the HEWs, supervisors, and laboratory technicians. In general, the HEWs
and supervisors had positive reactions in that they believed the new tasks could
stimulate the working environments and could increase their connection to the
communities. However, from the perspective of the laboratory technicians, the
collection of samples with standard quality by the HEWs remained a challenge.
In a follow-up study on the outcomes, Datiko et al. [30] confirmed that the project
had a substantially improved on the case detection and the treatment outcome.
2.3.2 Social Protection, SP
SP programmes related to TB intend to provide supportive environments that en-
courage TB patients to complete their TB treatment. Unlike UHC, SP firmly targets
people with specific conditions. In the TB programmes, the conditions generally
refer to attending TB treatments regularly or participating in health education
events. With the focus on TB-affected households, the practices tend to be more
TB-specific than UHC practices, while the intervention effects are easier to ad-
dress. In echoing the risk factors for non-adherence to TB treatment, SP presents
an intuitive approach to improving TB patients’ outcomes.
Searching and screening
I reviewed the SP implementation through empirical or modelling evaluations of
the impacts on TB treatment and on epidemiological or economic outcomes. In
view of relating TB and SES to the keywords related to SP, I searched using the
following terms, tuberculosis AND (“social protection” OR “social support” OR
“cash transfer” OR “financial support”). Following this I retrieved 244 studies
among the initial search records published before July 2019 from the Web of Sci-
ence.
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Figure 2.3: PRISMA flow diagram: Social Protection
As Figure 2.3 shows, I retrieved 21 studies after excluding the studies that:
(1) did not highlight the impact of SP on TB outcome, (2) did not evaluate the
impacts of SP programmes, and (3) had previously been considered in collected
review articles. Here, I identified two large-scale social protection programmes in
the selected studies: the Bolsa Familia Programme (BFP) in Brazil (eight studies)
and the Community Randomized Evaluation of a Socioeconomic Intervention to
Prevent TB (CRESIPT) in Peru (two studies). To ensure that I formed a compre-
hensive summary of these two programmes, I separated them from the summary
of the others. With regard to the other studies, I identified four review articles and
two research articles that assessed TB treatment outcomes under SP, two mod-
elling studies that evaluated the economic outcomes and three modelling studies
that evaluated the epidemiological outcomes.
Treatment outcomes
One direct impact of SP is the improvement of treatment outcomes. All the reviews
[31–34] in my collection investigated the treatment adherence and outcomes in re-
lation to SP programmes. Although in practice SP highly depends on the regional
or cultural norms, the reviews consistently confirmed that the SPs were positively
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associated with treatment success or adherence. The SPs are either general or are
specifically related to food assistance [31], or to economic [34], socioeconomic, or
psycho-emotional [32] aspects, particularly in low- or middle-income settings [33].
Two studies [35, 36] published after the reviewed articles confirmed the consis-
tency of the overall effectiveness.
Economic outcomes
The SP that is focused on financial support is firmly aimed at mitigating the catas-
trophic costs. Based on the aggregated national data of seven countries, Rudgard
et al. [37] evaluated and compared two financial support schemes for TB control.
One provided financial support to TB patients in low SES groups while the other
focused on low SES groups that involved high TB risks. The results suggested
that the former will be overwhelmingly effective and will require lower costs in
eliminating the burden of the catastrophic costs due to TB. Fuady et al. [38] built a
simulation model based on a statistical analysis of TB patient data from Indonesia
to study tested various combinations of financial support in terms of income loss,
food assistance, and transportation support. Their results suggested that financial
support alone cannot reduce the catastrophic costs for TB-affected households to
zero.
Epidemiological outcome
In addition to the direct effects on individual treatment and economic outcomes,
SP programmes can indirectly influence the dynamics of TB. For example, the
health education provided to TB patients may spread to their household or to
other affected households and even to the community as a whole, meaning the
overall awareness of TB within a community will increase. Evaluating these ex-
ternalities requires looking at the outcomes at a population level. In view of this,
I found three modelling studies that had evaluated the total effect of SP imple-
mentation based on aggregated datasets. Here, Reeves et al. [39] investigated
the relationship between the expenditure on SP policies and the different epi-
demiological outcomes in 21 European countries. The model’s predictions show
strong preventive effects on incremental SP spending in terms of TB notification,
incidence, and mortality after adjusting for gross domestic product and general
public health spending. Following Reeves et al. [39], Siroka et al. [40], applied the
analysis to the global scale. Here, the authors addressed how SP spending that
accounts for 1% of GDP could significantly reduce the incidence and prevalence of
TB as well as the attendant mortality, while diminishing returns to increasing SP
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expenditure were also found in the study. Elsewhere, Carter et al. [41] developed
a statistical model to address how the change in poverty levels correlated with the
global incidence of TB, in responding to the poverty reduction in SDG. Through
widely extending SP coverage, a three-quarter reduction in the global incidence of
TB could be expected by 2035.
BFP and CRESIPT
BFP is a national programme in Brazil that was launched in 2003 with the aiming
of using various conditional cash transfers to eliminate poverty across the country
[42]. I found eight studies related to BFP that fitted my criteria. Here, Durovni et
al. [43] and Oliosi et al. [44] found that being covered by BFP correlated to a higher
chance of treatment success in relation to dropout rate and death during treatment.
More specifically, Reis-Santos et al. [45] indicated that BFP leads to higher cure
rates for the patients who received the cash transfers. Also, I identified several
studies addressing the epidemiological effects. Lower TB incidence and lower
mortality rates were found in populations participating in BFP after adjusting for
social groups [46–49]. I also found a simulation modelling study from, Boccia et
al. [50], who used the findings from the aforementioned BFP studies in various
terms.
Focusing on a specific SES group, CRESIPT was a randomised clustering con-
trol project that was conducted in the shantytowns of Lima, Peru between 2014
and 2015 [51]. Similar to BFP, CRESIPT provided TB patients with financial sup-
port. In addition, CRESIPT employed monthly community meetings, provided
TB-related health education and focus group discussions to the patients and their
close contacts. If they attended the meeting, they would receive extra assistance
with food vouchers. I identified two studies that had evaluated the effect of CRE-
SIPT. Here, the general consensus was that the intervention served the purpose of
reducing the catastrophic costs of the TB-affected households [52] and improved
the clinical treatment outcomes [53]. However, to the best of my knowledge, the
epidemiological outcome of CRESIPT has not yet been revealed.
2.4 Discussion
Utilising three scoping reviews, I have identified the studies that have assessed
the links between SES and TB-related care-seeking and the potential impact of
SES-related interventions on TB control. In summary,
• the effects of SES on care-seeking prior to treatment are different depending
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on the setting, while, in general, higher SES usually implies better adherence
to TB treatment.
• Meanwhile, the influence of UHC programmes on TB have been poorly eval-
uated. While increasing the coverage may improve the accessibility of TB-
related services may also raise concerns regarding service quality.
• The implementation of SP programmes is varied, but the preventive effects
on different aspects of TB were consistently confirmed by the existing litera-
ture.
Notably, the studies related to BFP demonstrated the existence of an ecologi-
cal system in this field, which includes evidence, interventions, and evidence of
interventions. First, I identified the studies that had assessed the effects of SES
on various care-seeking behaviours in Brazil. This included the compliance to TB
treatment, to DOT, and to preventive latent TB treatment by TB patients in general
or by those who had specific attributes. Secondly, after considering the implemen-
tation of BFP, the intervention effects on the cure rate, treatment adherence, and
the epidemiological outcomes were evaluated. Lastly, a modelling study [50] iden-
tified that had developed a data-driven modelling scheme to utilise the evidence
for intervention projections. However, one crucial drawback of the BFP studies
related to the nature of the programme. In short, BFP is a national programme,
meaning the effects of the programme were based on ecological studies, which
implied that the effects of BFP could not be explicitly isolated from the other TB
control approaches. In addition, one conditionality for receiving a cash transfer
from BFP is that health checkups and health and nutrition seminars are regularly
attended. These approaches imply that BFP is aimed at increasing healthcare cov-
erage, the effects of which cannot be identified solely through the cash transfers.
Similarly, in terms of the CRESIPT project in Lima, Peru, a great proportion of
the empirical studies I found were conducted in Peru. In fact, five out of the 15
studies collected byThomas et al. [25] were related to the Peruvian capital, Lima.
The literature that addressed care-seeking before and after treatment revealed a
certain imbalance. In fact, most of the studies were related to SES in terms of risk
factors for TB treatment non-adherence or in terms of improving the adherence
through SES-related interventions. Furthermore, I did not find any review articles
that summarised the relationship between SES and treatment delay. The reason
for this imbalance can be attributed to data availability. Before TB is diagnosed or
before the treatment is initiated, the patients are not technically “TB patients” yet,
which means the TB-specific programmes do not cover them and thus their inter-
actions with the healthcare system would not be recorded. Therefore, routinely
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collected data on more generally healthcare purposes or retrospective surveys are
required for assessing the care-seeking behaviours that precede TB confirmation.
Similarly, the evaluations of UHC programmes which do not have to consider
TB-specific issues were scarce compared to those related to SP programmes.
In this chapter, I aimed at providing an elevated view of the context of interest
rather than gaining an in-depth understanding of a specific outcome. Therefore, I
did not search in broader terms, merely restricting my search to the Web of Science
and did not search more broadly. Also, I used a narrative technique to summarise
the selected studies rather than meta-synthesis in terms of measurement quality.
In short, I merely required a clarity of definitions and a good fit to my area of
interest.
To bring the non-intervention evidence into contact with behaviour change
motivations, I introduced the notion of TPB. Prior to that, I had considered the
Health Belief Model (HBM) [54, 55], which related to TB diagnosis in its early
development. However, under the framework of the HBM, I could not appropri-
ately locate peer influence, stigma, or health education in communities, so I opted
to apply the TPB, which involves the components of subjective/social norms as
a component. Also, the information-motivation-behavioural skills (IMB) model,
which has applications in treatment adherence in the sense of psychology, was a
potential behavioural theory [56, 57]. Here, the “motivation” term can be regarded
as the integration of attitude and subjective norms into the TPB, while the “infor-
mation” aspect summarises the knowledge related to the behaviour of interest,
which I classified as the attitude term in the TPB. The behavioural skills, however,
focus on self-efficacy rather than physical barriers such as income loss and travel
cost.
Spatial inequalities were related to TB incidence or risk of TB. For example,
a subnational spatial analysis, Pereira et al. [58], in Brazil found positive effects
of the social development index and per capita income on lower TB incidence
rates. In this review, I attempted to use the attitude or social norms in the TBP to
summarise the spatial or contexture effects. However, the retrieved studies were
usually conducted on specific sites or specific vulnerable population. They shared
homogenous background features, such as culture and beliefs. I suggested this is a
reason why the cultural effects were generally addressed in the qualitative studies,
e.g. Cremers et al. [3] and Saqib et al. [8], but hardly evaluated in the quantitative
analysis. Therefore, to address the spatial effects on care-seeking behaviours, more
subnational or international studies are required.
In a number of selected studies, I found the influence of risk perception and the
stigma of TB. These two factors can be regarded as socioeconomic factors or medi-
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ators of as the influence of the other socioeconomic factors. To simplify my search,
I did not include studies that assessed their upstream factors. However, as Craig
et al.’s [59] review revealed, highlighting the actions to reduce the stigmatisation
caused by SES has rarely been addressed.
In the Western Pacific region, the adult TB incidence rate tends to increase
with age. This is especially the case in China, Japan, Singapore, South Korea, and
Taiwan that the TB suffers account for the major part of TB-related burden. The
missing patients and the non-adherent to treatments in this region remains a huge
concern. However, the available studies related to SES-based TB interventions only
targeted children and young adults. In short, the income-based SES indices are
not applicable for the retired. Thus, shifting the focus to regional SES, saving-
based SES, asset-based SES, and psycho-socio-economic indices would be more
appropriate in these settings. Further research on care-seeking behaviours should
perhaps consider savings, investment income, living with children, or social event
engagement.
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Agent-based models (ABMs) and equation-based models (EBMs) span a spectrum
in the field of simulation modelling. At the ABM or discrete event simulation
(DES) end, all the individuals are modelled as entities, agents, individuals, build-
ing up a bottom-up system. Agents have their own attributes and rules for in-
teracting with an environment. Placing them in an environment of interest, their
rules of actions and interactions can jointly describe scenarios of interest. I can
then observe the system at the individual level, population level, or a more aggre-
gated view. At the EBM or system dynamics (SD) end, a system is described by
a set of equations. Equations capture the behaviours which drive the dynamics
of a system. In an EBM, I calculate variables of interest with mathematical func-
tions. The rules-of-thumb, advantages, and disadvantages of choosing between
ABMs and EBMs have been discussed in the literature [1–3]. In general, ABMs
can deal with a wider variety in non-linear behaviour, stochastic terms, and data
inputs with heterogeneity in individual-levels, and EBMs simplify systems and
keep clarity in model specification and requires less computation resources. How-
ever, both of them have apparent drawbacks: ABMs are often computationally
expensive and data-hungry; EBMs may require strong assumptions which depart
from complex reality.
In fact, the paradigms of ABMs and EBMs are not incompatible with each
other. Coupled simulation including both ABMs and EBMs has the potential to
exploit the benefits of both. Brailsford et al. [4] showed two case studies of hy-
brid modelling in healthcare, anticipating that hybridising SD and DES can bring
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healthcare modelling to the “holy grail”. Heath et al. [5] started from a technical
perspective to discuss ideas for mixing aspects of ABMs, DES, and SD in depth.
Although the methodology was not precisely described, they concluded that intro-
ducing one approach within another is possible with proper adaptations. In prac-
tice, multi-scale and metapopulation modelling illustrate applications coupling
ABMs and EBMs. Multi-scale modelling either uses EBMs to describe response
to external shocks of many sub-models of an ABM, or constructs an ABM where
every agent has an EBM embedded. For example, Banos et al. [6] used an EBM to
control transportation among many ABM cities; Caudill and Lawson [7] modelled
epidemics in hospital wards while every patient has an EBM of human-pathogen
interaction embedded. Metapopulation models can define different populations
using different modelling paradigms. For example, Manore et al. [8] modelled
a mosquito-borne disease, with an equation-based mosquito layer and an agent-
based human layer, the two layers could transmit the disease to each other.
Excluding multi-scale and metapopulation modelling, this chapter investigates
a closer hybridisation between ABMs and EBMs in the health context. The hy-
brid modelling in this chapter indicates not only having both paradigms of ABMs
and EBMs but also allowing a single individual switch between an agent and a
count number in equations. This chapter is interested in examples that instanti-
ated agents as more details were required and reduced them to variable values for
improved computational feasibility.
3.2 Search strategy and data extraction
3.2.1 Query
I searched entries systematically in the electronic database Web of Science. I re-
quired only clarity in methodology and implementation. I constrained the search
for publications written in English and published before July 2019. Both journal
articles and conference proceedings were accepted. The query was formulated
with the terms from the following three domains:
Set 1: Equation-based models (EBMs) An EBM describes the behaviour of a sin-
gle entity through a dynamic system of equations. In infectious disease modelling,
terms like compartmental models, differential equations and their derivatives are
commonly used. In health services research or operational research, the terms
“System dynamics” dominates the discourse. The keywords were combined as
follows: (“equation based” OR “system dynamic*” OR “differential equation*”
OR “Compartment*”)
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Set 2: Agent-based models (ABMs) An agent-based model, alias multi-agent
system, describes behaviours of a collection of multiple entities. In infectious
disease modelling, since “agent” means pathogen as well, ABMs are sometimes
called individual-based models. Again, considering potential articles in opera-
tional research, I regarded microsimulation and discrete event simulation as types
of ABMs although in some contexts they are differentiated. The related keywords
were composed as follows: (“agent based” OR “individual based” OR “multi
agent” OR microsimulation OR “micro simulation” OR “discrete event simula-
tion”).
Set 3: Topics related to disease dynamics I targeted models related to disease
dynamics but not restricted to any lifestyle factors, specific diseases, or medica-
tions. The terms were as follows: (“disease*” OR “medic*” OR “epidemiolog*”
OR “health” OR “infect*”)
3.2.2 Selection criteria
In title and abstract screening, I included articles based on the following consider-
ations:
Topics: I focused on behaviours related to disease dynamics. These could involve
any process, such as the exposure process, self-protection, behaviour, and care-
seeking. I did not consider models at microbiological or immunological scales. It
is to be noted that, since I was not focusing on human-specific behaviour, studies
for non-human populations were eligible if they met the other criteria.
Having an ABM and EBM: I required studies have both an ABM and EBM in a
single simulation. I included them only if there was communication between the
two paradigms.
Individuals switching between agents and values for equations: Although my
search might fetch multi-scale and metapopulation models in the initial hits, I in-
cluded them only if they had individuals transferring between the two paradigms.
Inclusion/exclusion based on the nature of methodology required an assess-
ment of the detailed descriptions at the full-text stage
Model implementation: I was interested in how hybrid models work in prac-
tice, so I excluded the studies without a real example of implementation.
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3.2.3 Data extraction
Focusing on technical details, I extracted three sets of methodological information
from the selected studies. The first and the second were for ABMs and EBMs re-
spectively: the terminology used for them, the types of modelled entities, stochas-
ticity, discrete time or continuous time, the use of data. The last one captured the
relation between the agent-based and equation-based components: what and how
they communicated with each other, how they synchronised.
3.3 Results
3.3.1 Search results
Figure 3.1 shows the results of my search and selection process. Identifying from
319 initial searched result, I included 7 studies: 2 journal articles and 5 conference
proceedings. The publication dates ranged from 2007 to 2016. The studies can be














excluded, with reasons (n = 7)
a) Comparing ABM and EBM: 3
b) No EBM submodel: 2









Figure 3.1: PRISMA Flow Diagram
Chapter 3. Review: Hybrid modelling 45
3.3.2 Topics
Disease outbreak models
I found two studies using ABMs when outbreaks are initialising and EBMs when
the infected populations reach threshold count values [9, 10]. Bobashev et al.
[9] built a sequential modelling scheme: as the number of the infected agented
reaches a threshold, the agents are summarised to determine the variables values
of the EBM and the simulation switches to an EBM. The study claimed the ABM
had better capability to capture the nature of an epidemic, while the EBM saves
simulation resources and can be a good approximation if the epidemic is estab-
lished. Using a similar concept about EBMs and ABMs, Alam et al. deployed
a parallel hybrid scheme modelling HIV outbreaks in specific clusters alongside
an endemic environment [10]. While the study focused on an intervention that is
based on clusters defined by virus genetics, the model of HIV outside the target
cluster did not require individual-level resolution.
Disease onset models
Leonenko et al. [11] demonstrated a hybrid modelling scheme utilising EBMs
and ABMs according to enhance the detail of disease status represented. The
framework was exemplified with TB and HIV epidemiology. The ABM part is in
charge of the people with active diseases because the agents have complex health
states and transition rules. The EBM part deals with the demographic dynamics
and exports newly infected people to the ABM part. Then, the ABM part calculates
and reports the force of infection in the system. The study aimed to speed up the
ABM simulation by transferring the agents that are less interested to values in the
EBM part.
Care seeking models
Focusing on the healthcare process, five of the collected studies modelled people in
healthcare settings by ABMs, and otherwise by EBMs [12–15]. Prospective Health
Technology Assessment (ProHTA) is a new approach evaluating innovative health
technology with synthesised interdisciplinary knowledge before deployment into
practice. To introduce hybrid modelling to ProHTA, Djanatilev et al. [12] devel-
oped a modularised framework. The framework standardised population dynam-
ics, disease-specific changes, healthcare, and healthcare finance. Within them, only
the healthcare part is agent-based simulation. The study showed the potential to
use hybrid modelling in ProHTA. Extending from Djanatilev et al. [12], Djanatliev
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and German [13] switched the implementations from directly to indirectly cou-
pling (to be discussed later). The study improved the clarity of the job of each
sub-model and improved the simulation efficacy. Mielczarek and Zabawa [14]
assessed the impact of population dynamics on future healthcare demand. The
model used an ABM to project the disease process of people with cardiovascular
diseases and their respective healthcare needs. Lastly, Viana et al. [15] hybridised
an infectious disease EBM and a clinic patient flow ABM. The ABM imported
the patients from the EBM and adapted the healthcare capacity according to the
epidemiology.
3.3.3 Coupling methods
I found two types of coupling protocol in the literature. Some allowed their sub-
models to listen to events emitted from each other directly (direct coupling). The
others employ controllers to collect, summarise, and distribute information to sub-
models (indirect coupling).
Direct coupling
Some models allowed their submodels to send information directly to the other.
Bobashev et al [9] did not simulate ABMs and EBMs simultaneously. The EBM
summarised the information of the ABM after the epidemic reached the threshold
to populate initial values, i.e., they used a one shot coupling. Mielczarek and
Zabawa [14] used a unidirectional communication where the ABM fed the patients
to the EBM every timestep without feedback. For the models with bidirectional
communication Djanatliev et al. [12] and Leonenko et al. [11] applied a turn-based
update where submodels used the information from the other models at the end
of the previous timestep. Between two time points, the submodels were simulated
independently.
Indirect coupling
The other studies employed central controllers to collect, summarise, and dis-
tribute information to submodels. The controllers might also validate the infor-
mation to maintain the functionality of the submodels. Alam et al. [10] used a
phylogenetic tree simulation model to connect the two submodels. The tree sim-
ulation directed the ABM according to the epidemiology of the EBM part. Viana
et al. [15] provided a coupling method with lower technical requirements. The
model had EBM and ABM parts built in different software and they communicated
to each other via an external spreadsheet. In each time step, the two submodels
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read and wrote the spreadsheet serially. Lastly, Djanatliev and German [13] pro-
vided an implementation for hybrid modelling based on a process-oriented simu-
lation scheme. In the approach, the agents did not actively schedule events to the
simulator but only respond to the events assigned by the central controller. The
central controller scheduled every event for agents given the status of the EBM
part. Therefore, the agents only take the events approved by the EBM part, and
the ABM part does not require the details of the EBM part.
Information passing between EBMs and ABMs
Classically, EBMs are executed in discrete-time, and ABMs can be both executed
in discrete-time (turn-based) or continuous-time (event-driven). For hybrid mod-
elling, the information in discrete-time and continuous-time parts are always mis-
aligned. Therefore, synchronising the information between the modelling paradigms
plays an important role in the validity of hybrid modelling. For example, an action
of an agent might be triggered if a variable x in an EBM reaches 4. At time 0, x
is 3. After a timestep, x reaches 5 at time 1. Technically, x was in 4 at a certain
timing between 0 and 1. However, the action of the agent is triggered until time
1. On the other hand, an EBM would require an extremely fine timestep to ensure
events in an ABM could be included within a tolerable lag time.
All the studies found, apart from Bobashev et al. [9] as well as Mielczarek and
Zabawa [14], required no bidirectional synchronisation. The others discretised the
continuous-time components and applied a turn-based simulation. In particular,
for the models using indirect coupling, the central controllers summarised the in-
formation to pass to each other in every timestep. Djanatliev et al. [12] discussed
the issue in depth. The results compared the theoretical and the simulated pop-
ulation dynamics, showing a system fluctuation due to the synchronisation issue
but the overall trend of the population was not biased.
3.4 Summary
Although hybrid modelling was encouraged by literature, applications in the
health-related domain are still scarce. The applications showed that hybrid mod-
elling allows high complexity while keeping the computational cost as low as pos-
sible. Studies ranged from theoretical work to applications with explicit healthcare
settings, indicating the potential of hybrid modelling related to health. However,
the implementation methodology was typically poorly described. Synchronising
the information between EBMs and ABMs requires careful assessment. Informa-
tion loss from the hybridisation procedure needs to be quantified.
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Linking back to this thesis, I focus on the care-seeking of TB patients while
I need the disease transmission process to investigate the influence of the care-
seeking on population level transmission. The examples I found demonstrated
the use of EBMs for population dynamics and ABMs for healthcare and disease
progression processes. My population of interest without ongoing TB-related care-
seeking can be modelled by an EBM and while the patients undergoing complex
care-seeking processes and changes in their disease status could be detailed using
an ABM.
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Chapter 4
Review: health behavioral
modelling in agent-based models
4.1 Introduction
Behaviour is central to many questions related to human health. Risk factors
making substantial contributions to disease burden (e.g. smoking, obesity) in-
volve lifestyle choices. Many of these behaviours may be influenced by peers
through social networks of family and friends. Even after the disease has begun,
behaviours such as healthcare seeking or adherence to medication often play a key
role in determining outcomes. As such, health-related behaviour includes aspects
that are relevant to determining both disease incidence and outcomes.
Modelling is increasingly used in public health as a means to bring together
evidence, understand epidemiology and estimate the impact of interventions [1].
Agent-based models (ABMs) in particular have advantages in representing com-
plex individual behaviours [2]. ABMs have great flexibility in the way they repre-
sent behaviour, incorporate heterogeneity, and can make model state spaces more
manageable and less complex (e.g. in cases of history-dependence or multiple,
overlapping conditions). It is not surprising, therefore, that there is widespread
use of ABMs to investigate emergent behaviour among individuals who influence
one another. ABMs have become a key tool in behavioural economics [3], and
Robertson [4] has argued that they are a natural methodology for many questions
in behavioural operational research. [1]
However, many different approaches to modelling health-related behaviour
within ABMs have been attempted, with studies being published in a wide range
of journals representing very different disciplines. I therefore sought to system-
atically review this literature to summarise the approaches used, with particular
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focus on the way behavioural rules for agents have been implemented, the de-
terminants modelled as influencing behaviour, and the conceptual behavioural
models employed. Based on this analysis, I identify gaps in utilisation of certain
methods and suggest areas for future work.
4.2 Search strategy and data extraction
4.2.1 Search strategy and query
I searched entries systematically in the electronic databases Pubmed, Web of Sci-
ence and Scopus in order to cover studies from the medical domain and a wide
range of other disciplines. I did not require studies with well-validated data or
results but only clarity in methodology, so journal articles and conference pro-
ceedings were both admissible.
I formulated my search terms around three aspects: ABM, health, and decision
making. Specifically speaking, my query was: “agent based" OR “individual
based" OR “multi agent" OR microsimulation OR “discrete event simulation"
OR “computational economics"), (health OR disease* OR epidemi* OR medic*
OR hospital OR illness OR well-being) and (Behavio* OR Decision). All studies
before 1 January 2019 published in English with full text available were screened.
4.2.2 Selection criteria
At title and abstract screening, I included articles based on the following eligibility
criteria:
Model type: I only included models constructed from individual-level units and
with temporal dynamics. In the first clause in my query above, microsimulation,
agent-based models, and their relatives were included.
Human agent: The individuals whose behaviour is modelled should be human.
For example, models of influenza transmission from birds to humans that focused
on bird behaviours were excluded.
External environment: I only included studies that described models involving
human interaction with the external environment, for example human to human
or human to health care system interaction. Models only considering within-
individual processes (e.g. immune response to pathogens and pharmacodynam-
ics) were excluded.
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Implementation: Review and conceptual articles which do not include imple-
mentation of the model or example simulations were excluded.
Following title and abstract screening, full articles were accessed and the fol-
lowing inclusion/exclusion based on the nature of behavioural modelling were
applied:
Type of health-related behaviour: The health-related behaviours of interest in
this chapter were defined a priori as: 1) behaviours that are known factors in-
fluencing the risk of ill health, positively or negatively (e.g. smoking, physical
activity and diet); 2) behaviours specifically intended to prevent diseases, such
as vaccination and voluntary screening; and 3) decisions made by patients (e.g.
care seeking and returning to work during recovery). Articles not related to these
categories of behaviour were excluded.
Agent-oriented decision making: This review is interested in agent-oriented be-
haviours so I excluded the behaviours of decision makers as opposed to individ-
uals. For example, the design of emergency department workflows by hospital
managers and disease diagnosis by clinicians would both be excluded. Decisions
of parents to vaccinate their children were included because the parents are af-
fected directly if their children get infected.
Contact behaviour: Models of social contact patterns or sexual partnership for-
mation (relevant to infectious disease transmission) were explicitly excluded un-
less the contact behaviours depend on health status or perceived health status. For
instance, behaviour around sexual partner formation that considers risks of sexual
transmitted diseases would be included; daily commuting patterns, which may
influence the transmission of infectious disease would be excluded.
4.2.3 Data extraction
Through iterative piloting, I developed an appraisal form for extracting informa-
tion from collected studies. The form had three sets of questions. The first set was
about general information: type of behaviour, terminology used for ABM, pur-
pose of modelling, and conceptual behavioural model (conceptual driver for be-
haviour). The second set examined the determinants of behaviour considered. The
third set examined implementation details: variable type of behaviour, method for






















excluded, with reasons (n = 328)
a) Mismatched topic: 76
b) Not agent-oriented behaviour: 108
c) No implementation: 68
d) Only contact behaviour: 75

















Figure 4.1: PRISMA flow diagram
Figure 4.1 shows the results of my search and selection process. The main
reasons for exclusions were: 1) not agent-oriented behaviour, 2) no model imple-
mentation, and 3) contact behaviour only. As a result, I identified 109 studies for
inclusion: 94 journal articles and 15 conference proceedings. The earliest paper
I identified was published in 1999 with the number of studies sharply increasing
from around 2010 (see Figure 4.2). I divided the type of health related behaviour
modelled into one of four domains: 1) lifestyle choice (24 studies), such as diet
and body weight control; 2) addictive behaviour (32 studies), such as smoking
and drug use; 3) preventive action (35 studies), such as vaccination and insurance
purchase; and 4) Healthcare access (18 studies), such as care-seeking, sick leave
taking, and leaving healthcare after recovery. The majority of the studies were
classified as either addictive behaviour or preventive action.
Table 4.1 compares modelling purpose, terminology used for ABMs, concep-
tual behaviour model, and determinants across these domains of health related
behaviour. I firstly investigated the descriptions of ABMs in the retrieved studies.
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“Agent-based model” was the most commonly used term (79 studies, 72.5%) and
“microsimulation” was the second (14 studies, 12.8%). “Individual-based model”
appeared to be a special term only applied in infectious disease modelling. I did
not identify any studies matching the keywords “computation economics”.
I classified the purposes of modelling into four groups from theoretical to
practical: theory demonstration (demonstrating a theoretical statement), model
demonstration (exemplifying a modelling framework with a realistic scenario),
phenomena explanation (explaining empirical phenomena), and policy projection
(forecasting and evaluating the outcome of policies). In preventive action, I found
60% of the models were for theory demonstration. In addictive behaviour, more
than half of the models were for policy projection.
In the rest of this section I consider the typology of approaches used by these
behavioural models for: the conceptual behavioural models; including the deter-












Lifestyle Addictive behaviour Preventive action Healthcare access
Figure 4.2: Number of studies by year and groups of behaviours. Lifestyle: diet, BMI
control, and physical activity; Addictive behaviour: alcohol consumption, smoking, drug use, and
problem gambling; Preventive action: self-protection and vaccination; Hospital access: care seeking,
compliance to health care, taking sick leave, and returning to work during recovery.
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Table 4.1: Summary of included studies by characteristics and health domain.
Lifestyle Addictive behaviour Preventive action Healthcare access Total
N 24 32 35 18 109
Terminology of ABM
Agent-based model 21 (87.5%) 19 (59.4%) 26 (74.3%) 13 (72.2%) 79 (72.5%)
Multi-agent model 0 (0%) 1 (3.1%) 1 (2.9%) 0 (0%) 2 (1.8%)
Individual-based model 0 (0%) 1 (3.1%) 5 (14.3%) 1 (5.6%) 7 (6.4%)
Discrete event simulation 0 (0%) 3 (9.4%) 0 (0%) 4 (22.2%) 7 (6.4%)
Microsimulation 3 (12.5%) 8 (25%) 3 (8.6%) 0 (0%) 14 (12.8%)
Behavioural driver
Utility (Economics) 8 (33.3%) 2 (6.2%) 11 (31.4%) 3 (16.7%) 24 (22%)
Perception 0 (0%) 0 (0%) 10 (28.6%) 1 (5.6%) 11 (10.1%)
Intention/motivation 3 (12.5%) 4 (12.5%) 1 (2.9%) 2 (11.1%) 10 (9.2%)
Imitation/accessibility 3 (12.5%) 4 (12.5%) 2 (5.7%) 0 (0%) 9 (8.3%)
Mixture 0 (0%) 0 (0%) 1 (2.9%) 0 (0%) 1 (0.9%)
Not specified 10 (41.7%) 22 (68.8%) 10 (28.6%) 12 (66.7%) 54 (49.5%)
Purpose of model
Model demonstration 4 (16.7%) 4 (12.5%) 2 (5.7%) 2 (11.1%) 12 (11%)
Theory demonstration 3 (12.5%) 3 (9.4%) 21 (60%) 4 (22.2%) 31 (28.4%)
Phenomena explanation 9 (37.5%) 6 (18.8%) 6 (17.1%) 5 (27.8%) 26 (23.9%)
Policy projection 8 (33.3%) 19 (59.4%) 6 (17.1%) 7 (38.9%) 40 (36.7%)
Determinants
Personal characteristics
Age, sex, location 17 (70.8%) 16 (50%) 4 (11.4%) 4 (22.2%) 41 (37.6%)
Socioeconomic status 19 (79.2%) 9 (28.1%) 4 (11.4%) 6 (33.3%) 38 (34.9%)
Health status 7 (29.2%) 11 (34.4%) 9 (25.7%) 10 (55.6%) 37 (33.9%)
Preference 10 (41.7%) 16 (50%) 12 (34.3%) 4 (22.2%) 42 (38.5%)
Financial cost 9 (37.5%) 9 (28.1%) 4 (11.4%) 2 (11.1%) 24 (22%)
Non-financial cost 8 (33.3%) 2 (6.2%) 7 (20%) 0 (0%) 17 (15.6%)
Neighbour
Health status 2 (8.3%) 0 (0%) 20 (57.1%) 0 (0%) 22 (20.2%)
Behaviour 9 (37.5%) 14 (43.8%) 9 (25.7%) 1 (5.6%) 33 (30.3%)
Global variable
Health status 2 (8.3%) 0 (0%) 5 (14.3%) 0 (0%) 7 (6.4%)
Behaviour 3 (12.5%) 2 (6.2%) 2 (5.7%) 1 (5.6%) 8 (7.3%)
Environment 9 (37.5%) 8 (25%) 3 (8.6%) 5 (27.8%) 25 (22.9%)
4.3.2 Conceptual models driving behaviours
Fifty four out of 109 included studies did not employ a conceptual framework for
their behavioural modelling, with direct use of data on behaviour predominating.
Among those that did, I identified four main types of behavioural drivers: utility
from the concept of economics (24 studies), perception (11 studies, e.g. health be-
lief model, HBM [5]), intention (10 studies, e.g. theory of planned behaviour, TPB
[6]), imitation or diffusing by accessibility (9 studies), while one study [7] jointly
used TPB and utility. The classification was based on both directly indicating by
studies or mentioning relevant keywords.
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Decision driven by utility
These studies were identified by their use of economic terms such as I extracted
the models with economic concepts by identifying the keywords of “economics”,
“utility”, “pay off”, “game”, and “demand elasticity”.
The first variant is the game theoretical approach, which conceptualises the
economic system as interactions between agents or interactions between agent
and the system. The agents in such models are specified as game players; game
players maximise their expected utility given available information from the envi-
ronment under assumptions relating to the likely strategies of the other players.
In vaccination studies, I found a preponderance of simulations based on game
theory, in particular the “vaccination game”. Vaccination games have been used
in discussing voluntary vaccination since this approach was introduced by Bauch
and Earn [8]. There are 7 studies included that implemented the vaccination game
theoretical framework as an agent-based simulation[9–15]. Within this framework,
modellers can also consider incomplete or imperfect information, e.g. Iwamura et
al. [11], in order to model effects such as information passing.
The second variant is the econometric approach, where utility maximisation
is implicit and determinants alter some behavioural response variable (e.g. con-
sumption) according to some regression model [16]. For instance, uses price elas-
ticities of sugar-sweetened beverages (i.e. the percentage change in demand for
a given percentage change in price) to determine agent’s calorie intake, which in
turn, influences body weight. 29% of economic behavioural models were based
on regression analyses of empirical data.
Decision driven by perception or cognition processes
The HBM is directly adapted from cognitive theory in psychology, which studies
the cognitive process during decision making. An HBM agent summarises dif-
ferent aspects of perceptions about outcomes (susceptibility, benefits, severity and
barriers) that, in conjunction with its motivations, trigger a relevant behavioural
action. “Perception” is at the heart of HBM. Identifying perceptions requires cog-
nitive data which is difficult to obtain from observational studies or trials; surveys
specific to the relevant issues are a potential data source to inform HBMs. Karimi
et al. [17] provided an example of how to obtain the perception components by
questionnaire. Alternatively, modellers can set mathematically-formulated fore-
casting rules for these perceptions, e.g. Brailsford and Schmidt [18]. Without de-
tailed perception data, Mei et al. [19] applied fuzzy cognitive maps to estimate the
effects of available variables that might potentially inform perceptions. This ap-
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proach amounts to using machine learning for a model that mimics the cognitive
process to match specific observed behavioural patterns and make predictions.
Five studies relating to disease prevention [20–24], did not mention HBM di-
rectly, yet focused on forming a perceived risk of infection during epidemics. As
such, these models did not fully explore the potential use of the HBM in predicting
behaviour.
Decision driven by the intensity of intention or motivation
The TPB is the most influential behavioural model of health behaviours in the psy-
chology literature. The TPB regards an action as an outcome of an intention which
is a combination of personal attitude, subjective norms and perceived behaviour
control. Attitude refers to the knowledge and belief of an behaviour; subjective
norm is the influence from significant others, neighbours, and social contexts,
which is frequently aliased by peer influence, social influence or social norm; the
last part is a measurement of personal ability to fulfil the plan. I also considered
the social norm approach adopted by Perkins and Berkowitz [25], which focuses
on social influence, to be a special case of the TPB. In addition, the theory of
reasoned action [26], the predecessor of the TPB, was considered.
In total, by using the terms “intention”, “attitude”, “social norms”, “subjective
norms”, I identified 10 studies basing their model on TPB [27–35]. Continuing
the work of Brailsford and Schmidt [18], Brailsford et al. [28] analysed the fea-
tures of the HBM and the TPB, and highlighted the advantages of the TPB in
dealing with empirical data. In practice, they asserted that although HBM is feasi-
ble and comprehensible, some important components, such as clues to action and
health motivation, are abstractly defined, resulting in difficulty in collecting data.
By contrast, TPB components are more aligned with data. Purshouse et al. [33]
demonstrated how to combine the TPB and data using a probit regression model
to map variables in data onto the TPB components. They used survey data to ini-
tialise the baseline population and applied an evolutionary algorithm to estimate
the effect of each variable, instead of using empirical covariates. Zhang et al. [34]
combined the TPB framework with economic features in order to determine TPB
components from aggregated data. For example, price elasticity of foods were a
surrogate of behaviour control in their models.
Four studies [29–32] highlighted peer influence on subjective norms, but ne-
glected the other aspects of planned behaviour. Starting from an a priori specifi-
cation of conceptual components, Fitzpatrick et al. [30] modelled college drinking
mathematically and emphasised what kind of data can support policy making in
the field. Fitzpatrick et al. [31] extended this work using elicited data and policy
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options in their simulations. Collinson et al. [29] modelled the mass media as
primary determinant of social norms influencing protective behaviours during an
epidemic.
Decision driven by imitation and diffusion
The last group of the collected conceptual models has behaviour driven by imita-
tion and diffusion by accessibility. This approach replaces the direct examination
of cognitive process or the belief of behaviour with an indirect link via the pro-
cess of behaviour diffusion. I excluded here studies which had been grouped
under other conceptual models with strong peer influence, such game theoretical
and social norm approaches. Hammond and Ornstein [36] employed the “Follow
the Average” (FTA) model [37] to modelling Body Mass Index (BMI) control be-
haviour. Their agents adjusted their BMI in order to match the average BMI of
their neighbours. The other studies described the health behaviours as communi-
cable diseases. The behaviours can be transmitted through social networks. Mao
[38] modelled spreading word of mouth as an infectious process; agents discuss
with each other and adapt their self-protection against an infectious disease. Gor-
man et al. [39] regarded alcohol consumption as an infectious disease. The model
labelled every agent as susceptible drinker, current drinker (the infected), or for-
mer drinker (the recovered). In addition, I identified models used Huff’s gravity
model [40] to compose the intensity of a behaviour or the accessibility of having
a behaviour. For example, Li et al. [41] weighted food shops by preference and
distance with the Huff model, determining the food choice.
4.3.3 Determinants of behaviour
Investigating heterogeneity is an important use of ABMs. Each agent can behave
differently according to their individual features. The lower part of Table 4.1 shows
the determinants at a personal-, neighbour-, and global-level that were included
in studies on different topics.
Personal features and costs
There was considerable variation in the types of personal traits incorporated into
the ABMs across the different types of behaviour. The use of age, sex, and loca-
tion and socioeconomic status was common in studies of lifestyle choices, less so
in addictive behaviour and healthcare access studies, and rarely used in illness
prevention models. Interestingly, socioeconomic status were considered in 79.2%
of lifestyle models but only 28.1% of addictive behaviour models. This suggests
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that most of addictive behaviour models assumed a less important role for socioe-
conomic status in decisions. Individual preferences or attitudes, summarised the
personal incentives which were not measured by the other variables, were used in
50% of addictive behaviour studies and 34.3% of preventive action studies.
Neighbour influence
Modelling the interactions among agents is a central feature of ABMs. The role
of neighbour traits was included most frequently in the disease prevention mod-
els, and in particular, the infectious disease studies. The main route of influence
in these studies was through individuals using neighbour’s health status to com-
pose their own risk perceptions of a disease. However, neighbour behaviour was
also widely used in lifestyle and addictive behaviour models (40% of each), where
neighbours’ behaviours influenced an agent’s preference for diet, alcoholic drink-
ing, smoking, or drug abuse.
Incorporating neighbour traits, embedding a social network or a grid map
modelling is required so the neighbours can be distinguished from the others. In
terms of conceptual model, neighbour effects can be modelled through features
of opponents of a game in economic model; social norms in the TPB; perceived
threat or cue to action in the HBM.
Global variables
Global variables are overall indices or background societal features in the models.
Few studies included a role for aggregate health status or behaviour at the system
level (6.4% of all studies). I identified some studies where agents adapted to
policy change. In Li et al. [32], intervening on health education changed food
consumption decisions. Likewise, Zhang et al. [34] utilised economic drivers, such
as tax, to influence agents’ food choices. Dray et al. [42] modelled community use
of drug-detecting dogs; drug-using agents would feel threatened by their presence
and reduce drug trading.
4.3.4 Implementation details
I analysed the anatomy of the implementations in the retrieved studies around:
how determinants were summarised and what kind of behaviour was modelled.
The implementation details of each study are detailed in Appendix A.
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Behaviours defined as binary or categorical variables
Forty eight of included studies used binary representations of behaviour, 24 of
them drawing from a Bernoulli distribution. Of these 24, the trigger probability
was often specified from regression analysis of survey data and the behaviours
studied were often around smoking and alcohol drinking behaviour (e.g. Adams
and Schaefer [43], Rahhali et al. [44]). Where empirical data were lacking, theory
was often used to motivate a formula or algorithm for the trigger probability.
Some models of behaviour during epidemics used a modelled perception of risk
to specify the trigger probability (e.g. Zhang Fa et al. [24]).
Triggering behaviour based on exceeding some threshold was also common
here, often using a cumulative exposure. For example, Carley et al. [45] triggered
care seeking behaviour based on the level of illness reached. Barrett et al. [20]
modelled preventive behaviours that were triggered when a disease prevalence
exceeded a threshold.
Game-theoretic approaches have been used to model protective behaviour against
infectious diseases (9 studies). For example, in vaccination games (e.g. Fu et al.
[10] and Iwamura et al. [11]), susceptible agents can decide to be vaccinated or
not depended on their perceived risk of infection and their neighbours’ vaccina-
tion status. This literature tended to focus on theory and use less empirical data.
More than two categories of behaviour have also been considered; using multi-
nomial logistic regression, as in Riva and Smith [46], and using multiple thresholds
their own comparators (see Barrett et al. [21]).
Behaviours defined as continuous variables
Using continuous variables as actions were found in the subjects of lifestyle and
addictive behaviours. In body weight controlling, continuous actions were usually
formulated with mathematical functions. In this approach, Orr et al. [47] built
a body weight control process with hierarchical functions of related behaviours.
They showed the potential of connecting many behaviours in a simulation model.
Dealing with the amount of alcohol drinking and smoking, which were in rich
data settings, tended to employ regression models. While the regression mod-
els required the assumption of linearity, it is difficult to incorporate theoretical
components of interest but lacked data. Representing behaviour by continuous
variables was common for studies of lifestyle and addictive behaviours. In obe-
sity studies, actions were often specified via mathematical functions. For example,
Orr et al. [47] defined a body mass control process using hierarchical functions
of related behaviours, to illustrate this approach to modelling multiple linked be-
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haviours. Studies of alcohol and smoking often had more relevant data available,
and tended to use regression approaches.
Triggering behaviours through optimisation
Triggering an event using optimisation, or more specifically utility maximisation,
is a standard approach in neoclassical economics. I retrieved 17 studies using
this approach in their models , mainly focussing on lifestyle and patient choice.
Behaviours were represented by categorical variables, continuous variables, and
vectors of decisions. Some approaches long these lines use both theory and em-
pirical data. For example, Trogdon and Allaire [48] formulated a utility including
food consumption as a positive term and high body mass as a negative term, in
order to model food choices under a constrained budget. Optimal strategies have
also been considered for game-theoretical behavioural models, where individuals’
utility is dependent on the actions of others.
Triggering actions through imitation or diffusion
Finally, some models directly mapped to the conceptual model of imitation and
diffusion. Instead of generating a variable to represent a decision or a behaviour,
five models used transmission models to propagate decisions between agents
through neighbour imitation. Five models included behaviours changed by imita-
tion or transmission. Hammond and Ornstein [36] modelled a community which
people always try to adjust their Body Mass Index to the average of their neigh-
bours. Perez et al. [49] described a drug user network which drug users change
drug use levels according to their peers. These agents in these models were iden-
tical, however heterogeneity in levels of imitation can be modelled. For example,
Hammond and Ornstein [36] provided a realistic application with more personal
attributes, such as age and sex, showing the feasibility of greater realism.
4.3.5 Roles of data
Table 4.2: The role of data in modelling by purpose of model.
Model demonstration Theory demonstration Phenomena explanation Policy projection Total
N 12 31 26 40 109
Data usage
Drive model by data 4 (33.3%) 3 (9.7%) 14 (53.8%) 25 (62.5%) 46 (42.2%)
Fit model to data 0 (0%) 2 (6.5%) 4 (15.4%) 3 (7.5%) 9 (8.3%)
Both 2 (16.7%) 0 (0%) 8 (30.8%) 10 (25%) 20 (18.3%)
No data involved 6 (50%) 26 (83.9%) 0 (0%) 2 (5%) 34 (31.2%)
Data plays an important role in linking models to reality. I identified two roles
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of data in the studies I included: 1)driving model by the data of the values of de-
terminants (e.g. age) or effects of determinants (evidence from literature to inform
the effect of age on smoking behaviour), 2) and calibration (fitting the behavioural
model to some target data as part of the study, including fitting regression mod-
els). Table 4.2 compares role of data and model purpose.
In theory demonstration, real data were rarely involved. Only five studies
tried to inform their models with empirical elements. Phenomena explanation
and policy projection, included diverse use of data. In the included studies, a third
used regression models to summarise determinants. Often determinant data for
the modelled population was taken from one source, and the regression applied to
these features derived from data from another population (and study). Empirical
covariates for these studies were usually taken from survey data. Where data
was not used, most models assigned determinants either assumed values or used
values related to some simplifying criterion (e.g. yielding an equilibrium).
4.4 Discussion
In this article, I have systematically reviewed the approaches used in agent-based
models to model individual health-related behaviours. I found that use of ABMs
to model health-related behaviour is expanding rapidly, and work is being un-
dertaken across a range of disciplines and with a focus on a number of aspects
of behaviour. The purpose of the modelling varied, with exploration of theoret-
ical models predominating for disease prevention (e.g. vaccination behaviours)
and applied policy evaluation predominating in studies on substance abuse. I
focussed on describing the approaches used for the conceptual frameworks un-
derpinning behavioural models, the determinants of behaviour, and approaches
to implementing behaviours in models; as well as how these varied by topic of
interest.
4.4.1 Conceptual model, determinant, and model implementation
Introducing a conceptual behavioural model before implementation provides the
modeller with a convenient way to clarify and summarise underlying assump-
tions. The major quality of using conceptual models in ABMs is be an imple-
mentation blueprint that allows a modeller to pay more attention to the question
itself and a terminology guideline to fit audiences. For instance, when a model
mentions economic utility, it implies agents are utility maximisers, considering
balance between benefit and cost; modellers should define a utility function or
a pay-off matrix, clarify approaches to projection and time preference, and then
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optimise utility with respect to possible choices. These information are commonly
acquired by people in economics. In terms of implementation, utilising a concep-
tual model does not strictly frame an ABM. Some components of the identified
conceptual models can map to each other by simply carrying different meanings.
For instance, cost in economic approach can be interpreted as a perceived barrier
in the HBM, and a measure of perceived behaviour control in the TPB. Due to the
quantitative nature of economics, economic models are relatively well formulated.
The steps of implementation across my collection are homogeneous but the details
of how to implement were diverse. In addition, there are extensions that can be
utilised for specific details. For example, dynamic programming (policy iteration,
Howard [50]) assists the modeller to introduce future outcomes in the long run;
defining constant variables allow heterogeneity among population. Applying the
concept requires judging the benefits and cost of variables or identifying variables
related to heterogeneity. Once the steps and utility function defined, economic
model can be executed in ABMs. Nevertheless, data from empirical model does
not include benefit/cost judgements.
The TPB and the HBM are fundamentally psychological approaches for health
behaviour. They have lesser linked with model implementation than economic ap-
proach. This has the advantage that various types of implementation are possible,
but the disadvantage that modellers cannot easily find guidelines for implementa-
tion, and the description takes time to be understood by readers. For this reason,
the HBM and the TPB are more typical in health behaviour discussions, but appear
less frequently than economic models in my review. The motivation for applying
HBM and TPB is not in laying out an implementation plan, but in providing rea-
sonable explanation and realistic policy implications. The main difference between
HBM and TPB is that HBM focuses on future outcomes while TPB focuses on cur-
rent status and experience. A secondary difference is that HBM drives a behaviour
mainly by self-oriented variables, while TPB allows influence directly from social
networks and environments. For example, in terms of peer influence in my re-
view, HBM allowed a neighbour’s health status to influence risk perception and
TPB utilised neighbour’s behaviours directly to change agent’s behaviour. Imi-
tation and diffusion models focus on neighbour effect mainly. It can be seen as
a reduced form of the other conceptual models considering neighbour influence.
As the relevant models in my search minimised other determinants and less data
were involved, all of them were theoretical works.
Furthermore, as for the half of identified models which did not specify con-
ceptual models, the appropriateness of using an underlying model or not should
be clarified first. I note that the specification may be less appropriate under the
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following conditions. First, when individual level data are available and manage-
able, a conceptual model might be less important. Second, when the behaviours
involved follow hierarchical decision making steps or case-dependent scenarios,
conceptual models cannot capture the behaviour straightforwardly. For instance,
the body weight control models of Orr et al. [47] and Wang et al. [51] applied
diet behaviour as an upstream process; they needed to balance complexity of each
component for clarity. Last, when the size of upstream parameters is small, a con-
ceptual model may introduce unnecessary complexity and over-parametrisation.
4.4.2 Roles of data
While studies focussed on smoking and drinking made heavy use of survey data
to empirically inform parameters, studies on illegal drug use were more reliant
on theoretical approaches (e.g. theoretical drug markets, see Hoffer et al. [52]) to
model agent behaviours. Data are less available for these behaviours and subject
to recall and social desirability biases, which may account for this.
Using conceptual models seemed favoured when data were lacking. The mod-
els based on empirical studies (e.g. Xenakis et al. [53]) were closely tied to the
behavioural outcomes and determinants data collected. Therefore there was less
flexibility to include further assumptions and sub-models around behaviour. Only
a few papers used conceptual frameworks with components directly linked to data
[17, 28, 33].
4.4.3 A reporting framework for health behavioural modelling?
Our analysis of the methodological and implementation approaches showed high
heterogeneity. Flexibility is an important feature of ABMs, however, identifying
common features and developing a reporting protocol for models of this type
would be useful. Grimm et al. [54] provided a widely-used reporting protocol
to aid communication among modellers, but this was developed by modellers in
ecology, focusing on overall model building process. Smajgl and Barreteau [55]
developed an ABM reporting framework based on work modelling human be-
haviour for environmental studies. In the field of health behaviour modelling, a
specialised protocol that was better matched to the models used and accessible
to those without any computer science background would be more easily applied
and also facilitate working in interdisciplinary teams. Instead of whole model,
I focused on a specific modelled behaviour so I zoomed in by introducing con-
ceptual models. As part of my analysis of model implementation, I categorized
various aspects of their approach (see also Appendix A); this could be used as a
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basis for reporting implementation. The diversity of modelling approaches and
domains remains a challenge for standardized reporting.
4.4.4 Strength & Limitations
My work does have some limitations. The review did not include double data
extraction or sifting, and did not pre-register a protocol. The very diversity in
topic, emphasis and extent of reporting made the job of identifying approaches
used by these studies more difficult. I did a search on broad topic around health
behaviour so the second set of keywords were not strongly defined for specific
behaviours. However, most studies found were within public health. Indeed, I
excluded many studies in drug market that focussed on whole market dynamics
without details of drug use, since these studies did not report on implementation
of behavioural models. Excluding decision support required some judgement:
decision support is usually the ultimate purpose of modelling in public health,
and without some assessment at title/abstract stage, a huge number of studies
would be included for full-text review.
However, this work is the most comprehensive and systematic effort to identify
and classify approaches to modelling behaviour in ABMs applied to questions
around health. I had a transparent and reproducible search strategy and have
gone to some lengths to identify qualitative features and their quantitative patterns
within this literature. Since use of ABM is still emerging in health-related fields,
the relatively new idea is often criticised as a “black box” approach. My work
attempted to “unbox” the models by detailing their components in a systematic
way. I anticipate that my analysis framework may aid translation between agent-
based modelling and health-related research. However, I stopped short of trying
to identify a unified framework to cover all aspects of the studies I found because
of their multifaceted diversity. I aimed to balance breadth and depth of synthesis.
4.5 Summary
In this chapter, I reviewed how to model health-related behaviours in agent-based
modelling. Referring to the purpose of this thesis, the review highlighted 1) con-
ceptual behavioural model can guide the parametrisation as well as data collection
and 2) using data is a key to bring a theoretical work to policy making. Mean-
while, the selected studies also informed this thesis how to include the influences
from upstream determinants and how they fitted to behavioural model.
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This thesis investigates the relationship between TB-related care-seeking and socio-
economic status (SES). I used the setting of Taiwan throughout this thesis. I con-
sidered that Taiwan (1) has the National Health Insurance programme, which
covered the healthcare system universally and collects claim data routinely, and
(2) has an intermediate TB burden with a steady declining trend but without ap-
parent TB-HIV coinfection. Before assessing the SES and TB in depth, this chapter
introduced the population and TB epidemiology in Taiwan with a statistical anal-
ysis of notification data coupling with a synthetic population. I also revealed a
difficulty of TB control in Taiwan due to the ageing population.
The research in this Chapter was published in Ku and Dodd 1.
5.1 Introduction
In 2018, tuberculosis (TB) was still the top infectious killer in the world [1]. The
End TB strategy aims at a 90% reduction in TB incidence rate by 2035 compared
with 2015, but the current global rate of decline of around 2% per year is not
on track to achieve this [2]. Latent TB infection risk accumulates over lifetimes
while TB transmission is ongoing. The prevalence of latent TB infection is highest
1Ku CC, Dodd PJ. Forecasting the impact of population ageing on tuberculosis incidence. PLoS




in older age groups [3], who not only have had the longest exposure, but were
often exposed to higher TB transmission rates in the past. Ageing, with associated
higher rates of progression [4], thus acts as a demographic driver towards higher
per capita TB incidence [5]. In the Western Pacific region, many countries have
their highest [6, 7] per capita TB incidence rates among older age groups [1].
Among Western Pacific region countries, China, Hong Kong (China), Japan, South
Korea, Singapore, and Taiwan are facing both high TB burden and population
ageing [6, 7].
The age profile of future TB incidence is critical for forecasting public health
needs and rational policy design [8]. First, older populations will have higher
TB (and background) mortality rates [9, 10], which implies added difficulty in
meeting treatment success targets. Secondly, older adults have more comorbidi-
ties and more complex health care needs, which may lead to a longer care-seeking
process and higher healthcare expenditure per case. For instance, patients with
chronic lung diseases may have signs or symptoms overlapping with TB, making
correctly diagnosing their TB slower and more costly [11]. Thirdly, the propor-
tion of TB cases in older age groups should inform policy making, for example
suggesting integrating TB care entry points into long-term care programmes, or
through clinician training highlighting older people as a TB risk group with their
own diagnostic and management challenges [11].
Quantitatively forecasting the TB incidence age profile needs combined mod-
els forecasting demographic change and statistical forecasts of age-specific TB in-
cidence. However, a time series analysis producing age-specific forecasts of the
TB incidence has not been published to my knowledge. Use of autoregressive in-
tegrated moving average (ARIMA) models, often including the seasonality of TB
incidence is more common,[12] and comoving time series analysis has been ap-
plied [13] without age-specific information. Age-specific TB incidence modelling,
including the use of age-period-cohort (APC) models, has been undertaken but
without producing epidemic forecasts (e.g. Iqbal et al. [14] and Wu et al. [15]).
Mechanistic mathematical modelling, with age structure, also has the potential
to generate forecasts [5, 16–18]. Among them, Arregui et al. [18] provided the
age-specific incidence forecast and mentioned the effect of population ageing. In-
deed, Arregui et al. [18] developed forecasts for the effects of demographic change
on TB epidemics, focussing on four relatively young countries; our interests are
in developing statistically rigorous time-series approaches and in focusing on an
example of a much older population.
In many settings, the demographic transition and population ageing are out-
pacing declines in TB incidence, so methods to understand and forecast the im-
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pact of changing demography on TB epidemics are needed. I, therefore, devel-
oped a statistical method capturing age-specific incidence trends and forecasting
future epidemics while accounting for demographic change so more methods to
understand and forecast the impact of changing demography on TB epidemics are
needed.
5.2 Methods
Setting and data sources
TB incidence in Taiwan has steadily declined from 64 confirmed TB cases per
100,000 in 2007 to 41 per 100,000 in 2017. Since 2005, the proportion of TB cases
in Taiwan over 65 years of age has been over 50% and increasing. Between 2007
and 2017, the average age in Taiwan increased from 36 to 40, and the proportions
of adults above 65 rose from 10% to 14% [7].
Notification data of culture-confirmed TB cases, excluding foreigners, were
obtained from the Taiwan Center for Disease Control (TCDC) surveillance sys-
tem. Counts were reported by age group, sex, month, and county. Ages were
reported as (0-4, 5-9, ..., 65-69, 70+) years. The demographic data were obtained
from the Department of Statistics, the Ministry of the Interior, Taiwan. These
data included the mid-year population estimators, deaths, migration in single-
year ages, and fertility in five-year age groups (15-19, ..., 45-49). I used data
in 2005-2018 as a training set. The demographic data from 2005 to 2017 were
collected for the population demographic modelling (a shorter period because
of the release schedule). All the training data in this article were published
by the Taiwan officials and free access on the Open Government Data Platform
[https://data.gov.tw]. Also, a processed dataset specified for this study can be
retrieved from https://github.com/TimeWz667/AgeingTB. The usage is licensed
by the Open Government Data License: [https://data.gov.tw/license].
Importantly, I assumed no case detection gaps existed during the time frame
covered by this article. I, therefore, regarded “TB notification” and “TB incidence”
as synonymous with the number culture-confirmed tuberculosis cases notified
during a specific period.
Age-specific incidence modelling and forecasting
I considered annual incidence rates by age and sex. The incidence rates by age
groups and sex were calculated as the yearly notification counts divided by cor-
responding mid-year population estimates. Females and males were analysed
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separately with the same parameterisation. I modelled the incidence rates us-
ing Lee-Carter Models (LCMs) [19] formulated with age and time-varying terms.
The LCMs were initially designed for mortality rate modelling, where they now
predominate. Estimation, forecasting, bootstrapping methods for LCMs are well-
developed.
I performed a likelihood-based LCM estimation, and also the comparable Pois-
son regression:
log(E(yage,t)) = αage + βageκt + log(nage,t) (5.1)
where E(.) is expectation function, t ∈ {2005, . . . , 2018} is the calendar year, yage,t
is incident cases at (age, t), nage,t is population size at (age, t), αage is age effect term,
κt is period effect term, and βage is coefficients adjusting period effects for different
age groups, and age ∈ {0 − 4, 5 − 9, . . . 70+} represents the age categories. To
maintain identifiability, I imposed the constraints Σtκt = 0 and Σageβage = 1.
Given the conditions, I followed the fitting procedure provided by Brouhns et al.
[20] for likelihood maximisation.
Two nested Poisson models, one using an age-profile and a discrete period
effect, αage + κt, and another using an age-profile and a linear effect, αage + tκ ,
were used as comparators. Akaike information criterion (AIC), Bayesian infor-
mation criterion (BIC), and log-likelihood were considered as the goodness of fit
metrics. The definitions of these metrics were identical to the ordinary Poisson
regression model [21]. See Appendix B for the details of the LCM specification in
our approach.
For forecasting, inspired by the Lee-Carter demographic forecasting, I used
Autoregressive Integrated Moving Average (ARIMA) models with drift [22], con-
structed from the LCM period effects. In forecasting, the death and birth processes
applied semiparametric bootstrap sampling [23].
Population modelling and forecasting
I constructed a synthetic population with birth, death and migration processes.
The demographic methods adapted from those used in the Taiwan National De-
velopment Council’s population projection report [7]. The demography was mod-
elled by single age (0-100 years old) and sex. Mortality forecasting used the Lee-
Carter model [19] below 84 years of age, and we used the Coale-Kisker method
[24] for those aged over 85 years in death rate modelling as it was found to have
better reliability for small sample sizes in inferring of death rates. The birth fore-
casting used the fertility rates of women in childbearing ages, from 15 to 49, with
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a modified LCM [25]. For consistency with incidence forecasting, semiparametric
bootstrap sampling was used for deaths and births [23]. The Migration process
was modelled by linear regression with age effects and a linear trend; the forecast-
ing applied residual bootstrap sampling with the age-specific parameters seen in
2017. The forecasts were used for the next step by aggregating to the age groups
as that of the incidence data. See Appendix C for the detailed methodology of the
synthetic population.
Forecasting overall TB incidence
The TB incidence model and the demographic model were built independently.
Forecasts of age-specific TB incidence were weighted by forecasted population de-
mography to obtain forecasts of per capita TB incidence for the whole population.
TB incidence was calculated as per 100,000 rates by given strata. TB incidence rate
reductions were calculated with respect to the incidence in 2015 and presented as
percentages. For simplicity, some results were presented with age groups of 0-14,
15-34, 35-64, and above 65. In forecasting, the 95% prediction intervals and mean
values were computed from 10,000 bootstrap samples. Uncertainty was propa-
gated from every submodel. To compare with the global reduction target of the
End TB strategy [2], I forecasted the incidence until 2035. The milestones of 2020,
2030 and 2035 of the End TB strategy of percentage reductions in per capita-year
TB incidence from 2015 were used as intermediate outcomes.
Incidence attributable to demographic change
I performed a scenario analysis to clarify the potential impact of demographic
change. While forecasting the age-specific TB incidence to 2035, I kept the popula-
tion size and age structure fixed as it was in 2018. This TB incidence was compared
against values including projected changes in population structure by computing
the fraction of total TB incidence attributable to demographic change in each year
as (I1,t − I0,t)/I1,t, where I1,t and I0,t are the incident cases with and without de-
mographic change respectively and t is the calendar year. This corresponds to the
definition of population attributable fraction [26].
All the analyses were performed using R 3.5.1 [27] and analysed/visualised by
R package StMoMo, TSA, ggplot2 [28–30]. See Appendix J for the links of codes and




Figure 5.1 shows the estimators of the Lee-Carter models of the incidence data.
The age effect estimators (αage) suggested the baseline incidence rates increase
with age. In both sexes, the higher levels in age groups older than fifteen years
correspond to higher TB incidence rates. The point estimators of age-period ad-
justments (βage) showed no specific trend. However, there are large uncertainties
for all estimates pertaining to under 15 year age groups due to the small numbers
of notifications observed. The period effect estimators (κt) had nearly constant
slopes with calendar years. Figure 5.1 also demonstrates the forecasting of period
effects with 95% prediction intervals: prediction intervals of both sexes grew at a
constant rate with calendar time. Table 5.1 shows the goodness of fit of the LCMs,
the nested age-period Poisson models, and age-trend Poisson models. In AIC,
BIC and log-likelihood on the training data, the LCM result is preferred over the
other two although it costs a higher degree of freedom. Figure 5.2 shows the two-
way residual plots of females and males by calendar years and age-groups. The
positive and negative values were presented in red and blue blocks, respectively.
As the blocks are reasonably random coloured, I identified no specific pattern by
calendar years and age-groups. See Appendix D for the details of the goodness of
fit, and residuals plots.








































































































































































































Figure 5.1: Lee-Carter model fitting and forecasting of the annual TB incidence.
(Data: 2005-2018, Forecasting: 2019-2035). 95% confidence intervals of estimators
and prediction intervals of forecasts were calculated through bootstrapping with
10,000 sample size.
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Table 5.1: Summary of model comparison.
Age-Trend Age-Period Lee-Carter Model
Model family Poisson Regression
Period effect Linear Discrete Discrete
No. observations 420 420 420
No. parameters 32 56 86
Log(Likelihood) -1855 -1819 -1682
AIC 3773 3751 3531
BIC 3902 3977 3871
AIC: Akaike information criterion, BIC: Bayesian information criterion
Figure 5.2: Residual plot by age and calender year.
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5.3.2 Population forecasting
Figure 5.3 shows the demographic change from 2005 to 2035. In Figure 5.3-A, the
population will reach a maximum of 23.6 million in 2023, and will start shrinking
to 23.2 million in 2035. The proportion of the population aged over 65 is increasing
across the period and will reach 27% in 2035. The proportion of the population
aged under 15 is declining to around 11%. Figure 5.3-B compares the age structure
of the Taiwanese population in 2018 and 2035, highlighting the population ageing.
Figure 5.3: Demographic change. (Data: 2005-2017, Forecasting: 2018-2035)
Incidence forecasting and age structure
Figure 5.4 demonstrates the trends of the population TB incidence rate and TB
incidence rates by age-group (< 15, 15− 34, 35− 64, 65+). The forecast in Fig-
ure 5.4-A suggests that the TB incidence in 2035 will be 22 (95% Prediction Interval
(PI): 19-25) per 100,000. The overall incidence reduction will reach 54% (95% PI:
45%-59%) in 2035, which is 37% short to reach the goal of the End TB Strategy.
Figure 5.4-B shows the age-specific incidence rates will have 60% to 80% reduc-
tions from 2015 to 2035 apart from the 5-9 group. The rate reductions in most
age groups will be higher than the forecast reduction of 44% in the whole popu-
lation. Figure 5.4-C shows the overall incidence rates by age group as a stacked
histogram. The TB incidence rates from age groups below 65 will be gradually
decreasing whereas the above 65 will nearly stay constant from 2018 to 2035. Fig-
ure 5.4-D shows the proportion of TB incidence in each age group. The proportion
among adults aged over 65 years will reach 68% (95% PI: 67%-69%) and 79% (95%
PI: 78%-81%) in 2025 and 2035, respectively. In 2035, more than 97% of incident
cases will occur among those aged 35 years or older, indeed the contribution from
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Figure 5.4: TB incidence rate forecasting. A. Overall incidence rate per 100,000-
year. In the forecasting, dashed line features the mean values and the shaded area
is 95% prediction interval. B. Incidence rate reductions by five-year age groups
during 2015-2035 with 95% prediction interval. C. Incidence rates attributed to
age groups. D. Proportions of age groups in Incidence cases.
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Figure 5.5: TB incidence with and without demographic change. (ribbons show
95% prediction intervals)
Table 5.2: Summary of reductions in TB incidence with and without demographic
change.
Year
Percentage reduction in per capita TB incidence
from 2015 (mean and 95% PI):
Percentage of total TB
incidence attributable to
demographic change





2020 23.1% (18.2%, 27.2%) 26.6% (22.2%, 30.8%) 4.6% (1.6%, 7.5%)
2025 35.2% (27.2%, 40.7%) 47.0% (41.0%, 52.2%) 18.3% (15.5%, 21.2%)
2030 45.0% (35.9%, 50.5%) 61.6% (56.0%, 66.4%) 30.0% (27.3%, 33.0%)
2035 53.7% (44.5%, 58.9%) 72.1% (67.1%, 76.1%) 38.8% (36.1%, 41.7%)
PI: prediction interval
Figure 5.5 shows the forecast incidence rates with and without demographic
change. In the scenario without demographic change, the forecast suggests that
the incidence in 2035 will be around 13 per 100,000 compared to 23 with demo-
graphic change and the 90% reduction target of 4.5 per 100,000. The 95% predic-
tion intervals for forecasts with demographic change continuously expand year
by year, whereas without demographic change they converge to a constant width
within five years. Table 5.2 shows the impact of demographic change. Up to 2020,
TB incidence rates will have 23% and 27% reductions with and without demo-
graphic change respectively. Considering the demographic change, the annual
incidence rates are projected to reduce by 54% (95% PI: 45%-59%) from 2015 to
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2035; without demographic change, the reduction will be 72% (95% PI: 67%-76%).
In both scenarios, the trends of annual incidence rates showed diminishing reduc-
tions to the time scale. In 2035, the forecasts suggested that 39% (95% PI: 36%-42%)
of incident TB cases can be attributed to demographic change.
5.4 Discussion
A substantial proportion of tuberculosis (TB) incidence in Taiwan is among people
aged over 65 years. Social and economic development typically bring reductions
in TB incidence but also reduced birth and death rates and population ageing.
This study provides a novel investigation into the potential impact on TB incidence
from population ageing using statistical modelling and forecasting. Current trends
of TB incidence decline and demographic change suggest TB incidence rates in
Taiwan will decrease to 25 per 100,000 by 2035. This represents a 45% reduction
since 2015, missing the End TB goal of 90% reductions in TB incidence rates. I
have shown that higher age-specific incidence rates in older age groups can mean
that population ageing acts against reductions in TB rates, with TB incidence in
2035 projected to be 39% higher than without demographic change.
Previous studies have employed statistical methods either to forecast TB inci-
dence, [12, 13, 31, 32] or to analyse patterns by age using age-period-cohort (APC)
models, [14, 15] but I are the first study to statistically forecast age-specific TB inci-
dence combining. Some transmission modelling studies [16, 18] have explored is-
sues related to age-structure, and Arregui et al. [18] generated forecasts. However,
the fitting in Arregui et al. was not likelihood-based and did not use age-specific
TB data, and so could not evaluate age-specific goodness of fit for TB projections
or compare alternative models with conventional metrics. I made novel use of
Lee-Carter models (LCMs), [19, 22] which employ an elegant low-dimensional de-
composition of age-specific rates to model trends and overall shape. LCMs were
originally introduced for mortality rate modelling and are now the dominant ap-
proach, but have been applied elsewhere. Within demography, Hyndman [25] and
Rueda-Sabater and Alvarez-Esteban [33] used LCMs to forecast the fertility rates,
and Cowen [34] fitted LCMs to abortion rates. Kainz et al. [35] modelled chronic
kidney disease prevalence as rate data, and Yue et al. [36] modelled cancer inci-
dence and mortality. However, I am the first to apply LCMs to TB, finding they
fitted better than Poisson Age-Period models. My approach offers a generalizable
and easily-implemented method for forecasting age-specific TB incidence and the
impact of demographic change on total TB incidence.
In my model fitting results, the age effects (αage) demonstrated the TB inci-
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dence rates positively correlated with age in both females and males. The period
effect estimators (κt) were almost linear despite not assuming linearity in the LCM
formulation. The declines may reflect improvements in infection control and case
detection and the declining latent TB prevalence in each age group. Improvements
in infection control and case detection both reduce the force of infection that will
induce further TB incidence. For latent TB, which is accumulated during one’s
lifetime and depends on historical TB prevalent TB in history, different cohorts
will have different prevalence. As TB incidence has been declining, the latent TB
prevalence in recent cohorts will be lower than in historical cohorts at the same
age. Lastly, the age-period interaction terms (βage) were used to demonstrate how
the incidence rate reduced differently in each age group, although no overall pat-
tern was identified. The variance of the estimators in young people was larger
because the only around 1% of incident TB (<100 cases every year in the recent
decade) were from people below 15 years old.
For Taiwan and many other high-income settings in the Western Pacific region,
TB notifications are thought to parallel TB incidence with only a small gap. [1, 37]
Taiwan lacks survey data (e.g. capture-recapture studies) to directly inform on the
magnitude of this gap. In settings where this gap is larger and changing over time,
interpretation of TB notification data is more problematic, and notifications may
not be a good proxy for incidence. Even in a declining TB epidemic with evolving
case-mix, it is possible that case detection may change differently over time in
different age-groups; we have not attempted to include such effects. Taiwan does
not have United Nations Population Division demographic forecasts, hence my
bespoke demographic modelling. For most nations, these forecasts could be used
‘off the shelf’. I have presented results on percentage reductions in both per capita
TB incidence rates and in total TB incidence (e.g. Table 2), which are similar
because of Taiwan’s small projected population change over the period considered;
this may not be true in all settings. Later, in Section 8.7, I will measure the case-
detection gaps in Taiwan with a modelling approach.
The decline in TB incidence in Taiwan probably has multiple contributory
causes, including improvements in TB control, socio-economic development, and
the reductions in the prevalence of latent TB as a result of declining transmission.
For an infectious disease like TB, reduced transmission can amplify and sustain
over time changes in underlying causative factors, complicating their analysis.
The low TB rates in children aged under fifteen may reflect low exposure to TB
in this group or potentially lower rates of case detection. My assessment of the
impact of population ageing on TB incidence and case-mix has particular current
relevance to many WHO Western Pacific region countries [1] and will be relevant
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to many more countries and regions in the future. My analysis could provide a
template for analysts who wish to explore issues related to future TB incidence
and demography where age-specific data are available.
My analysis accounted for cohort propagation of latent tuberculosis infection
(LTBI) in a phenomenological way. LTBI represents accumulated lifetime risk of
infection by exposure to active tuberculosis disease. Older individuals in most
settings have higher LTBI prevalence due both to longer cumulative exposure and
(in declining epidemics) exposure to a higher mean infection rate over their life-
time. The ageing through of these LTBI positive cohorts thus generates a secular
time trend in reactivation disease rates at a particular age. My approach does not
explicitly model LTBI prevalence, because this would introduce additional param-
eters and, without LTBI data, identifiability issues. However, LTBI cohort effects
are accounted for in my current approach indirectly by modelling the secular
trends in age-specific incidence rates.
Another limitation of our approach is that it would fail to account for non-
linear threshold behaviour, such as during outbreaks. However, in many high-
income settings (including Taiwan), the steadily declining tuberculosis incidence
implies the net reproduction number is below one. It is worth noting that accord-
ing to Taiwan CDC surveillance, in 2005, 0.72% of TB cases in Taiwan were coded
as HIV; neglecting HIV is unlikely to have impacted our results.
Extending the model by adding exogenous variables is possible. My analysis
did not address the impact of other variables for simplicity and clarity. Important
predictors could include socioeconomic status and comorbidities such as diabetes
mellitus. [38] However, projections would require additional time-series analysis
to forecast these explanatory variables.
Older age as a risk factor for TB disease has perhaps been under-explored
since age is not a modifiable risk factor, and since in most current high-burden
settings populations and the typical age of TB cases are fairly young. My result
that population ageing will act to slow declines in TB incidence tallies with that
of Arregui et al. [18], obtained for different settings using very different methods,
and quantifies the magnitude of this effect However, the importance of older age
groups to TB control is already evident in many Asian populations, [16] and this
will be an increasingly widespread facet of global TB control if reductions in in-
cidence continue and accelerate in the future. Older populations will also have
their own particular challenges in terms of access, diagnosis and comorbidities
complicating their care. Public health planning to develop adapted strategies for
care and control to meet these changing population needs is essential.
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5.5 Conclusion
The Lee-Carter model provides a tool to project age-specific tuberculosis incidence
and hence forecast overall TB incidence while accounting for demographic change.
In Taiwan, population ageing may slow the decline of TB incidence by 39% over
the period 2015 - 2035. TB care and control programmes will increasingly need to
address the needs of older adults, who will comprise a growing majority of the
TB epidemic.
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Tuberculosis (TB) is a curable infectious disease but has become the world’s lead-
ing infectious killer with unacceptably slow progress towards meeting global tar-
gets laid out in the End TB strategy [1]. These targets include the elimination of
catastrophic costs due to TB [2], in recognition of the financial impact TB illness
and care-seeking imposes on households [3]. One of the key gaps in TB control
is the “missing millions”: 4 in 10 people developing TB globally are either not
diagnosed and treated, or are not notified to national TB programmes (NTPs) [1].
Understanding the health system pathways of patients who are seeking care for
TB is key in identifying low-hanging fruit for TB control: programmatic shortcom-
ings that mean patients are either missed, not notified, or incur ruinous expense
in their efforts to obtain care.
Cascade of care analyses for TB have addressed the drop-offs at different stages
from those needing treatment through to those completing treatment for active TB
[4], and for latent TB infection [5]. This work has recently been extended with
the introduction of patient pathway analysis (PPA) for TB [6], which provides a
standardized analysis approach for drawing together data from different sources
to identify misalignment between capacity for TB diagnosis and treatment, and
patients’ preferences in seeking care [7]. Initial work was undertaken in 5 countries
[8–12], and notably found low coverage of diagnostic capacity for TB at facilities
where patients typically first present [13]. This work has argued that more needs
to be done to ‘meet the patients where they are’ [14], in line with the patient-
centred care pillar of the End TB strategy.
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However, work has so far relied on cross-sectional and aggregate data, mean-
ing it has not been able to track the pathways of individuals as they interact with
the health system. This makes it hard to investigate the key issue of delays prior
to diagnosis. It also means it is not possible to understand patterns of refer-
ral between levels of facilities, the true complexity and heterogeneity of patient
pathways, or the factors that influence these. Going beyond capacity alignment
requires routine individual-level data with high coverage. Any data that includes
individuals’ interactions with the health system before a diagnosis of TB requires a
methodology to interpret these events as related to TB care-seeking in light of their
characteristics and timing. In this study, I develop a generalizable methodology
for individual patient pathway analysis (IPPA) that makes use of health insurance
data and apply it to Taiwan to construct and analyse the care pathways of patients
who ultimately were diagnosed and treated for TB.
6.2 Methods
6.2.1 Setting
TB incidence in Taiwan has been declining: from 64 TB cases per 100,000 in 2007
to 39 per 100,000 in 2018. Taiwan is a high-income country and its healthcare
system fully integrated with the National Health Insurance (NHI) programme.
The NHI is compulsory (over 98% enrollment in 2017), and covers most essential
healthcare services in both public and private sectors. The National Health Insur-
ance Research Database (NHIRD) comprises records of all healthcare claims (e.g.
diagnostics and medications) funded by the NHI.
6.2.2 Data
This chapter used a longitudinal dataset from the National Health Insurance Re-
search Database (NHIRD). The dataset was released with a simple random sam-
pled one million population based on the registration between 1996 and 2000, and
its representativity had been validated with age and sex distributions in general
population [15]. From the one million sampled individuals, this chapter used the
individual characteristics (age, sex), healthcare records, and healthcare facilities
visited from 2000 to 2010 for the analysis. The main reason for clinical visits and
clinicians’ diagnoses upon prescription are recorded in the NHIRD using the In-
ternational Classification of Diseases, Ninth Revision, Clinical Modification (ICD-
9-CM). Appendix F lists the details of the dataset and describes the raw data.
The study was approved by the ethics committees of the University of Sheffield.
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The NHIRD was provided by the National Health Insurance Administration, Min-
istry of Health and Welfare and managed by National Health Research Institutes
(Registered number 100290). The interpretation and conclusions contained herein
do not represent those of National Health Insurance Administration, Ministry of
Health and Welfare or National Health Research Institutes.
6.2.3 Construction of individual patient pathways
To construct individual patient pathways, I restricted my sample to patients who
between 2003 and 2010 met previously validated criteria for TB [16]. To include
care-seeking prior to diagnosis, I used their records from 2000 to 2010 and followed
a three-step process. First, I introduced a dynamic three-dimensional patient state
with dimensions related to evaluation, treatment, and clinician consideration of
related illnesses (all with default values of zero). Secondly, this state was used to
parse sets of records into separate episodes of TB-related care (periods with ≥ 1
state non-zero; see Figure 6.1). Thirdly, the state values were used to interpret
and label the stages of each episode, resulting in a pathway. The Taiwan CDC
guidelines [17], WHO guidelines [18], and expert opinion on current clinical prac-
tice were used to define the algorithm for state transitions and stage labelling (see
Table 6.1). In the rest of this section, I describe this approach in more detail.
The evaluation dimension represents the use of diagnostic procedures relevant
to differential diagnosis of TB. Evaluation tools were ranked as probably for TB
and possibly for TB according to how specific their use was to TB. Evaluation
possibly for TB was triggered by various tools for examining the respiratory sys-
tem and antibiotics for pneumonia. Evaluation probably for TB was triggered by
the use of tools including chest computed tomography scan, chest x-ray, acid-fast
bacteria culture, Mycobacterium tuberculosis culture, and tuberculin skin tests (see
Appendix E for detailed definitions).
The treatment dimension represents the use of anti-TB drugs. In accordance
with Taiwan CDC guidelines, anti-TB treatment requires more than two types of
anti-TB drugs prescribed continuously for at least four weeks. Treatment was
either first-line or second-line according to the drugs prescribed (see Appendix E).
The related illnesses dimension captures potential clinician consideration of
alternative diagnoses. Increased values were triggered by features including ICD-
9-CM codes corresponding to acute respiratory infections, chronic lung diseases,
and nontuberculous mycobacterial infections.
Each state’s value could return to zero after a ‘time-out’ period if no relevant
trigger records occurred. A patient’s treatment state also returned to zero after
treatment completion. The choice of time-out sets a memory time-scale beyond
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which records no longer influence a patient’s state. The default time-out was 60
days, and sensitivity analyses used 30, 90 and 120 days.
Care-seeking episodes were defined as collections of records including anti-
TB treatment (excluding exploratory treatment), during which a patient’s state
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Figure 6.1: Patient pathway construction. Bars show patient states in three do-
mains where non-zero. Background colours show the stage label within a path-
way. (A) Basic patient pathway: (1) corresponds to initial care-seeking; (2) and
(3) represent escalating clinical consideration of TB; (4) is treatment initiation; and
(5) represents diagnostic evaluation while on anti-TB treatment. (B) Separated
evaluation series. Considering there is no count in Related illness dimension the
evaluation (6) would be dropped as separated by longer than 60 days and the
pathway would begin at (7). (C) Interrupted evaluation. With evidence of clin-
ician consideration of a related illness, the evaluation at (8) is included in the
pathway.
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all dimensions equal to zero (see Figure 6.1-A). Episodes could include records
related to care-seeking prior to TB diagnosis. Without evidence that alternative
diagnoses were being actively considered (i.e. related illness state and evaluation
state both return to zero), prior evaluations are dropped from an episode (Fig-
ure 6.1-B). If there was evidence of ongoing consideration of alternative diagnoses
to TB (non-zero related illness state), diagnostic procedures relevant to TB would
be included in the episode even if the evaluation state returned to zero in the
interim (Figure 6.1-C); this is termed an ‘interrupted evaluation’.
To complete pathway construction, time within parsed episodes was labelled as
one of four main stages according to the values of the state (Figure 6.1, background
colors): Waiting Stage (before evaluation), Evaluating Stage (under evaluation for
possible TB), TB Detecting Stage (under evaluation for probable TB), and Treating
Stage (on TB treatment). Figure 6.2 shows all possible flows between states of my
patient pathways.



















Figure 6.2: Stages/states of patient pathways.
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Table 6.1: Definitions and descriptions of stages/states
Stage State Description
Waiting Waiting
Waiting for first TB-related
evaluation or treatment
Evaluating Evaluating
Being evaluated by procedures
which can narrow the possibility




Previous evaluations do not
narrow the possibility down to TB
because of (1) comorbidity, (2)
false negative, or (3) self-referral.
Re-Evaluating
Visiting Evaluating State after
Interrupted Evaluation
TB-Detecting TB-Detecting
Being evaluated by procedures
which can identify TB





Being treated with first-line TB
regimen
Treatment change
Switching between two TB
treatments or temporal treatment




Being treated with second-line TB
regimen or any regimen after
Treatment change
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6.2.4 Analyses of individual patient pathways
Individual patient pathways were analysed to understand the coverage of services
at different levels of the health system and referral patterns between them. Hospi-
tals were classified into one of four levels following a standard classification (A for
primary care/ general practice; B for regional hospitals with inpatient capacity; C
for larger district hospitals; D for large hospitals with a range of specialists). I
then calculated the coverage of each service at a given level of facilities (the pro-
portion of facilities of the given level where the service was available), as well as
the patient access to these services (proportions of levels of hospitals where pa-
tients initially sought care). I summarized these metrics with a modified version
of the PPA visualization introduced by Hanson et al. [7] I also visualized the
flow of patients between health service levels by pathway stage. I computed the
distribution of delays from initial care-seeking to first reaching facility with anti-
TB treatment capacity, to first reaching the facility where ultimately treated, and
treatment initiation.
The heterogeneity in patient pathway complexity and time spent in different
stages was visualized by sequence frequency plots, separately for sub-pathways
leading up to, and following, treatment. To summarize time taken to reach a given
stage of care, I also visualized the number of pathways reaching a given sub-
stage by time after initial care-seeking. I calculated the proportions: of all clinical
encounters among the pathways with the 10% least common sequence patterns;
of these pathways for which treatment started over one year after initial care-
seeking; of all pathways experiencing interrupted evaluation. Finally, I analysed
risk factors, including age, sex, area, comorbidity and hospitals at initial care-
seeking, for interrupted evaluation using logistic regression.
The pathway extraction was performed in Python 3.6; statistical analysis and
visualisation in R 3.5.1 with ggplot2. Appendix G for implementation details,
links in Appendix J for online documents and related code repositories.
6.3 Results
6,258 patients met my criteria for TB between 2003 and 2010. My algorithm gen-
erated 7,255 distinct pathways for these patients: 88% of patients had only one
pathway. The use of longer timeouts resulted in fewer distinct pathways: 7,528
for 30 days, 6,963 for 90 days, and 6,831 for 120 days (See Appendix H, sensitivity
analysis). Table 6.2 demonstrates the demographies of selected patient pathways
and notification data. In the patient pathways, males contributed 70% of patient
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pathways; 50.5%, 49%, and 0.5% of pathways were from those aged over 65, be-
tween 15 and 64, and below 14, respectively. The age and sex distributions of
patient pathways were close to that of notification data in both 2005 and 2010.
Table 6.2: Demography of selected patient pathways compared with the notifica-





All 7255 (100%) 16472 (100%) 13237 (100%)
Sex
Female 2158 (29.7%) 5069 (30.8%) 4106 (31.0%)
Male 5097 (70.3%) 11403 (69.2%) 9131 (69.0%)
Age
<15 36 (0.5%) 139 (0.8%) 97 (0.7%)
15-64 3558 (49.0%) 8064 (49.0%) 6192 (46.8%)
≥65 3661 (50.5%) 8269 (50.2%) 6948 (52.5%)
6.3.1 TB-related services coverage and assess
Coverage and access by level of the health system are shown in Figure 6.3-A. This
diagram was adapted from Hanson et al. [7], composed of TB service availabil-
ities and accessibilities at first care-seeking attempts by different hospital levels.
From Figure 6.3-A-1, the sizes of bars indicate the proportions of hospital levels at
initial care-seeking. That is, there were 43%, 17%, 23% and 17% patient pathways
initialised in level A to D, respectively. Figure 6.3-A-2 reveals the percentage of
hospitals in each level that can provide the TB service of Evaluation possibly for
TB. Taking Figure 6.3-A-1 and Figure 6.3-A-2.1 together, Figure 6.3-A-2.2 assesses
how many patient pathways can access the TB service at their initial care-seeking.
Namely, 7.3% of the patient pathways started with level A hospitals and can ac-
cess the service at their initial care-seeking. In summary, initial care-seeking was
most common at level A, but further evaluations and treatment rarely occurred at
this level; only a minority of these facilities (around 15%) had the capacity for TB
diagnosis and treatment. Coverage at facility levels higher than A exceeded 93%.
Figure 6.3-B shows the associated flow of patients between levels of the health
system, with an upwards flow across all stages. Around 50% of patient pathways
began at levels A or B (36% where TB treatment was unavailable), but over 74% of
pathways initiated treatment at levels C or D. Figure 6.4 shows the associated flow
of patients between inpatients and outpatients, with an upwards flow across all
stages. Around 85% of patient pathways were started as outpatients, while 40%
of pathways initiated treatment as inpatients. There were 10% of pathways started
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TB detection as in-patients but treated as out-patients.
A 1 2.1 2.2 3.1 3.2 4.1 4.2
Level Initial care−seeking Evaluations possibly for TB Evaluations probably for TB TB treatment





































































Figure 6.3: Alignment between the capacity for TB diagnosis and treatment, and
patients’ preferences in seeking care. Hospital levels: A for primary care/ general
practice; B for regional hospitals with inpatient capacity; C for larger district hos-
pitals; D for large hospitals with a range of specialists. (A) Coverage of and access
to TB services at different levels of Taiwan’s health system modified. This panel is
a modified version of the visualization introduced by Hanson et al. [7] Coverage
is the proportion of facilities at that level offering a service; access is the product
of coverage and the fraction of patients seeking care at that level. (B) Patient flows
between levels at each stage, including clinician- and self-referral (vertical heights
of bands are proportional to numbers).
Delays from initial care-seeking to: a facility offering TB treatment; the fa-
cility ultimately providing treatment; and to treatment initiation are shown in
Figure 6.5. 16% of pathways initiated treatment at their initial visit. By day 60,
TB treatment was available for 90% of the pathways and 80% had arrived at the
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facilities ultimately providing their treatments. By day 180, 84% of pathways had
started treatment. The median system delay (from initial care-seeking to treatment




























Figure 6.4: Patient flows between outpatients/inpatients at each stage, including
clinician- and self-referral (vertical heights of bands are proportional to numbers).
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Hospital which can provide TB treatment
Hospital which initialises TB treatment
Treatment start
Figure 6.5: Delays from initial care seeking. The curves indicate the proportion
of pathways by time that have: reached hospitals providing TB treatment (red);
reached the hospital which ultimately initiates their TB treatment (blue); and
started treatment (green). The vertical line on day 41 denotes the median sys-
tem delay.
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6.3.2 Heterogeneity among patient pathways
The typology of pathways before and after treatment start is shown in Figure 6.6.
Before treatment starts, simpler pathways were most common. Second line anti-TB
treatments (including fluoroquinolones) were used in 34% of pathways. However,
the most complex pathways (i.e. pathways with the rarest 10% of sequence types,
see Figure 6.6), exhibited intricate patterns of evaluation interruptions and re-
evaluations; 100% of these pathways included interrupted evaluation.
B. During Treatment
A. Before Treatment
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Figure 6.6: Cumulative pathway typology before and after treatment initiation.
The aggregated number of pathways with a given sequence of stages (y axis) ver-
sus the proportion of their time in each stage (x axis). (A) Sequence patterns before
treatment initiation (B) Sequence patterns from treatment initiation to treatment
outcome. Completed = treatment period longer than 180 days. Censored = end
with the end of data time frame. LTFU = lost to follow-up, incompleted treatment
for no reason. See chapter text and Table 6.1 for stage definitions.
The pattern of delays from initial care-seeking to later stages of care is shown
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in Figure 6.7, truncated at one year. The long tail of 7% of pathways yet to start
treatment a year after initial care-seeking is clearly visible. One year after initial
care-seeking, 21% of pathways were still on TB treatment (40% of these on second-
line treatment), 41% had completed treatment, 18% were lost to follow-up, and
10% of patients had died. 55% of the 10% most complex pathways were yet to





0 100 200 300

























Figure 6.7: Time from initial care-seeking to given care stage. Completed: treat-
ment period longer than 180 days. Censored: end with the end of data time frame.
LTFU: lost to follow-up, incompleted treatment for no reason. See chapter text and
Appendix E for stage definitions.
6.3.3 Interrupted evaluation
Interrupted evaluation occurred in 16% of all pathways, but these pathways in-
cluded 48% of all visits/records and comprised a majority of the most complex
and delayed pathways (see above). The median delay from initial care-seeking
to treatment initiation in pathways with interrupted evaluation was 313 days (in-
terquartile interval 164 - 607 days). Table 6.3 shows that pathways for patients
aged 65 or older, odds ratio (OR) 2.4 (95% confidence interval (CI): 2.1 - 2.8) com-
pared with patients aged 15-64, those with chronic lung conditions, OR 1.9 (95%
CI: 1.6-2.2), and pathways, and which included 2003 (the year of the severe acute
respiratory syndrome (SARS) epidemic), OR 2.3 (95% CI: 2.0-2.7), were signifi-
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cantly more likely to experience interrupted evaluation. Pathways for patients
with diabetes mellitus and who sought care at hospitals higher than Level A were
significantly less likely to include interrupted evaluation, OR 0.64 (95% CI: 0.53-
0.78).
Table 6.3: Logistic regression analysis of risk factors for interrupted evaluation.
Number IE (%) Crude OR(95%CI) Adjusted OR(95%CI) P(Wald’s test) P(LR-test)
All 7255 1125(16%)
Age <0.001
< 15 36 4(11%) 1.18 (0.41,3.34) 0.97 (0.33,2.8) 0.952
15− 64 3558 342(10%) reference
≥ 65 3661 779(21%) 2.54 (2.22,2.91) 2.42 (2.1,2.8) <0.001
Sex 0.817
Female 2158 315(15%) reference
Male 5097 810(16%) 1.11 (0.96,1.27) 0.98 (0.85,1.14) 0.817
Area <0.001
Center 1332 234(18%) reference
East 419 76(18%) 1.04 (0.78,1.38) 1.12 (0.83,1.51) 0.458
Kaohsiung city 1507 267(18%) 1.01 (0.83,1.23) 1.09 (0.89,1.33) 0.419
North 740 98(13%) 0.72 (0.55,0.92) 0.77 (0.59,1) 0.054
South 1087 179(16%) 0.93 (0.75,1.15) 0.95 (0.76,1.19) 0.672
Taipei city 2170 271(12%) 0.67 (0.55,0.81) 0.75 (0.62,0.92) 0.005
Comorbidity
CLC 1192 277(23%) 1.86 (1.6,2.17) 1.91 (1.62,2.24) <0.001 <0.001
DM 1191 136(11%) 0.66 (0.55,0.8) 0.64 (0.53,0.78) <0.001 <0.001
HIV 30 4(13%) 0.84 (0.29,2.4) 1.52 (0.51,4.49) 0.451 0.472
Initial level at <0.001
A 3104 539(17%) reference
B 1275 203(16%) 0.9 (0.76,1.08) 0.78 (0.65,0.93) 0.007
C 1644 210(13%) 0.7 (0.59,0.83) 0.68 (0.57,0.82) <0.001
D 1232 173(14%) 0.78 (0.65,0.94) 0.75 (0.62,0.92) 0.005
Pathway
overlaps 2003 2110 493(23%) 2.18 (1.91,2.48) 2.32 (2.02,2.66) <0.001 <0.001
OR: odds ratio, CI: confidence interval, LR-test: likelihood-ratio test, IE: Interrupted Evaluation,
CLC: chronic lung condition, DM: diabetes mellitus, HIV: human immunodeficiency virus
Comorbidities and Pathway overlaps 2003 are binary variables, applying ’None’ as the reference
groups. Crude and adjusted ORs were calculated from the results of univariate and multivariate
logistic regressions respectively.
Figure 6.8 reveals the distribution of healthcare visits before treatment initia-
tion by the Lorenz curve [19] regarding chronic lung condition and IE. From left
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to right patient pathways were sorted by the number of healthcare visits, and the
y-axis cumulated the number of visits. Three-quarters of patient pathways shared
only one-quarter of the visits. However, the 10% patient pathways with the most
visits shared 50% of all healthcare visits. The two colour curves feature propor-
tions of the attributes of CLC and IE by moving averages through every 10% of
patient pathways. The proportion of IE shows that 77% of the right 10% of path-
ways experienced IE before treatment initiation. The curve of patients aged 65
showed the older patient needed more healthcare visits to treatment start. The
curve of CLC shows a U-shape, which is relatively common in the pathways with
very low and very high visits. However, the trend of CLC curve, framed between
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Figure 6.8: Lorenz curve of visits during evaluation
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6.4 Discussion
In this study, I constructed individual patient pathways of tuberculosis care-seeking,
diagnosis and treatment, using routine national health insurance data in Taiwan.
To do this, I developed a generalizable method to algorithmically interpret insur-
ance claim records in light of the context of previous and future events on the
pathway. This approach was necessary in order to determine whether healthcare
utilisation prior to eventual diagnosis was in fact related to a given episode of
TB episode. Even in this well-resourced setting, there is low apparent coverage
of TB care capacity at the lowest-level facilities where patients most commonly
started seeking care, and substantial heterogeneity in the duration and complexity
of TB-related care pathways.
The most complex patient experiences and the most prolonged delays prior to
treatment were associated with what I have termed interrupted evaluations. These
pathways are those that include unusually long delays between the first relevant
diagnostic procedure and TB diagnosis, as well as evidence that alternative causes
of disease are being considered. Interestingly, my regression analysis showed that
patients with diabetes mellitus (DM) were significantly less likely to experience
interrupted evaluation, perhaps indicating an awareness among clinicians of DM
as a risk factor for TB. However, patients whose care-seeking overlapped with the
2003 SARS epidemic, patients who had chronic lung conditions, or patients aged
65 or above were all significantly more likely to experience interrupted evaluation.
The SARS epidemic may have shifted attention towards alternative aetiologies of
respiratory symptoms, as well as potentially generating increases in case-load that
distorted usual practice. Comorbid chronic lung disease may have obscured TB
symptoms, which would be unfortunate as chronic lung disease (e.g. chronic
obstructive pulmonary disorder) shares risk factors with TB and may causally
increase the likelihood of TB and worsen outcomes [20–22]. Lastly, differential
diagnosis of TB may be more complex for older adults, and successful treatment
is more challenging [23].
In addition to service coverage, I was also able to analyse the referral flows
of patients between different levels of the healthcare system. I found a general
trend for escalation in level from initial care-seeking, with most patients seeking
care at lower levels and most being treated at higher levels. While coverage of
TB services was very high except at the lowest level, 36% of first attempts to seek
care were still at facilities without the capacity to diagnose or treat TB. Patients
did rapidly reach facilities where TB treatment was available, but 34% initiated
treatment at a facility other than the first one they visited offering TB treatment,
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and the median delay between arriving at the facility where they were treated and
treatment initiation was 6 days. These features may represent a lack of confidence
or familiarity in diagnosing TB among clinicians at the primary care level. Further
investigations to understand the reasons for this are warranted.
My work builds on the patient pathway analysis (PPA) introduced in a series
of recent papers [7–13]. I was able to obtain similar outputs, including similar
conclusions around coverage at the facility level typical of initial visits, but there
are a number of differences which stem from my use of longitudinal individual-
level data. My coverage statistics for the availability of diagnosis at facilities are
based not on direct facility data, but on inferred availability from events in patient
records. This will underestimate the actual coverage at facilities where tools are
available but have not been used for patients in my data. This is likely to be
particularly true at the lowest level of care. Importantly, my definition of ‘initial
care-seeking’ differs from that used up to now in PPA, where initial care-seeking
refers to patients’ preferred location to first access care for symptoms related to
TB, determined from retrospective surveys [7]. My initial care-seeking events need
not involve the initiation of care; indeed multiple visits are typical between initial
care-seeking and treatment initiation, including missed opportunities for earlier
diagnosis. My approach to identifying care-seeking related to a particular TB
episode also differs from that used in Chen et al. [16]. Due to the potential for
interrupted evaluation. This is why my median delay from initial visit to treatment
(41 days) is somewhat longer than theirs (29 days), and longer than the median
health system delay reported by a systematic review [24].
The key strengths of this work lie in the use of individual-level data from a
large population-representative sample, and the analyses of heterogeneity, referral
patterns, and determinants that this allowed. Due to the compulsory National
Health Insurance system, I had available data relating to essentially all clinical
encounters over a long period of time in individuals diagnosed with TB. Through
my algorithm, I was able to identify early TB care-seeking seeking events prior
to diagnosis and analyse their patterns. It has been argued that the correct start-
point for cohort-based analysis of patient care is the initial attempt to seek care
rather than successful diagnosis or treatment initiation [6]. However, this has pre-
viously relied predominantly on experiences reported retrospectively by patients
[24], which are subject to recall biases. I was also able to link patient-level covari-
ates, including comorbidities for risk-factor analysis.
The main limitations of my analysis are around the nature of routine data, and
the assumptions needed by any algorithm to interpret these records in terms of
TB-related care-seeking. For example, my choice of ‘time-out’ period to determine
110 6.4. Discussion
whether respiratory-related care-seeking events were part of a TB patient pathway
affects how protracted and fragmented pathways are prior to diagnosis. The initial
value of 60 days was based on a previous study evaluating health system delay
of TB diagnosis in Taiwan [16]. However, sensitivity analyses varying the choice
of time-out showed that my main conclusions were not substantially affected. I
relied on clinician coded ICD-9-CM codes to characterise clinical encounters; there
may have been miscoding or omission of relevant secondary diseases for multi-
morbid patients. The choices of timings characterising treatments were based on
standard treatment, and may not have applied to extra-pulmonary TB, although
rates of extra-pulmonary TB are low in Taiwan. In addition, my methods may
work less well for TB patients with underlying chronic lung disease, for which
they also interact with health services. Finally, my analysis cannot account for
the delay between the start of infectiousness or symptoms and initial care-seeking.
Prevalence-to-notification ratios in high TB burden settings typically correspond
to a mean disease duration over a year [25, 26], whereas the predominant ap-
proaches to measuring delays by asking patients typically result in shorter delays
of the order 6 months [24]. My analysis sheds light on the health system delay
contribution in this setting (from care-seeking to diagnosis) and suggests mean
durations are strongly influenced by the few individuals with very long delays.
I developed an approach to analysing patient-level routine data using health
insurance data for Taiwan, but this analysis framework could be adapted and ap-
plied to other settings, as well as forming the basis of further analyses for Taiwan.
The prerequisite for this analysis is individual-level high-coverage routine data on
healthcare utilisation, ideally beyond just TB services. While such data are still
relatively rare in many high TB burden settings, there is increased development
of case-based notification systems for TB, and there are subnational health infor-
matics and linkage efforts that may allow such an analysis [27]. Use of different
diagnostic codes, different locally relevant comorbidities (e.g. HIV) and clinical
practices could all be included by adapting the open source code for my analysis.
Likewise, consideration should be given to different ‘time-out’ values as these are
inevitably related to a system and patient characteristics. Future work building on
my analysis for Taiwan will include analysis considering health system costs and
patient prescription charges, analysis with respect to proxy measures of socioeco-
nomic status, and developing simulation models replicating observed patterns of
patient care-seeking.
Chapter 6. Individual patient pathway analysis 111
6.5 Conclusion
Patient-level routine healthcare data can be analysed to generate individual patient
TB care-seeking pathways. Training to improve clinician awareness of TB in key
risk groups at the lowest level of the health system may improve patient experience
of accessing TB care in Taiwan.
Bibliography
[1] World Health Organisation. Global tuberculosis report 2017; 2017.
[2] Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al.
WHO’s new End TB Strategy. Lancet. 2015;385(9979):1799–1801.
[3] Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden
for tuberculosis patients in low-and middle-income countries: a systematic
review. Eur Respir J. 2014;43(6):1763–1775.
[4] Subbaraman R, Nathavitharana RR, Satyanarayana S, Pai M, Thomas BE,
Chadha VK, et al. The Tuberculosis Cascade of Care in India’s Pub-
lic Sector: A Systematic Review and Meta-analysis. PLoS Med. 2016
Oct;13(10):e1002149.
[5] Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of
care in diagnosis and treatment of latent tuberculosis infection: a systematic
review and meta-analysis. Lancet Infect Dis. 2016 Nov;16(11):1269–1278.
[6] Chin DP, Hanson CL. Finding the Missing Tuberculosis Patients. J Infect Dis.
2017 Nov;216(suppl_7):S675–S678.
[7] Hanson CL, Osberg M, Brown J, Durham G, Chin DP. Conducting Patient-
Pathway Analysis to Inform Programming of Tuberculosis Services: Methods.
J Infect Dis. 2017 Nov;216(suppl_7):S679–S685.
[8] Naidoo P, Theron G, Rangaka MX, Chihota VN, Vaughan L, Brey ZO, et al.
The South African Tuberculosis Care Cascade: Estimated Losses and Method-
ological Challenges. J Infect Dis. 2017 Nov;216(suppl_7):S702–S713.
[9] Fekadu L, Hanson C, Osberg M, Makayova J, Mingkwan P, Chin D. Increasing
Access to Tuberculosis Services in Ethiopia: Findings From a Patient-Pathway
Analysis. J Infect Dis. 2017 Nov;216(suppl_7):S696–S701.
112
Bibliography 113
[10] Masini E, Hanson C, Ogoro J, Brown J, Ngari F, Mingkwan P, et al. Using
Patient-Pathway Analysis to Inform a Differentiated Program Response to
Tuberculosis: The Case of Kenya. J Infect Dis. 2017 Nov;216(suppl_7):S714–
S723.
[11] Fatima R, Haq MU, Yaqoob A, Mahmood N, Ahmad KL, Osberg M, et al.
Delivering Patient-Centered Care in a Fragile State: Using Patient-Pathway
Analysis to Understand Tuberculosis-Related Care Seeking in Pakistan. J
Infect Dis. 2017 Nov;216(suppl_7):S733–S739.
[12] Garfin C, Mantala M, Yadav R, Hanson CL, Osberg M, Hymoff A, et al. Using
Patient Pathway Analysis to Design Patient-centered Referral Networks for
Diagnosis and Treatment of Tuberculosis: The Case of the Philippines. J
Infect Dis. 2017 Nov;216(suppl_7):S740–S747.
[13] Hanson C, Osberg M, Brown J, Durham G, Chin DP. Finding the Missing
Patients With Tuberculosis: Lessons Learned From Patient-Pathway Analyses
in 5 Countries. J Infect Dis. 2017 Nov;216(suppl_7):S686–S695.
[14] Reid MJA, Goosby E. Patient-Centered Tuberculosis Programs Are Necessary
to End the Epidemic. J Infect Dis. 2017 Nov;216(suppl_7):S673–S674.
[15] National Health Insurance Research Database, Taiwan;.
[16] Chen CC, Chiang CY, Pan SC, Wang JY, Lin HH. Health system delay
among patients with tuberculosis in Taiwan: 2003-2010. BMC Infect Dis.
2015 Nov;15:491.
[17] Centers for Disease Control, Ministry of Health and Welfare, R O C (Taiwan).
Taiwan Guidelines for TB Diagnosis & Treatment (6E). Centers for Disease
Control, Ministry of Health and Welfare, R.O.C.(Taiwan); 2017.
[18] World Health Organization. Implementing tuberculosis diagnostics: policy
framework. World Health Organization; 2015.
[19] Lorenz MO. Methods of Measuring the Concentration of Wealth. Publications
of the American Statistical Association. 1905 Jun;9(70):209–219.
[20] Inghammar M, Ekbom A, Engström G, Ljungberg B, Romanus V, Löfdahl CG,
et al. COPD and the risk of tuberculosis–a population-based cohort study.
PLoS One. 2010 Apr;5(4):e10138.
114 Bibliography
[21] Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and
chronic respiratory disease: a systematic review. Int J Infect Dis. 2015
Mar;32:138–146.
[22] Yakar HI, Gunen H, Pehlivan E, Aydogan S. The role of tuberculosis in COPD.
Int J Chron Obstruct Pulmon Dis. 2017 Jan;12:323–329.
[23] Lee JJ, Wu RL, Lee YS, Wu YC, Chiang CY. Treatment Outcome of Pulmonary
Tuberculosis in Eastern Taiwan—Experience at a Medical Center. J Formos
Med Assoc. 2007 Jan;106(1):25–30.
[24] Sreeramareddy CT, Panduru KV, Menten J, Van den Ende J. Time delays in
diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC
Infect Dis. 2009 Jun;9:91.
[25] Horton KC, MacPherson P, Houben RMGJ, White RG, Corbett EL. Sex
Differences in Tuberculosis Burden and Notifications in Low- and Middle-
Income Countries: A Systematic Review and Meta-analysis. PLoS Med. 2016
Sep;13(9):e1002119.
[26] Borgdorff MW. New measurable indicator for tuberculosis case detection.
Emerg Infect Dis. 2004 Sep;10(9):1523–1528.
[27] Davies MA, Tsondai P, Tiffin N, Eley B, Rabie H, Euvrard J, et al. Where do
HIV-infected adolescents go after transfer? - Tracking transition/transfer of
HIV-infected adolescents using linkage of cohort data to a health information






Continuing the analysis of the care-seeking pathways from Chapter 6, this chap-
ter explores their linkages to upstream socioeconomic determinants at individual
and regional levels and downstream economic burdens on the patients during
care-seeking. Explicitly, for socioeconomic determinants, I disassemble the care-
seeking pathways and link them to various socioeconomic status (SES) variables
through regression analyses matched to the different data types. For economic
burdens, I used the Lorenz curves and Gini coefficients to measure the inequality
of costs incurred. The messages from this chapter will feed into the modelling
parametrisation in the following chapters.
I structure this chapter as following sections. Section 7.2 introduces the data
and definitions used in this chapter. Section 7.3 includes three subsections: Sub-
section 7.3.1 investigates the care-seeking before the first TB-related procedure
prescribed; Subsection 7.3.2 investigates the care-seeking during evaluation (be-
fore treatment start); Subsection 7.3.3 investigates treatment outcomes. The last





I used the 7,255 care-seeking pathways extracted in Chapter 6 as the core data.
In the following sections, I extracted the features mapping to different stages of
care-seeking. Apart from the care-seeking pathways, I used the basic information
and socioeconomic attributes in the National Health Insurance Research Database
(NHIRD) [1] as covariates. Also, I linked to the national statistics of Taiwan for
socioeconomic factors at regional level. The national statistics were published by
the Taiwan officials and free to access on the internet.
7.2.2 Covariates
Individual SES The Nation Health Insurance programme (NHI) determines the
insurance fee by considering salary income, working status, family structure, and
vulnerability. For people with a paid job, they pay the insurance fee directly;
for an unemployed with working family members, one of their working family
members is in charge of paying the insurance fee; the fee of those who in low-
income households, living in welfare institutions, or the retired without working
family members are funded by the government. For employed people (including
self-employed), the income level affects the insurance fee as well. Since the in-
come from the NHIRD might have different validities for different occupations, I
adjusted the systematic bias addressed by Lien 2011 [2] to sustain the validity.
Explicitly, the individual SES variables are as follows.
Employment: categorical variable with levels of unemployed (reference), em-
ployed with income lower than the median among the TB patients, and
otherwise.
Subsidised: receiving a subsidy for low-income household, binary variable.
Vulnerable: unemployed adults without dependants and living in a welfare in-
stitution, binary variable.
Regional SES I used the residential area from the NHIRD to link to the regional
statistics. I included: population density (crowding), ageing (regional burden),
hospital density (healthcare accessibility), and proportion of population deprived
(regional poverty). I transformed fractional indices into natural logarithmic scales
before analysis. For each variable, I used the finest scale for the statistic (from
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district to county). I interpolated or extrapolated to nearest data points if data
missed at any time point. Table 7.1 lists the details of the regional SES indices.
Table 7.1: Regional SES indices
Variable Data type Level Rescale Definition
Offshore Boolean District (Town) In an offshore island of Taiwan
PopDen Ratio City (County) standardised Population density, residents per square
kilometre
HospDen Ratio City (County) log, standardised Hospital density, hospitals per square
kilometre
Ageing Ratio District (Town) log, standardised The ratio of people above 65 and under
15 years old
Poverty Proportion District (Town) log, standardised Low-income households among all
households
log: taking natural logarithm Standardisation: centering the means to zero and rescaling the
variances to 1
Other covariates I also considering the comorbidity of chronic lung conditions
(CLCs), diabetes mellitus (DM), and human immunodeficiency viruses infected
(HIV). The definitions of these comorbidity can be found in Appendix E. I consid-
ered if a pathways overlapped with 2003 as a covariate because there was a pan-
demic of Severe acute respiratory syndrome (SARS), which affected care-seeking
related to all respiratory illness.
7.2.3 Regression models
Throughout this chapter, the features of care-seeking pathways include binary, cat-
egorical, and time-to-event (delay) data. I employed logistic regression for binary
variables, multinomial logistic regression for categorical variables, and the Cox
Proportional Hazard models for time-to-event variables. As for the missing values
in the fields, I assumed they were missing completely at random and dealt with
them by deleting the pathways.
7.2.4 Equality measurements
I used the Lorenz curve [3] and Gini coefficient [4] to investigate the inequality in
the costs during care-seeking before treatment. The costs considered included the
healthcare costs that occurred to the healthcare system, the out-of-pocket payment
(a copayment term to the NIH) from patients, and the number of healthcare visits
as an index of time cost.
The Lorenz curve is a common approach in economics to measure inequality
in income and cost. The curve graphs the cumulative percentage of overall costs,
given a percentage of individuals from whom with the lowest cost to higher and
is formulated as follows. First, sort all care-seeking pathway increasingly by the
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value of a cost. Second, calculate the cumulative cost for every care-seeking path-
way from the first. Last, rescale the cumulative cost to percentages of the overall
cost and plot them against the respective percentages of the pathways. A Lorenz
curve is with a diagonal line from (zero percentage of pathways, zero cost) if it
represents perfect equality. Within the triangle area under the perfect equality
line, the Gini coefficient is defined as the area between the perfect equality line
and the Lorenz curve. The Gini coefficient ranges from zero to one, and a higher
Gini coefficient indicates high inequality.
In addition, I added measures of SES on the Lorenz curves to enhance the
information conveyed. I summarised SES factors by moving average with a width
equal to 10% of pathways. For example, the value for the 50th percentile of the
care-seeking pathway is the average of the pathways from 45th to 55th percentiles.
7.3 Results
There were 7,255 care-seeking pathways extracted in Chapter 6. However, 111
care-seeking had missing residential area, so only 7,144 were eligible for the fol-
lowing covariate analysis. Tables 7.2 summarised the number of pathways for
the analysis in each stage. For the analyses of initial care-seeking (Table 7.3) and
treatment outcomes (Table 7.6), the 7,144 care-seeking pathways were included.
3,572 care-seeking pathways with Evaluation Delay were used in the analysis be-
fore evaluation and 5,241 care-seeking pathways with Diagnosis Delay were used
in the analysis during evaluation (before treatment start).
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Table 7.2: Summary of sample size in each stage
Excluded pathways with missing regions
All pathways All pathways Pathways with Pathways with
Evaluation Delay Diagnosis Delay
Variable
All 7255(100%) 7144(100%) 3572(100%) 5241(100%)
Age
<15 36(0.5%) 36(0.5%) 23(0.6%) 20(0.4%)
15− 34 875(12.1%) 857(12%) 423(11.8%) 554(10.6%)
35− 64 2683(37%) 2638(36.9%) 1253(35.1%) 1831(34.9%)
≥ 65 3661(50.5%) 3613(50.6%) 1873(52.4%) 2836(54.1%)
Sex
Female 2158(29.7%) 2124(29.7%) 1168(32.7%) 1612(30.8%)
Male 5097(70.3%) 5020(70.3%) 2404(67.3%) 3629(69.2%)
Employment
Unemployed 3696(50.9%) 3631(50.8%) 1719(48.1%) 2644(50.4%)
Lower income 2772(38.2%) 2743(38.4%) 1458(40.8%) 2024(38.6%)
Higher income 787(10.8%) 770(10.8%) 395(11.1%) 573(10.9%)
Vulnerability
Subsidised 217(3%) 217(3%) 99(2.8%) 130(2.5%)
Vulnerable 1773(24.4%) 1742(24.4%) 771(21.6%) 1249(23.8%)
Regional Det.
Offshore 29(0.4%) 29(0.4%) 14(0.4%) 26(0.5%)
Hospital Level
A 1192(16.4%) 1180(16.5%) 558(15.6%) 871(16.6%)
B 1191(16.4%) 1170(16.4%) 547(15.3%) 850(16.2%)
C 30(0.4%) 29(0.4%) 9(0.3%) 19(0.4%)
D
Comorbidity 3104(42.8%) 3065(42.9%) 2732(76.5%) 2280(43.5%)
CLC 1275(17.6%) 1247(17.5%) 412(11.5%) 919(17.5%)
DM 1644(22.7%) 1610(22.5%) 253(7.1%) 1115(21.3%)
HIV 1232(17%) 1222(17.1%) 175(4.9%) 927(17.7%)
Pathway
overlapps 2003 2110(29.1%) 2090(29.3%) 1179(33%) 1486(28.4%)
Lower income is the employment with income below the median among patients, otherwise, higher
income
HospDen: hospital density, PopDen: population density, Poverty: percentage of unprivileged
population, CLC: chronic lung condition, DM: diabetes mellitus, HIV: human immunodeficiency
virus
Hospital Level is level at initial care-seeking
Comorbidities and Pathway overlaps 2003 are binary variables
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7.3.1 From initial care-seeking to initial evaluation
I first analysed the hospitals at initial care-seeking by levels: A for primary care/
general practice; B for regional hospitals with inpatient capacity; C for larger dis-
trict hospitals; D for large hospitals with a range of specialists. Table 7.3 demon-
strates the results of the covariates analysis with a multinomial logistic regression
model of the hospital accesses at initial care-seeking. Level A was the reference
for Level B, C, and D. The odds ratio were based on the multinomial odds. For
example, the OR in the column of Level B and the row of males was the odds
of starting care-seeking at Level B against Level A for males versus odds of start-
ing care-seeking at Level B against Level A for females while holding the other
predictors at fixed values. In the binary covariate by definition, the OR was the
ratio of pr(level = B|sex = males, x = X)/pr(level = A|sex = males, x = X) and
pr(level = B|sex = f emales, x = X)/pr(level = A|sex = f emales, x = X), where
the x is the set of predictors other than sex fixed at X and pr(.) is probability
function. The care-seeking pathways for patients males, and with chronic lung
conditions (CLCs) were more likely to start at Level B and C hospitals compared
with Level A. The pathways for patients with paid jobs were less likely to initiate
care-seeking at Level B and C hospitals compared, or more likely to start at Level
A and D alternatively. The vulnerable and subsidised patients have higher proba-
bilities of starting with Level B. However, the subsidised hardly initiated at Level
D hospitals (odds ratio (OR) 0.55 (95% confidence interval (CI): 0.32 - 0.94).
After initial care-seeking, I extracted 1) whether the patients received TB eval-
uations at initial care-seeking (no evaluation delay), and 2) the duration between
initial care-seeking and initial evaluation (evaluation delay). Tables 7.4 shows their
associations with the covariates. In general, half of the care-seeking did not have
evaluation delay and the diagnosis delay was 40 days in median. Conditioning on
the variables except for the SES factors, care-pathways started initial care-seeking
at Level A were more likely to have no evaluation delays. The employment and
vulnerability did not show significant associations with evaluation delays and its
existence. The patients who were living in areas with higher population density
were more likely to receive TB evaluations at initial care-seeking (OR: 0.93, 95%
CI: 0.88-0.98).
Figure 7.1 layouts the distributions of costs by the Lorenz curves and Gini
coefficients. Among the healthcare system, out-of-pocket, and time costs, the time
cost was the most homogenous (Gini: 0.63). In both the healthcare system and
out-of-pocket costs, about 90% of overall costs occurred among the top quartile of
care-seeking pathways. Considering the individual SES, out-of-pocket expenses
were rarely incurred by the subsidised (green line) and the vulnerable (blue line).
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Table 7.3: Multinomial Logistic regression analysis, hospital levels at initial care-
seeking
Hospital Level at Initial Care-Seeking (Reference = A. primary care/GP)
B. Regional C. District D. Medical Centre
Baseline Mean Mean Mean
Total 18% 23% 17%
Variable OR (95% CI) OR (95% CI) OR (95% CI)
Age
<15 0.000 (0.000, 0.000) 0.631 (0.265, 1.502) 0.476 (0.138, 1.642)
15− 34 Reference Reference Reference
35− 64 1.148 (0.905, 1.457) 1.166 (0.945, 1.440) 1.096 (0.873, 1.376)
≥ 65 1.242 (0.981, 1.572) 1.128 (0.914, 1.392) 1.271 (1.007, 1.603)
Sex
Female Reference Reference Reference
Male 1.305 (1.117, 1.524) 1.258 (1.096, 1.444) 1.041 (0.895, 1.210)
Employment
Unemployed Reference Reference Reference
Lower income 0.797 (0.665, 0.956) 0.835 (0.712, 0.980) 0.923 (0.768, 1.109)
Higher income 0.738 (0.559, 0.973) 0.638 (0.499, 0.815) 1.292 (1.015, 1.645)
Vulnerability
Subsidised 1.732 (1.204, 2.493) 1.202 (0.814, 1.776) 0.547 (0.319, 0.936)
Vulnerable 1.630 (1.339, 1.984) 1.159 (0.963, 1.394) 1.536 (1.258, 1.876)
Regional Det.
Offshore 1.812 (0.752, 4.366) 0.517 (0.146, 1.836) 1.106 (0.356, 3.435)
Ageing 1.001 (0.998, 1.003) 1.001 (0.999, 1.004) 1.001 (0.999, 1.004)
Log(HospDen) 0.555 (0.360, 0.855) 1.189 (0.810, 1.746) 1.612 (1.058, 2.456)
Log(PopDen) 1.013 (0.961, 1.067) 0.972 (0.928, 1.019) 1.223 (1.157, 1.292)
Log(Poverty) 0.914 (0.806, 1.037) 0.804 (0.716, 0.903) 1.029 (0.898, 1.178)
Comorbidity
CLC 1.651 (1.376, 1.981) 1.509 (1.273, 1.789) 1.694 (1.407, 2.039)
DM 1.041 (0.867, 1.250) 0.950 (0.803, 1.125) 1.061 (0.883, 1.276)
HIV 0.672 (0.136, 3.316) 1.330 (0.415, 4.263) 5.707 (2.238, 14.557)
Pathway
overlapps 2003 1.153 (0.998, 1.332) 0.693 (0.602, 0.797) 0.827 (0.710, 0.964)
OR: odds ratio, CI: confidence interval, LR-test: likelihood-ratio test
Lower income is the employment with income below the median among patients, otherwise, higher
income
HospDen: hospital density, PopDen: population density, Poverty: percentage of unprivileged pop-
ulation, CLC: chronic lung condition, DM: diabetes mellitus, HIV: human immunodeficiency virus
Comorbidities and Pathway overlaps 2003 are binary variables, applying ’None’ as the reference
groups.
ORs were adjusted ORs calculated from the results of multinomial logistic regressions.
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Table 7.4: Regression analyses, before evaluation
From Initial Care-Seeking to Initial Evaluation
Zero Evauation Delay Evauation Delay
Baseline Mean (95% CI) Median (IQR)
Total 50.1% (49.0%, 51.3%) 40 (13, 88)
Variable OR (95% CI) HR (95% CI)
Age
<15 1.102 (0.421, 2.889) 1.072 (0.701, 1.638)
15− 34 Reference Reference
35− 64 0.938 (0.746, 1.180) 0.941 (0.840, 1.055)
≥ 65 0.526 (0.418, 0.662) 0.849 (0.758, 0.950)
Sex
Female Reference Reference
Male 1.367 (1.180, 1.585) 1.038 (0.966, 1.116)
Employment
Unemployed Reference Reference
Lower income 0.906 (0.761, 1.079) 0.947 (0.868, 1.033)
Higher income 0.789 (0.610, 1.020) 1.047 (0.923, 1.189)
Vulnerability
Subsidised 0.863 (0.592, 1.259) 1.147 (0.925, 1.421)
Vulnerable 0.973 (0.804, 1.179) 0.996 (0.898, 1.104)
Regional Det.
Offshore 1.338 (0.483, 3.704) 1.156 (0.680, 1.963)
Ageing 1.000 (0.997, 1.002) 1.001 (0.999, 1.002)
Log(HospDen) 0.957 (0.635, 1.444) 0.874 (0.706, 1.083)
Log(PopDen) 0.929 (0.883, 0.978) 1.019 (0.992, 1.046)
Log(Poverty) 1.074 (0.948, 1.216) 1.034 (0.970, 1.101)
Comorbidity
CLC 0.677 (0.569, 0.806) 0.989 (0.899, 1.089)
DM 1.292 (1.079, 1.546) 1.138 (1.036, 1.249)
HIV 0.825 (0.267, 2.549) 1.321 (0.684, 2.551)
Hospital Level
A Reference Reference
B 19.172 (16.126, 22.793) 1.161 (1.044, 1.291)
C 49.485 (41.188, 59.454) 1.134 (0.994, 1.293)
D 59.576 (48.407, 73.322) 0.870 (0.743, 1.018)
Pathway
overlapps 2003 0.662 (0.573, 0.766) 0.695 (0.646, 0.747)
IQR: interquartile range, OR: odds ratio, CI: confidence interval, LR-test: likelihood-ratio test
Lower income is the employment with income below the median among patients, otherwise, higher
income
HospDen: hospital density, PopDen: population density, Poverty: unprivileged population, CLC:
chronic lung condition, DM: diabetes mellitus, HIV: human immunodeficiency virus
Comorbidities and Pathway overlaps 2003 are binary variables, applying ’None’ as the reference
groups.
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The pathways for patients with paid jobs were more likely to need higher numbers
of visits to receive their first evaluations.
Gini = 0.79 Gini = 0.82 Gini = 0.63
Healthcare System Cost Out−Of−Pocket Cost Time Cost (number of visits)
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Attribute (right axis) Employment Subsidised Vulnerable
Figure 7.1: Lorenz curves and Gini coefficients of costs before evaluation
7.3.2 From initial evaluation to treatment start
Between initial evaluation and treatment start, I again extracted whether the pa-
tients initiated TB treatment at initial evaluation (no diagnosis delay), and the
duration between initial evaluation and treatment start (diagnosis delay). Accord-
ing to the analysis in Chapter 6 I extracted if the evaluation process being inter-
rupted (IE) and used IE to stratify the diagnosis delay. Apart from the covariates
mentioned in the previous part, I included the hospital levels where the patients
received first TB evaluations.
Tables 7.5 shows the results of covariate analysis. Overall, 26% of the care-
seeking did not have diagnosis delay, 21% with IE, and the diagnosis delays with
and without IE were 238 and 21 days in median respectively. The pathways for
older patients were more likely to have longer evaluation periods: for the aged 65
and above, lower probability of zero diagnosis delay (OR: 0.43, 95% CI: 0.36-0.52),
higher IE (OR: 3.87, 95% CI: 2.76-5.43). and lower rates to treatment start with and
without IE (HR: 0.58, 95% CI: 0.42-0.79, and HR: 0.64, 95% CI: 0.58-0.71 respec-
tively). Starting TB evaluations at Level C and Level D hospitals were associated
with lower probabilities of zero diagnosis delay and longer delays without IE.
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Table 7.5: Regression analyses, during evaluation
From Initial Evaluation to Treatment Start
Zero Diagnosis Delay IE Diagnosis Delay Diagnosis Delay
without IE with IE
Baseline Mean (95% CI) Mean (95% CI) Median (IQR) Median (IQR)
Total 26.6% (25.6%, 27.7%) 21.1% (20.0%, 22.3%) 21 (7, 47) 238 (128, 483)
Variable OR (95% CI) OR (95% CI) HR (95% CI) HR (95% CI)
Age
<15 1.233 (0.615, 2.471) 2.246 (0.690, 7.315) 1.436 (0.869, 2.372) 1.048 (0.359, 3.059)
15− 34 Reference Reference Reference Reference
35− 64 0.727 (0.612, 0.862) 2.259 (1.600, 3.188) 0.780 (0.704, 0.865) 0.689 (0.495, 0.960)
≥ 65 0.433 (0.363, 0.516) 3.874 (2.764, 5.429) 0.646 (0.582, 0.718) 0.578 (0.420, 0.794)
Sex
Female Reference Reference Reference Reference
Male 1.291 (1.141, 1.461) 0.966 (0.825, 1.131) 1.009 (0.942, 1.080) 1.013 (0.882, 1.164)
Employment
Unemployed Reference Reference Reference Reference
Lower income 0.935 (0.811, 1.079) 0.975 (0.811, 1.173) 1.011 (0.931, 1.097) 1.006 (0.859, 1.178)
Higher income 0.746 (0.608, 0.916) 0.694 (0.501, 0.961) 0.934 (0.835, 1.046) 0.992 (0.733, 1.342)
Vulnerability
Subsidised 1.625 (1.198, 2.203) 1.486 (0.980, 2.252) 0.827 (0.661, 1.035) 0.965 (0.691, 1.348)
Vulnerable 0.973 (0.829, 1.144) 1.017 (0.831, 1.244) 0.996 (0.908, 1.093) 0.852 (0.716, 1.013)
Regional Det.
Offshore 0.352 (0.105, 1.185) 0.776 (0.253, 2.384) 1.182 (0.772, 1.809) 0.691 (0.256, 1.864)
Ageing 0.999 (0.997, 1.001) 0.998 (0.995, 1.000) 1.001 (1.000, 1.002) 1.002 (0.999, 1.004)
Log(HospDen) 0.972 (0.691, 1.365) 0.918 (0.591, 1.428) 1.028 (0.849, 1.245) 1.144 (0.772, 1.696)
Log(PopDen) 1.003 (0.963, 1.045) 0.968 (0.916, 1.023) 1.011 (0.986, 1.037) 1.028 (0.979, 1.079)
Log(Poverty) 1.179 (1.065, 1.305) 1.084 (0.950, 1.236) 1.012 (0.954, 1.075) 1.069 (0.950, 1.203)
Comorbidity
CLC 1.152 (0.992, 1.338) 1.991 (1.673, 2.369) 0.740 (0.676, 0.809) 0.758 (0.654, 0.877)
DM 1.187 (1.025, 1.375) 0.639 (0.520, 0.784) 1.001 (0.921, 1.087) 1.311 (1.088, 1.580)
HIV 1.115 (0.510, 2.439) 2.113 (0.658, 6.783) 0.766 (0.459, 1.277) 1.029 (0.378, 2.802)
Hospital Level
A Reference Reference Reference Reference
B 0.452 (0.374, 0.548) 0.966 (0.733, 1.272) 0.932 (0.820, 1.060) 0.973 (0.772, 1.227)
C 0.595 (0.499, 0.710) 0.879 (0.672, 1.149) 0.788 (0.698, 0.891) 1.058 (0.841, 1.331)
D 0.430 (0.355, 0.519) 0.773 (0.585, 1.021) 0.799 (0.705, 0.906) 0.932 (0.734, 1.184)
Pathway
overlapps 2003 1.182 (1.050, 1.331) 2.620 (2.263, 3.034) 0.993 (0.924, 1.068) 0.476 (0.416, 0.544)
IE: Interrupted Evaluation, IQR: interquartile range, OR: odds ratio, CI: confidence interval, LR-test:
likelihood-ratio test
Lower income is the employment with income below the median among patients, otherwise, higher
income
HospDen: hospital density, PopDen: population density, Poverty: unprivileged population, CLC:
chronic lung condition, DM: diabetes mellitus, HIV: human immunodeficiency virus
Comorbidities and Pathway overlaps 2003 are binary variables, applying ’None’ as the reference
groups.
ORs were adjusted ORs calculated from the results of multivariate logistic regressions.
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Figure 7.2 demonstrates the cost distributions before treatment after initial
evaluation. The general patterns were similar to Figure 7.1, but the equalities
were higher in the healthcare system cost (Gini: 0.72) but lower in the time cost
(Gini: 0.70). Along with the individual SES, the proportions the vulnerable pa-
tients were more frequently with higher ranks of the healthcare system cost. In
the time cost, the individual SES factors were homogeneously distributed across
the percentages of the ranked care-seeking pathways.
Gini = 0.72 Gini = 0.8 Gini = 0.7
Healthcare System Cost Out−Of−Pocket Cost Time Cost (number of visits)
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Figure 7.2: Lorenz curves and Gini coefficients of costs during evaluation
7.3.3 Treatment outcomes
I analysed the risk factors of unfavourable outcomes of all-cause death and loss to
follow-up (LTFU). For the censored cases (ended with the end of the data cohort),
I deleted the data entries by assuming they were missing completely at random.
The definitions of treatment outcomes were the same as Chapter 6.
Tables 7.6 shows the results of multinomial logistic regression of treatment
outcomes using treatment completed as the reference group. Except for the care-
seeking pathway with censored treatment outcome, 68% of the pathways com-
pleted their treatment, 14% died, 18% were LTFU. Regarding all-cause death, the
odds were higher for pathways for TB patients aged 35-64 (OR: 6.52, 95% CI: 3.37-
12.63), aged 65 and above (OR: 21.96, 95% CI: 11.44-42.17), were male (OR: 1.25,
95% CI: 1.05-1.48), and with comorbidities. For SES factors, the employed with in-
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come higher than the median was a protective factor (OR: 0.41, 95% CI: 0.26-0.64)
while living in subsidised households associated with a higher risk of death (OR:
1.73, 95% CI: 1.18-2.54). Regarding LTFU, the odds were higher for pathways for
TB patients aged 35-64 (OR: 1.34, 95% CI: 1.08-1.65), were the vulnerable group
(OR: 1.34, 95% CI: 1.12-1.61), and with chronic lung condition (OR: 1.66, 95% CI:
1.40-1.95). The employed with income higher than the median was a protective
factor (OR: 0.66, 95% CI: 0.51-0.84).
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Table 7.6: Multinomial Logistic regression analysis, treatment outcome
Treatment Outcome (Reference = Treatment completed)
Dead, all cause LTFU
Baseline Mean Mean
Total 14% 18%
Variable OR (95% CI) OR (95% CI)
Age
<15 N.A. 1.049 (0.446, 2.469)
15− 34 Reference Reference
35− 64 6.521 (3.365, 12.639) 1.338 (1.084, 1.651)
≥ 65 21.960 (11.436, 42.169) 0.994 (0.802, 1.232)
Sex
Female Reference Reference
Male 1.248 (1.053, 1.479) 1.071 (0.929, 1.234)
Employment
Unemployed Reference Reference
Lower income 0.866 (0.716, 1.048) 0.956 (0.808, 1.131)
Higher income 0.412 (0.264, 0.644) 0.657 (0.513, 0.843)
Vulnerability
Subsidised 1.728 (1.175, 2.542) 0.908 (0.622, 1.327)
Vulnerable 1.185 (0.974, 1.443) 1.343 (1.116, 1.615)
Regional Det.
Offshore 0.636 (0.141, 2.861) 1.575 (0.652, 3.805)
Ageing 1.000 (0.997, 1.002) 0.999 (0.997, 1.002)
Log(HospDen) 0.727 (0.460, 1.148) 1.135 (0.768, 1.677)
Log(PopDen) 1.034 (0.975, 1.096) 0.989 (0.943, 1.037)
Log(Poverty) 1.038 (0.907, 1.189) 1.040 (0.924, 1.170)
Comorbidity
CLC 1.667 (1.408, 1.974) 1.655 (1.403, 1.953)
DM 1.208 (1.010, 1.445) 1.059 (0.891, 1.259)
HIV 7.678 (2.540, 23.205) 1.542 (0.622, 3.825)
OR: odds ratio, CI: confidence interval, LR-test: likelihood-ratio test, N.A.: not available
Lower income is the employment with income below the median among patients, otherwise, higher
income
HospDen: hospital density, PopDen: population density, Poverty: unprivileged population, CLC:
chronic lung condition, DM: diabetes mellitus, HIV: human immunodeficiency virus
Comorbidities and Pathway overlaps 2003 are binary variables, applying ’None’ as the reference
groups.
ORs were adjusted ORs calculated from the results of multinomial logistic regressions.
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7.4 Discussion
Care-seeking, including delays to treatment and treatment adherence, can be as-
sociated to socioeconomic determinants. These associations are the clues to inno-
vating TB control strategies. However, in Chapter 2 my review found that differ-
ent socioeconomic factors might act differently for different parts of care-seeking
processes in different settings. Continuing on from Chapter 6, I investigated the
relationships between SES and care-seeking pathways by decomposing these care-
seeking pathways. From the hospital visited for initial care-seeking, delays before
treatment start, to treatment outcomes, I found several links, which were rele-
vant to supporting future strategic recommendations for TB services provision in
Taiwan.
To the best of my knowledge, this study is the first study considering the
system delay (the period from initial care-seeking to treatment start) as separate
delays to evaluation start and treatment start. Also, I considered if the evaluation
processes for pathways experienced interruptions as a critical property determin-
ing the length of system delay. The analysis of the initial hospital levels includes
the care-seeking preference for patients with different characteristics. The path-
ways without evaluation delays or diagnosis delay correspond to the physician’s
immediate decision concerning the features or health status of patients. The delays
represent the patients’ care-seeking behaviours and health status, the time-spent
for diagnostics, as well as when physicians aware of the possibility of TB during
caring.
I found that social vulnerability did not always lead to the worst care-seeking
processes. The low-income subsidised population preferred going to higher-level
hospitals for their initial care-seeking and got TB treatment quicker. That may be
attributable to the national policy in Taiwan that exempted some out-of-pocket
cost to the eligible underprivileged population. Also, the results of the regional
SES implies that the physicians working in more impoverished areas are more
skilful at identifying TB. However, the social vulnerability associated with more
unfavourable outcomes of death and LTFU. Two hypotheses need testing. First,
that these patients initiated care-seeking after they were very ill. Second, that the
poor living standard and other physical barriers affected the mortality or kept
them from proper care. However, these hypotheses require qualitative data to ad-
dress. On the other hand, the effects of employment on care-seeking act in two
directions. The employed usually started care-seeking with lower-level hospitals
and had a lower chance of zero diagnosis delay. On the other hand, their evalua-
tion processes were hardly ever interrupted.
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I used the Lorenz curve and the Gini coefficient for measuring the inequality of
costs. Since the Lorenz curve did not consider the nature of heterogeneity among
the population, I attached the moving average of SES variables to strengthen the
interpretation. Thus, I observed that the social security net in Taiwan protected
vulnerable groups from out-of-pocket cost, although they started care-seeking at
higher-levels. However, in the number of visits before treatment initiation, the
vulnerable patients suffered from time cost similar to other patients.
I found that age played a vital role in care-seeking pathways. The older adults
with TB-suggestive symptoms sought care at higher-level hospitals. However, for
most of the indices I assessed, they were more likely to have longer system delays
even after controlling for comorbidities. The difficulty in diagnosing TB for older
adults is expected as an increasing challenge in the future.
For the treatment outcome of death, this study did not consider the back-
ground death rates. For example, age and sex have been commonly linked to
background mortality, older people and males usually have higher death rates. In
order to understand better the TB-specific death rates, I need to characterise them
by offsetting background mortality.
Furthermore, this study did not appropriately address socioeconomic factors
for older adults. My SES variables from the NHIRD were mainly based on em-
ployment. For those who retired, they had no salary income by definition. An
SES based on housing, the capacity of subsistence, and social segregation could
be considered. Also, I suggest stratifying care-seeking behaviours by age or career
stage to consider the transitioning of decision making corresponding to life stages.
Reflecting on the Theory of Planned Behaviour (TPB)[5] used to conceptualise
the linkage with socioeconomic determinants, the SES factors in this study cap-
tured the components of the subjective norm (SN) and perceived behavioural con-
trol (PBC) to some extent (see Chapter 2). Employment, income, vulnerability, and
the density of hospitals can be considered proxies of perceived behavioural con-
trol. They are related to apparent barriers to care-seeking. The regional poverty
and regional ageing index can be considered as referring to the social context or
the subjective norm. However, I did not assess the attitude toward seeking care
for TB. The risk perception, self-stigma, and stigma require qualitative approaches
to consider further.
The SES variables of interest might depend on each other and cause collinear-
ity in the regression models. For example, the income level is associated with
seniority in a job, which is increasing along with age increases. I used categor-
ical variables to reduce the potential influence, such as combining income level
and employment. Further analysis, using dimension reduction, could shed more
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light on the effects of SES on care-seeking. Multiple Correspondence Analysis
(MCA) [6], which is a dimension reduction method for categorical data, might
be a solution. For example, Birch et al. [7] used MCA to summarise variables
about assets before inputting them into covariate analysis of TB treatment non-
adherence. However, referring back to the exact SES properties, identifying which
affect care-seeking after dimension reduction is challenging. Alternatively, struc-
tural equation modelling (SEM) [8], which uses structural assumptions to sum-
marise upstream variables with conceptual components (latent variables), could
build firmer links between SES variables and care-seeking features. For example,
Alegria-Flores et al. [9] used SEM to introduce a behavioural theory to investigate
treatment adherence.
7.4.1 Recommendations for future studies
This chapter is a bridge connecting evidence to modelling and interventions. For
modelling, the messages are 1) zero delay and lower delay do not have the same
upstream determinants, and 2) the hospital level at initial care-seeking mediates
the effects of employment and vulnerability on the delay to evaluation started.
As for policy implications, the key messages are 1) hospital levels at initial care-
seeing affects the time -to-evaluation started, and 2) those under subsidisation for
low income household require support for treatment adherence.
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Care-seeking of TB patients plays an essential role in TB epidemiology. Especially
in responding to the urgency of TB elimination and the maturity of TB treatment
and diagnostics. The marginal returns on improving diagnostic sensitivity and
treatment efficacy are diminishing. Instead, actions such as active case finding,
that improve potential TB patients’ access to TB diagnosis and treatment are re-
ceiving growing attention. In this thesis, I want to investigate the care-seeking
and diagnostic processes of TB patients to find the possibility of introducing new
SES-related interventions and evaluate their effectiveness. From the IPPA, I have
detailed results describing care-seeking pathways. This chapter then intends to
consider the transmission process, which is usually an essential component in
evaluating the impact of an infection control strategy on a population level.
Agent-based modelling which models a system from every individual is suit-
able to link detailed individual data to population influence. However, in my
setting, the overall Taiwanese population is approximately 23 million. The popu-
lation size is too infeasible to perform Monte Carlo inferences, such as for statisti-
cal model fitting. Simplifying the IPPA results to aggregate levels and employing
an EBM might be a solution to capture the TB dynamics in Taiwan, but it can-
not implement TB control strategies concerning individual attributes and evaluate
their impact on the individual level. Given 10,000 incident TB cases and an ex-
pected disease duration of half a year, the expected TB prevalent cases is 5,000 in
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an endemic equilibrium. Constructing an ABM for this number has a relatively
low computational cost. As I investigated in Chapter 3, hybrid modelling allowed
us to switch some agents out of the main focus to EBMs and mitigate the compu-
tational burden. I therefore only need to construct an ABM of TB patients while
modelling the others in an EBM.
Reviewing the previous chapters, Chapter 5 analysed the demography and TB
epidemiology in Taiwan using public data. Chapter 6 did an empirical study to
detail the care-seeking pathway by aligning the TB-service provision and demands
in Taiwan using individual healthcare data. Chapter 4 reviewed the methods to
model health behaviour, including care-seeking in ABMs. Chapter 3 reviewed
the methods and applications to hybridise ABMs and EBMs in a simulation to
improve performance. This chapter then, is to combine these results in order to
build a simulation model.
8.1.1 Aim and objectives
The aim of this chapter is to developed and validated a hybrid model which fits
the epidemiological features of TB in Taiwan and can compactly include the in-
formation extracted from the IPPA results. I will test various parametrisations as
well as prior parameters and select one which is the best fit to data in the sta-
tistical sense. I will optimise the hybrid model until it can perform Monte Carlo
experiments in a personal computer in manageable simulation time.
8.1.2 Overview
Figure 8.1 demonstrates an overview of the modelling scheme in this chapter. The
first column layouts the data to be synthesised; the second includes the statisti-
cal model linking the data to parameters driving simulation models; the third are
simulation models; the fourth column included the outputs I want to deliver using
the simulation models. (1) Starting from the upper parts, I use the IPPA results
to construct a state-space model of the care-seeking process, StSp. I tested various
parametrisation and find a version which has the best performance in reconstruct-
ing the distribution of the system delays, from initial care-seeking to treatment
start, in the IPPA summary. (2) I use a statistical model to estimate the TB-specific
death rates after treatment initiated and other dropouts according to the IPPA re-
sults. The results will be an input to the following models. (3) I wrap StSp to
agents and add dropout process to formulate an ABM of the care-seeking process,
CSM. (4) Given the results of the age-sex distribution at notification from Chapter
5, I use CSM to construct the time-series of the initial care-seeking rates. (5) I
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construct a mean-field model of TB dynamics, MFM, which is a compartmental
EBM. I use the initial care-seeking rates from (4) and the notification rates by sex to
calibrate MFM. (6) Start with MFM, I replace the compartments model those who
seek care for active TB with CSM as the final hybrid model, HM. Also I compare
the simulations of MFM and HM, ensuring the consistency. Since MFM stands the
mean-fields of the system of interest, HM can render the same dynamics as MFM
on average almost surely.
This chapter structures by following the modelling scheme. Section 8.2 con-
structs and calibrates StSp. Section 8.3 estimates the TB-specific mortality and loss
to follow-up rates using the IPPA results. Section 8.4 wraps StSp into CSM and
estimates the initial care-seeking rates. Section 8.5 constructs and calibrates MFM.
Section 8.6 brings CSM and MFM together to build and valid HM. Section 8.7 sim-
ulates the TB epidemiological indices and economic burden of TB in Taiwan with
CSM and HM. Lastly, Section 8.8 discusses the technical aspect of the modelling
and the results.
I use the abbreviations of StSp, MFM, CSM, and HM to indicate the model
builds with certain model parametrisations and calibrated parameters (or poste-
rior parameter sets). Also, to be noted that “rates” in this thesis are annual rates,
otherwise, stated.
Figure 8.1: Modelling scheme
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8.2 Care-seeking state-space modelling, StSp
In the IPPA, I described the care-seeking pathways with four stages according to
the prescriptions of TB-related diagnostics and treatment, namely, Waiting, Eval-
uating, TB Detecting, and Treating Stages, from the viewpoint of patients. Also,
I profiled the alignments of capacities and accessibilities of the medications from
the viewpoint of healthcare provision. In this section, I intend to use state-space
models to combine both to allow the model to be responsive to the potential inter-
ventions on patients’ care-seeking obstacles and healthcare provision.
8.2.1 Methods
Table 8.1 lists the options for constructing StSp. I tested various state-spaces,
different methods to model the skips of states, and different baseline hazard func-
tions.
State-space
Following the four stages in the IPPA, after initiating care-seeking, a patient path-
way starts with Waiting Stage; after prescribing a procedure which can possi-
bly identify TB, the patient goes to Evaluating Stage; after a procedure which
can probably identify TB, TB-Detecting Stage; After TB treatment starts, Treating
Stage. Evaluating and TB Detecting Stages can be interrupted by misperception
or the complexity of health status. In the state-space model, I firstly included the
four stages as the basic four states. Apart from the four stages investigated in the
IPPA, I introduced an additional state indicating the patients arrive at hospitals
which are capable of providing TB diagnostics. Arriving at this state means a
patient start having a chance to get diagnosed and to receive TB treatment.
The basic state-space in my options include all states mentioned, that is, Wait-
ing (W), Diagnostics Available (A), Evaluating (E), TB Detecting (D), and Treating
(T). Considering performance in simulation and the robustness of parameters, I
explored two reduce state-spaces, WAET and WAT as Table 8.1 shows. I reduced
the state-space by turning some states invisible but not alter the definitions of the
states. For example, from WAEDT to WAET, I added up the durations of E-D and
D-T to be the duration of E-T.
Zero delays
In Chapter 6, I found that a considerable proportion of the care-seeking pathways
did not have all the four stages. That is, skipping some stage before reaching Treat-
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W A E T
WAEDT
W A E D T
State skip No skip
... A E D ...
δE δD
Zero inflated
... A E D ...
δE δD
P (δE = 0) P (δD = 0)
Competing
... A E D ...
δA→E δE→D
δA→D
Stage: W, Waiting; A, Diagnostics available; E, Evaluating; D, TB Detecting; T, Treating
δx, duration in the state before x
P (δx = 0), probability of zero duration in the state before x
δx→y , duration of x before y
ing Stage was common in the setting. To capturing the skipping, I examined three
parametrisations as the second part of Table 8.1. In the first option, I regarded the
zero delays as extremely short delays and, hence, analysed them as zero in the
response variables in the regression analysis. The second applies the Zero-Inflated
approaches [1], which is a mixture distribution made of a Bernoulli process indi-
cating zero value and a time-to-state distribution for the rest. The last option uses
multi-state models to specify state transitions. In each state, the following states
will compete for being the next. For example, in Waiting if Treating comes earlier
than the others, the next will be Treating but not Diagnostics Available.
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Predictors
I considered the predictors of age, sex, individual socioeconomic status (SES),
regional SES, and comorbidities for simulating durations between transitions in
my state-space models. These features applied the same definitions as in the
SES analysis of Chapter 7. Some patients of care-seeking pathways had missing
residential areas, and I used the areas of the hospitals which they initiated care-
seeking instead. As for the missing values in the other field, I presume they missed
completely at random and dealt with them by deleting the pathways.
Regression models
Throughout the state-space modelling, I employed the Cox Proportional Hazard
models for linking the predictors to time-to-states and logistic regression for prob-
abilities if the zero-inflated distribution applied. For the time-to-states, after es-
timating the coefficients of predictors, I extracted the baseline hazard functions
and parametrised them. I considered the exponential and Weibull distributions
to model the baseline hazard functions for each combination of state-space and
skipping method.
It is to noted that, I considered the time-to-Diagnostics Available and the time-
to-states after that separately. I firstly selected the optimal time-to-Diagnostics
Available parametrisation according to the Akaike information criterion (AIC)
before modelling the following time-to-states. For robustness of estimation, I
trimmed the care-seeking pathways which had system delays over 95% quantiles.
Model selection
The main focus of this state-space modelling was to find a good parametrisation
in simulating the system delays. Given the same distributions of the predictors, I
simulated the care-seeking pathways using the candidate state-space models and
calculated system delays. I then compared the distributions of system delays in the
IPPA results and the simulated system delays by the Kullback-Leibler divergence
(KL-divergence) [2]. Then, I selected a state-space model with the smallest KL-
divergence.
The analysis was implemented by the procedure as follows. Given a candidate
state-space model,
• Estimate the parameters of the state-space model.
• Based on the model and the parameters, use the predictors of care-seeking
pathways to sample simulated care-seeking pathways (7,255 pathways).
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• Calculate the 7,255 system delays of the 7,255 pathways.
• Summarise the system delays in the median value.
• Calculate the KL-divergence of the simulated system delays against empiri-
cal system delays.
• Repeat step 2 to 5 by 1,000 times, and fetch 1,000 median system delays and
KL-divergences accordingly.




On average, 65% of patients who arrived at a hospital have TB diagnostics available
at their initial care-seeking. For those who could not have TB diagnostics due to
the capability, the time-to-Diagnostics Available was 31 days in the median with
first and third quartiles of 10 and 68 days. Considering predictors with the Zero-
inflated Cox regression, I found the Weibull distribution provided better goodness
of fit than the exponential distribution.
Model selection
Table 8.2 shows the simulated system delays and KL-divergences. In general, the
state-space WAET performed better than WAT and WAEDT. Most of the candidate
models can simulate the mean of the median system delay around the empirical
median system delay. The candidate models without state skipping usually ren-
dered longer system delays; the simulations using the models with Zero-Inflated
distributions were closer to the empirical given the same state-space and base-
line hazard. Across the candidate models, the WAET state-space with the Zero-
Inflated Exponential time-to-state distributions was the optimal choice, showing
KL-divergence of 0.018 (95% CI: 0.011-0.025).
Chapter 8. Hybrid modelling 139
Table 8.2: Simulations of state-space models
State space State skip Baseline hazard Med System Delay KL-divergence
(Mean, 95% CI) (Mean, 95% CI)
WAT
No skip Exponential 53 (46, 62) 0.125 (0.115, 0.135)
No skip Weibull 36 (31, 42) 0.069 (0.061, 0.079)
Zero inflated Exponential 29 (25, 33) 0.113 (0.099, 0.126)
Zero inflated Weibull 30 (26, 34) 0.102 (0.088, 0.116)
WAET
No skip Exponential 95 (81, 108) 0.519 (0.502, 0.537)
No skip Weibull 59 (50, 69) 0.254 (0.241, 0.269)
Zero inflated Exponential 49 (41, 59) 0.018 (0.011, 0.025)
Zero inflated Weibull 32 (27, 38) 0.045 (0.034, 0.055)
Competing Exponential 46 (39, 54) 0.028 (0.021, 0.035)
Competing Weibull 30 (25, 36) 0.091 (0.078, 0.104)
WAEDT
No skip Exponential 126 (108, 148) 0.897 (0.875, 0.917)
No skip Weibull 67 (56, 81) 0.43 (0.412, 0.449)
Zero inflated Exponential 55 (46, 66) 0.025 (0.017, 0.033)
Zero inflated Weibull 31 (26, 37) 0.038 (0.028, 0.049)
Competing Exponential 40 (34, 47) 0.145 (0.135, 0.154)
Competing Weibull 24 (21, 28) 0.111 (0.101, 0.121)
System Delay (Med, IQR)
Data 41 (7, 111)
Stage: W, Waiting; A, Diagnostics available; E, Evaluating; D, TB Detecting; T, Treating
Med: Median, IQR: interquartile range, OR: odds ratio, CI: confidence interval
KL-divergence: Kullback–Leibler divergence
8.3 Dropout estimation
Using the IPPA results, I seek to estimate the TB fatality rates in this section. Also,
I want to estimate the rates of loss to follow-up (LTFU), which is compatible with
the IPPA results, to support the care-seeking ABM in Section 8.4 as well as the
mean-field model in Section 8.5.
8.3.1 Methods
Data and notations
I used the IPPA results and demographic data from the Department of Statis-
tics, the Ministry of the Interior, Taiwan. I exacted the time-to treatment out-
come and treatment outcome from the IPPA results and grouped the time-to
treatment outcome by treatment outcomes. The demographic data included the
mid-year population estimators and deaths by single-year ages from 2000 to 2010.
The demographic data were published by the Taiwan officials and free access
on the internet; the usage is licensed by the Open Government Data License:
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[https://data.gov.tw/license]. The data descriptions are as follows:
agp: age-group ∈ {<15, 15-34, 35-64, 65+}.
y: treatment outcome (completed: 0, death: 1, LTFU: 2) extracted from IPPA re-
sults.
t: time-to treatment outcome.
drage,sex,year: crude annual death rate of age, sex, year. Number of deaths over
mid-year population.
f ragp: TB-specific death rate per person-year of age group, agp
lragp: LTFU rate per person-year of age group, agp
Model
I derived the statistical model from a state-space model parametrisation. There
are three types of treatment outcomes occurring: all-cause death, LTFU, and treat-
ment completion. Treatment completion depends on the absence of the other two
outcomes. I assumed death and LTFU follow Exponential distributions, which has
a non time-varying hazard. The rates for death and LTFU are ( f ragp + drage,sex,year)







−( f ragp + drage,sex,year + lragp) f ragp + drage,sex,year lragp Treating
0 0 0 Death
0 0 0 LTFU
(8.1)
Convert T to transition probability matrix P given time-to event t through
P = 1− mexp(−tR), where mexp(.) is matrix exponential function. Therefore, I
have






1− p f ragp+drage,sex,yearf ragp+drage,sex,year+lragp p
lragp
f ragp+drage,sex,year+lragp p Treating
0 1 0 Death




− t( f ragp + drage,sex,year + lragp)
)
and the values in the first row of P matches the probabilities of treatment out-
comes at time t. Then, under a Bayesian framework, I used weak prior of uniform
distributions, U(0, 0.5) for f ragp and lragp. The full model is
Foreach pathway i {
yi ∼ category(pri)
pri[0] = 1− pi
pri[1] =
f ragp + drage,sex,year












f ragp ∼ U(0, 0.5)
lragp ∼ U(0, 0.5)
}
To be noted that, I ignored the index i for agp, age, sex, and year for clarity,
but they are specified for each pathway. By dropping the agp strata, I also used a
simplified model to estimate the aggregated TB-specific death and LTFU rates.
I used Markov Chain Monte Carlo (MCMC) to sample to posterior distributions
of f ragp and lragp. I ran three chains of MCMC for the estimation procedure.
The analysis in this section was performed in JAGS 4.3.0 [5] with the interface of
R2jags [6] in R 3.5.1
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Results
Considering the convergence of the posterior distributions, I discarded the first
2,000 iterations and collected every 10 iterations after that until 500 parameter
sets retrieved for each chain. As Figure 8.2 shows, the traces of the posterior
parameters converged and the samples drawn from the three chains were close.
Table 8.3 shows the results of the estimation of TB-specific death rates and LTFU
rates. Apart from the youngest group, the TB-specific death rates rose along with
age. The TB patients aged 65 and above had highest TB-specific death rate of
0.19 (95% credible interval (CrI): 0.173-0.206). The TB patients aged below 15
shows a wider 95% CrI reflecting the relatively small sample size. Without age
stratification, the TB-specific death rate was estimated at 0.116 (95% CrI: 0.106-
0.126).
In terms of LTFU rates, apart from the oldest group, the rates were around 0.25
per person-year. The TB patients aged below 15 shows a wide CrI as well. I found
that the oldest age group had the lowest LTFU rate of 0.208 (95% CrI: 0.16-0.189),
showing an opposite direction to TB-specific death rate. Comparing the goodness
of fit, the estimators of DIC prefers the model with age group strata.
Table 8.3: Estimators of TB-specific death rates and LTFU rates
Age Number
TB-specific death rate LTFU rate
DIC
Mean (95% CrI) Mean (95% CrI)
<15 36 0.034 (0.002, 0.122) 0.265 (0.118, 0.449)
16904
15-34 875 0.019 (0.009, 0.031) 0.244 (0.209, 0.285)
35-64 2683 0.071 (0.06, 0.083) 0.247 (0.228, 0.268)
65+ 3661 0.19 (0.173, 0.206) 0.174 (0.16, 0.189)
Aggregated 7255 0.116 (0.106, 0.126) 0.208 (0.196, 0.22) 17145
LTFU: loss to follow-up, CrI: credible interval, DIC: deviance information criterion
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Figure 8.2: Traces of posterior TB-specific death rates and LTFU rates
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8.4 Care-seeking agent-based modelling, CSM
From the previous steps, I have built a step-space model, StSp, for simulating the
care-seeking pathways and estimators for dropout occurrences based on the IPPA
results. Combining them, this step has the following three tasks.
• Constructing a self-contained agent-based model, CSM, which can assess the
outcomes without transmission processes.
• Ensuring the relationships between the time-series of initial care-seeking
(ICS) rates and notification rates and providing a likelihood function for
calibrating the transmission models in the next step.
• Providing the age-sex distributions of patients at their initial care-seeking at
each time point of interest in order to populate agents in the final hybrid
model.
These tasks aimed to keep the uncertainty between the ICS and notification to
minimal, making the model close to the empirical results and reality.
8.4.1 Methods
Using StSp from the previous section, I constructed an ABM. The agents are
started with untreated active TB and at their ICS. Death, spontaneous recovery,
and loss to follow-up might happen according to Section 8.3, and the agents will
be deleted from the system after that. I considered ages ranged from 0 to 99 by
single year, binary sexes, and years from 2005 to 2018.
In Taiwan, the TB notification recorded upon the prescription of anti-TB drugs.
The notification rates should align with the rates of arriving at Treating Stage. The
time difference between an initial care-seeking and its notification is the system
delay, by definition. However, the initial care-seeking rates cannot be assessed
by merely shifting the notification rates according to the system delays because
of dropouts between the two rates were different in different ages. Death and
spontaneous recovery without treatment might happen even if the patients have
perfect attendance during care-seeking. To investigate the relationship the sex-
age distribution at ICS and at the notification, I simulated cohorts started from
ICS for different ages, sexes, and years. For each combination of age, sex, and
year, I initialised 10,000 patient agents. I then calculated the proportion of the
patients who had started TB treatment (notification) after one year of a calendar
year. Given the probability of being notified, I inversely calculated the number
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of initial care-seeking by dividing the notification by the probabilities in the same
age-sex-year stratum.
After retrieving the four time-series of initial care-seeking and notification by
sex, I then used them to prepare a likelihood function linking to the simulated
data. Explicitly, I utilised the structural vector autoregression (SVAR) with one lag
terms to the four time-series. I controlled linear temporal trends and intercepts
before measuring the variance-covariance. Since the initial care-seeking rates were
built from the notification, I structured the covariance matrix by assuming the
dependency but kept the females and males independent. I used count data but
not rates because the population dynamic was considered as an exogenous process
in this thesis.
I used python 3.7 to perform the simulations and R 3.5.1 with packages vars [7]
to perform the time-series analysis.
8.4.2 Results
Figure 8.3-A shows that the proportion of patients being notified over people with
active TB who initiated care-seeking. The dropouts, combining death and self-
cure, increase along with age in both sexes. 15% of the patients aged 65 or above
cannot start treatment because of the dropout. I did not identify significant tem-
poral trends in the dropouts. With the age-specific dropout proportions, I calcu-
lated the number of initial care-seeking for both sexes every year. Figure 8.3-B
demonstrates the mean of initial care-seeking rates compared with the mean of
notification rates across 2005-2018 by ages. The differences between them increase
by ages. In the age groups above 70, the difference is 20 per 100,000 for females
and is 100 per 100,000 for males.
Figure 8.4 shows the trends of and notification and inferred initial care-seeking
rates by sexes. The differences in males are about twice as in females. Using SVAR,
I estimated the variance of the initial cares-seeking and notification numbers were
(140, 90) and (207, 135) for females and males respectively. The covariances were
98 and 146 for females and males. As a result, I formulated the likelihood function
linking the results to TB dynamics simulation by multivariate normal distribution
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as following:
























91 98 0 0
98 140 0 0
0 0 138 146
0 0 146 207
(8.5)
where f for female, m for male; µ were time-series from this section while x
denotes the respective values from simulation in Section 8.5.
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B. Notification and Initial Care−seeking
Figure 8.3: Dropouts before treatment by age







































Figure 8.4: Notification and inferred initial care-seeking rates by sexes
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8.5 The mean-field model for TB dynamics, MFM
One potential drawback of hybrid modelling is stochasticity in the simulation
time. Given the same population size and dynamics, the simulation time of ABMs
should be the upper bound of hybrid models. However, the time and memory
costs of hybrid simulation highly depend on the number of agents in the sys-
tem. Especially in model fitting, calibration procedures might input parameters
which generate unrealistically large agent-populations in early stages and gener-
ate crashes due to insufficient memory. In purely ABMs and EBMs, I can usually
expect the time and memory usages before model fitting but not in hybrid mod-
elling.
Therefore, in this section, I first developed a compartmental EBM (MFM) of the
system of interest. I tested a model structure for capturing TB dynamics in Taiwan
and specified priors of parameters. Also, I regarded the constructed model in this
section as the deterministic baseline model (or mean-field model). I expected the
hybrid model of the next section behaves like MFM on average.
8.5.1 Model structure
Figure 8.5: Modelling structure: mean-field model. U: uninfected, FL: fast la-
tency, SL: slow latency, P: active TB before care-seeking, C f : female active TB
during care-seeking, Cm: male active TB during care-seeking, T: active TB under
treatment, R: recovered
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I developed a model based on Ordinary Differential Equations (ODEs). As
the ODE system in Equations 8.6 and the conceptual model in Figure 8.5, there
are eight compartments in MFM: uninfected (U), fast latency (FL), slow latency
(SL), before care-seeking (P), females during care-seeking (C f ), males during care-
seeking (Cm), under treatment (T) and recovered (R). From the beginning, peo-
ple were born as U. After infection, U transit to FL which have a high primary
progress rate ract for being activated as P. If activation did not occur within five
years, FL turn into SL, which can progress to P as well, but the rate is lower than
the primary progression rate. P will seek care after a patient delay (δp) and transit
to C f and Cm by κ and 1− κ respectively. After a system delay (δs), C f and Cm will
flow to T and be notified at the same time. T go to R after treatment works. R
might relapse to P according to relapse rate rrel . The active TB, including P, Cm,
C f , and T are infectious with identical infectiousness, and they can die due to TB
following the TB-specific death rates estimated by Section 8.3. They can also spon-
taneously cure (rcure) without treatment. C f , Cm, and T might flow back to P by the
rate of rloss if the evaluation interrupted or loss to follow-up. The reinfection of TB
might incur to SL and R and bring them to FL after that, but the transmission rate
is lower the infection because of a discount from partial immunity (π). Table 8.4
lists the values or prior distributions, and definitions of the parameters.
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rrec + rloss + rcure
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T −νT + ∆T(t)
dR
dt
= rrecT + rcure
(




rrel + (1− π)Λ(t)
)
R +∆R(t)
The force of infection Λ(t) at year t is defined as:
Λ(t) = β(t)
P + C f + Cm + T
N
(8.7)
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where β(t) is the transmission parameter at year t and N is total population size.
Then, I defined the transmission parameter as a time-varying function:
β(t) = max(β0 × rrA(t)−A(2000)A , βlower) (8.8)
where A(t) is a population ageing index at t, β0 is the initial transmission parame-
ter, βlower is the minimal of β(t), and rrA is the risk ratio of per unit A(.) increment
from 2000. I considered two population ageing indices, average age and the pro-
portion of the population aged 65 and above. Also, I used the calendar year as an
index and a scenario with constant beta as comparators.
The population dynamics (∆ for every state) applied the synthetic demogra-
phy from Chapter 5. Though, I assumed no migration of those with active TB
during care seeking and presumed a perfect border control. As for the other com-
partments, I supposed the distributions of the latency among the immigrants and
emigrants are the same as the prevalence in the system. All newborns starts in the
compartment U.
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Table 8.4: Prior distributions and assumptions of parameters
Notation Parameter Value Unit Reference
Exogenous variables
1/rlat duration of fast latency 5 year By definition
rcure spontaneously cure rate 0.33 year−1 Tiemersma et al. [8]
rrec recovery rate (with treatment) 1 month−1 Assumed
rloss LTFU rate 0.208 year−1 Section 8.3
π partial immunity for reinfection 0.8 None Vynnycky and Fine [9]
µ TB fatality without treatment 0.122 year−1 Tiemersma et al. [8]
ν TB fatality after treatment 0.116 year−1 Section 8.3
Notation Parameter Prior distribution Unit Reference
Parameters to fit and their dependants
β0 initial β U(1, 40) year−1 Assumed
βlower minimal β U(1, β0) year−1 Assumed
ract primary progression rate 15% (5years)−1 Trauer et al. [10]
rract reactivation rate 0.01ract year−1 Assumed
rrel relapse rate 0.01ract year−1 Assumed
κ
proportion of female patients
at initial care-seeking
U(0.2, 0.4) % Chapter 5
rrA risk ratio of population ageing U(0.5, 1) None Assumed
δp patient delay U(7, 60) day Chiang et al. [11]
δs system delay U(7, 111) day Chapter 6
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8.5.2 Populating and equilibrating the model
I attempted to equilibrate the model by numerically solving the condition that all
fractions of compartments are in a steady state. I dropped the parameter sets that
led the model to disease-free equilibrium. I fixed all parameters and demography
to values in 2000 while equilibrating period. In this model, I included population
dynamics driven by real data. In reality, the population was growing in 2000. I
made a dynamic adjustment to keep the equilibrium without distorting the origi-
nal dynamics.
Explicitly, I transformed the model in numbers into fractions of compartments.
Consider
x(t) = X(t)/N(t) (8.9)
where x(t) and X(t) are the proportion and number of compartment x at t respec-

















For keeping the nature of population dynamics, the population in each com-
partment need an additional outflow with the rate corresponding to the overall
population growth in the initial year.
8.5.3 Calibration and model selection
I calibrated my model to fit the annual sex-specific TB notification and the inci-
dence of initial care-seeking from 2005 to 2018 as Figure 8.4 with the variance-
covariance estimated by Section 8.4. Explicitly, for each time point, the simu-
lated notification and initial care-seeking follows a multivariate normal with a
mean vector of the numbers of notification and initial care-seeking by sexes, and a
variance-covariance matrix in Equation 8.3. I employed the Approximate Bayesian
Computation with sequential Monte Carlo (ABC-SMC) procedure with a tolerance
adaptation scheme to the calibration by the methods derived in Del Moral et al.
[12]. Following the fitting algorithm, I set up 500 samples per iteration, and ran
until the convergence in the value of tolerance and the effective sample size. Also,
I solved the maximum likelihood estimator (MLE) and the maximum a posteriori
154 8.5. The mean-field model for TB dynamics, MFM
(MAP) by a genetic algorithm (GA). As ABC-SMC, 500 sample size per iteration
were used and I ran until the convergence in the maximum values (likelihood for
MLE, posterior probability for MAP).
I examined different rates of TB primary progression rates (10%, 15%, 20%, and
30% within 5 years after infection) and time-series indicating population ageing
(average age, the proportion of the population aged 65 and above (PrO), calendar
year, and constant). I used Deviance information criterion (DIC) to select the
optimal model among the options for the forecasting and intervention analysis
(Chapter 9). Also, I targeted the proportion of latency among the population in
2018 and 2035 at 20-40% roughly aligning the Global burden [13].
8.5.4 Results
Table 8.5 shows the DIC and the proportion of latency in 2018 and in 2035 given
different model assumptions after calibration. Using the primary progression
within 5 years at 15% and 20% rendered lower DICs in general. The compara-
tor of constant transmission parameter shows higher DICs across the primary
progression rates. Using calendar time as the index of population ageing shows
similar DICs to that of average age. The cases with PrO had the lowest DIC across
the range of the primary progression rates. I evaluated the models with primary
progression within 5 years and ageing index of (15%, PrO) and (20%, PrO) were
identically the best. However, considering the literatures, the primary progres-
sion probability with 5 years after infection, the estimation were ranged from 5%
[14, 15] to 15% [10]. Taken it together with the stochastics of the simulation, I pre-
ferred (15% PrO) and its posterior parameters (see Table 8.6) as my final selection.
Figure 8.6 compares the selected model, (15% PrO), and the time-series of
initial care-seeking rates and notification rates by sexes. The simulation captured
the trends and the patterns of the four time-series. The estimators of MAP and
MLE were close to data points without biases. The 95% credible intervals of the
posterior simulations fully covered the data points. However, the median time-
series of the posterior simulations were slightly above the data of initial care-
seeking rates and below notification rates.
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Figure 8.6: Posterior simulations with data points. The shaded areas are the 95%
credible intervals of the posterior simulations
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Table 8.5: Mean-field model, comparison
Primary progression







Constant 6212 42 (38, 46) 46 (42, 50)
Average age 4247 46 (39, 53) 44 (39, 51)
Population ≥ 65 3202 47 (42, 53) 44 (40, 49)
Calender year 5914 45 (38, 53) 44 (38, 52)
15
Constant 7031 28 (20, 36) 31 (22, 40)
Average age 2696 44 (31, 56) 41 (29, 52)
Population ≥ 65 2483 38 (29, 45) 35 (27, 41)
Calender year 4214 42 (29, 56) 39 (28, 51)
20
Constant 7866 22 (11, 32) 24 (12, 36)
Average age 6221 39 (25, 50) 36 (23, 46)
Population ≥ 65 2361 31 (20, 41) 28 (19, 37)
Calender year 6406 40 (27, 49) 37 (24, 45)
30
Constant 31846 14 (4, 26) 15 (4, 29)
Average age 11921 27 (12, 43) 25 (12, 39)
Population ≥ 65 16116 21 (8, 37) 20 (7, 34)
Calender year 10485 28 (13, 43) 26 (12, 39)
DIC: deviance information criterion
Table 8.6: Posterior distributions for parameters
Parameter Prior distribution Unit
Posterior
Mean (95% CrI) Median (Q1, Q3)
β0 U(1, 40) year−1 28.63 (21.11, 37.81) 27.93 (24.99, 31.98)
βlower U(1, β0) year−1 5.37 (1.28, 9.6) 5.5 (3.35, 7.27)
rrA U(0.5, 1) None 0.14 (0.03, 0.26) 0.13 (0.08, 0.18)
κ U(0.2, 0.4) % 0.30 (0.29, 0.31) 0.30 (0.29, 0.30.46)
δp U(7, 60) day 37.42 (9.14, 59.57) 40.41 (23.84, 50.98)
δs U(7, 111) day 75.65 (14.02, 111.92) 83.76 (56.24, 99.47)
8.6 Hybrid modelling, HM
Combining the advantage of ABMs in describing details processes and the effi-
ciency of EBMs, I developed a hybrid model for complex care-seeking processes
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and overall TB epidemics. Starting from MFM I developed and calibrated in the
last section, and I replaced the compartments after the active TB initiated care-
seeking and before completing TB treatment with the agent-based submodel de-
scribed in Section 8.4.
It should be noted that the EBM in this section always indicates the EBM sub-
model of HM while MFM indicates the EBM constructed in the previous section.
Similarly, the ABM in this section indicates the ABM submodel of HM.
8.6.1 Coupling and synchronisation of the EBM and ABM
Transmission and infection processes were modelled in the EBM as MFM. For
calculating the force of infection, the EBM requests the number of infectious peo-
ple in the ABM by a turn-based schedule. Once the value updated, force of in-
fection will change. The definition of transmission parameters β(t) is the same as
MFM, declining with population ageing until hitting the lower bound.
Tracing the number of infectious people is an important task of the ABM. In
the ABM, when a new active TB being added or an active TB being inactivated,
the number of infectious agents will be updated. However, the ABM calculates the
moving average of the number of infectious agents and reports to the EBM each
discrete time step. Before fetching the number of infectious in the ABM, the EBM
will update to the time when the event happened in the ABM.
Initial care-seeking process is a transfer from the EBM to ABM. In every time
step, I sampled a proportion of the active TB according to the rate of the invasion
of patient delay (δp) and transferred them to the ABM as patients. When a patient
is instantiated in the ABM, their details will be sampled according to age-sex
distribution modelled in Chapter 5 and distributions of the other personal features
fitted in Chapter 6.
Turn-based events might cause cycles of TB prevalence: ie more agents at the
beginning of each turn, and the number declining until the beginning of next
turn. To reduce the influence of this potential effect, I used a finer scale (10 per
observation interval) on the time steps than the observational interval of one year
to eliminate the information loss.
Death, recovery, loss to follow-up, and treatment success are events removing
agents from the ABM. The agents, after recovered and treatment success, will be
transferred back to the recovered of EBM. The patients dropped out because of
IE/LTFU will go to the active TB prior to initial care-seeking and have a chance
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to start care-seeking again. Those events applied a real-time update. The EBM
updates to the event time and takes the recovered or lost patient whenever an
event happens.
It is worth noting that T in MFM includes only the TB patients under treatment
before TB inactivated. Once the TB has been inactivated patients will be counted
as R. In the ABM part of HM, the agents will be transferred to R the EBM only if
the treatment competed.
8.6.2 Simulation and validation
I used the posterior parameters directly from the MFM results. As I kept 500 pos-
terior parameter sets in the previous section, I used them iteratively for simulating
HM results. That is, for each parameter set, given the values, I simulated outputs
using MFM and HM simultaneously and calculated the difference after that. I
calculated the difference between MFM and HM by the percentage difference:
di f f erence(hmt −m f mt) ≡





log(hmt)− log(m f mt)
)
× 100% (8.14)
where hmt and m f mt are variables at time t generated by HM and MFM respec-
tively, The approximation was derived from the first order Taylor expansion of the
logarithm function to prevent over-sensitive baseline value, i.e. m f mt.
8.6.3 Results: Validation
Figure 8.7 compares the simulations of and differences between MFM and HM by
sex-specific ICS and notification rates. The simulations of HM reproduced the pat-
terns of MFM for all the four time-series, and HM rendered a wider prediction in-
terval. In terms of the difference, the simulations of HM were unbiased, indicating
the MFM can represent the mean-field of the system. HM sometimes generated
sporadic outbreaks during simulation, but that did not cause HM crashed. Most
of the differences between HM and MFM simulations were within 30%. However,
some extreme outbreak cases of HM had 150% more than their MFM simulation.









































































































































































































































Figure 8.7: Comparison of the results of MFM and HM. Incidence and mortality
are in annual rate. Red lines indicate simulations; black lines indicate the median
values in each time stage; black dots are data points.
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8.7 Simulation outputs and results
8.7.1 Epidemiology
Figure 8.8 demonstrates the TB incidence, prevalence, and mortality rates between
2001 to 2035. As Figure 8.7 three columns were results of MFM, HM, and their
difference, respectively. The impacts of sporadic outbreaks showed in the preva-
lence and mortality as well. Also, the three indices by HM did not bias from MFM
results. The results forecasted that the TB incidence will be 42 (95% prediction
interval, PI: 22-136) per 100,000, and 19 (95% PI: 12-48) per 100,000 in 2020 and
2035 respectively.
Dropouts
Using CSM, Table 8.7 demonstrates cohort-based dropouts with 2019 and 2035
cohorts. The dropouts due to death and self-cure were categorised by stages: pre-
hospital care-seeking, between initial care-seeking and treatment initiation, after
treatment start. There is no LTFU because, in this cohort simulation, the patients
who had LTFU went back to pre-hospital care-seeking (compartment P), they will
recur to care-seeking until other dropouts or treatment completion happen. In
both 2019 and 2035 cohorts at the 12th month, around 5% will drop before care-
seeking, and around 10% will drop before TB treatment start. In total, in the first
year after symptoms onset, 15% of active TB will not have a chance to receive
TB treatment. The simulation forecasted that the distributions of dropouts in the
two cohorts will be close. Considering the trends of dropouts, dropouts in all
categories will happen in the first three months.
Figure 8.9 shows a population-based dropout cascades, which calculated from
the annual rates of incidence, ICS, notification, and cured by TB treatment. Fig-
ure 8.9-A demonstrates that the four rates are declining at similar rates. From
2005, there were about ten incident cases per 100,000 lost between ICS and notifi-
cation (treatment start). The gaps closed to 5 in 2015 and will be reducing within
my forecast end. In terms of the relative numbers as Figure 8.9-B, the period be-
tween ICS and notification always contributed to around 10% of incidence rates;
about 3% were during treatment.















































































































































Figure 8.8: TB epidemiology by MFM and HM. Incidence and mortality are in
annual rate. Red lines indicate simulations; black lines indicate the median values
in each time stage.
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Figure 8.9: A population-based dropout cascades by hybrid modelling
Chapter 8. Hybrid modelling 163
Table 8.7: Cohort-based dropouts, 2019 and 2035 cohorts
Dropout
3rd month 6th month 9th month 12th month
mean (95% PI) mean (95% PI) mean (95% PI) mean (95% PI)
In 2019
Pre-Hospital
Self-cure 3% (0.9%, 4.2%) 3.5% (1%, 5.2%) 3.6% (1%, 5.5%) 3.7% (1%, 5.7%)
Death 1.4% (0.5%, 2%) 1.7% (0.5%, 2.5%) 1.8% (0.5%, 2.7%) 1.8% (0.5%, 2.8%)
Before treatment
Self-cure 3% (2.1%, 4.3%) 5.3% (4.4%, 6.4%) 6.3% (5.5%, 7.2%) 6.7% (5.9%, 7.5%)
Death 1.1% (0.7%, 1.6%) 2% (1.5%, 2.5%) 2.3% (1.9%, 2.8%) 2.5% (2.1%, 3%)
During treating
Death 0.3% (0.2%, 0.6%) 0.7% (0.4%, 1%) 0.8% (0.6%, 1.2%) 0.9% (0.6%, 1.2%)
In 2035
Pre-Hospital
Self-cure 3% (0.9%, 4.2%) 3.4% (1%, 5.1%) 3.6% (1%, 5.4%) 3.7% (1%, 5.6%)
Death 1.5% (0.5%, 2%) 1.7% (0.5%, 2.5%) 1.8% (0.5%, 2.7%) 1.8% (0.5%, 2.8%)
Before treatment
Self-cure 3% (2.1%, 4.2%) 5.1% (4.3%, 6.2%) 6.1% (5.3%, 7%) 6.6% (5.8%, 7.4%)
Death 1.1% (0.7%, 1.7%) 1.9% (1.4%, 2.5%) 2.3% (1.8%, 2.8%) 2.4% (2%, 2.9%)
During treating
Death 0.3% (0.2%, 0.6%) 0.6% (0.4%, 0.9%) 0.8% (0.5%, 1.1%) 0.9% (0.6%, 1.2%)
PI: prediction interval
8.8 Discussion
This chapter forged a hybrid model of TB epidemiology, considering the care-
seeking process in Taiwan using the results of the former chapters in this thesis.
Chapter 6 empirically sketched the care-seeking pathways of TB patients with
links to socioeconomic factors. Chapter 2 featured the intervenable factors or
processes which can be considered when innovating TB control strategy. Chapter 4
summarised how to model health behaviours, including care-seeking behaviour
in ABMs. Section 8.2 searched, examined, and selected from various state-space
models, and used the best one, StSp, to simulate the patient pathways. Section 8.3
used a part of results from the pathways to estimate the parameters of TB-specific
death and LTFU under treatment. Section 8.4 used StSp, and dropout parameters
to develop an agent-based care-seeking model, CSM. Chapter 5 profiled the age-
sex distributions of TB notification in the near future by analysing the notification
data in Taiwan from 2005 to 2018. Section 8.5 used it to develop a mean-field
model, MFM, to capture the epidemiology of TB in Taiwan. Lastly, Chapter 3
reviewed the examples of coupling agent-based and equation-based simulations
in health fields. Section 8.6 combined the CSM and MFM part to develop a hybrid
model, HM, which can be employed to assess the SES-based interventions on
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population outcome.
8.8.1 Features of the final hybrid model
According to the strength of TB evaluation and treatment prescription, I identi-
fied Waiting, Evaluating, TB Detecting, and Treating Stages from the case-seeking
pathways. In this section, I built state-space models to capture the dynamics of
the transitioning among the stages. Then, among the options of state-spaces and
parametrisation, I selected two candidate models which have the best capability
of simulating the system delays with the lowest distance to that in the data.
I built and calibrated a hybrid model, i.e. HM, in this chapter. My models have
the following features.
HM can consider the intervention through the quantified effects in the under-
lying state-space model, StSp. Once a substantial intervention target is available, I
can propose impulses on the lengths of time-to-states or the probabilities of skip-
ping a state and evaluate the responses of the model according to the changes.
HM can consider the intervention by changing the TB service capability distri-
butions. The diagnostics availability in the constructed model were based on the
IPPA results with individual hospital data. By assigning the capacity of providing
some services to the hospitals in the IPPA results, I can assess their impulse-
responses as well.
With the hybrid modelling approaches, HM facilitated the country-level agent-
based simulations by collapsing the agents outside these who seek care for TB into
a compartment model. For my case, in population 23 million with a TB endemic
of 5,000 active TB cases, a simulation for 35 calendar years required only about
three minutes in personal computers (see Section 8.6 for specification).
Along with HM, I provided an equation-based comparator, MFM. The con-
cepts of MFM and HM are identical except for the details about the care-seeking
and treatment processes. I used MFM to test the functionality and to calibrate
the parameters before the hybrid modelling. Also, MFM provided a deterministic
view of HM. Given the comparison of the simulations of HM and MFM, I assert
that the HM results are compatible with the MFM results while HM revealed the
issues around stochasticity.
As a new application of hybrid modelling, HM maximised the utility of data
without adding uncertain modelling components or oversimplifying the compo-
nents of interest. In the EBM usual, I used stratification to address the hetero-
geneous among the strata, and I used a single summary statistic to simplify a
complex distribution to a term in an equation. These approaches introduce infor-
mation losses, requiring further justification to address the biases. In the ABM
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part, I modelled every component if it is involved in the process of interest. Some-
times, I do not have enough data or knowledge to inform all of them, so I needed
to assume the mechanism driving them and conduct many sensitivity analyses
to support these assumptions. For example, to model the transmission process, I
might need a social network modelling or data from a contact survey. However,
such surveys and modelling approaches come with high costs. Apart from the
processes I had data to support, I parametrised them in the EBM sub-model as
much as possible. If I expected a process would be relevant to the intervention
analysis, I would consider them in the ABM sub-model.
8.8.2 State-space modelling
According to the model selection of StSp, it is preferable to model periods before
and after the TB-related evaluation start. That is, partitioning system delays with
serial distributions are better than using a single distribution to model. In terms of
the parametrising stage skipping, zero-inflated distributions are better than multi-
state models. This results confirmed the covariates analysis in Chapter 6 that the
risk factors of non-zero delay and longer delay were diverse.
In my study, I used detailed data on the care-seeking pathways, which means I
could parametrise the connection between stage with various options of parametri-
sation. Thinking the studies which can only collect data of the overall system delay
or any delays to treatment start, my analysis strengthened the intuition of using
phase-type distributions for capturing the distributions of delays. For example,
The Coxian-Erlang distribution which has a zero-inflated term and few follow-
ing hidden stages serially composed of Exponential distributions. Practically, the
Coxian-Erlang distribution has been proved as a generalised distribution covering
many distributions for time-to-event data if the first three statistical moments are
fetched [16, 17].
8.8.3 Dropouts
I used different TB-specific death rates for before and after treatment start. The
former used the external sources and later used the values from the IPPA results.
For patients younger than 65, the fatality rates decrease after treatment while that
of the patients aged 65 or above increases. Ideally, under proper TB care, a patient
should be well off and reduce the mortality on average. However, the results were
not contradictory. The death rates were not necessarily lower than the death rates
before treatment starts concerning the health status decaying along with time.
I counted the spontaneous self-cure without treatment as a type of dropout
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but not a favourable outcome. Although self-cured patients stop suffering from
TB, they miss the opportunities of accessing proper diagnostics and receiving pre-
ventive treatment for latent TB infections. Moreover, unless reactivation, they will
never realise that their risk of getting TB are higher than uninfected population.
I presented dropout measurements from both cohort-based and population-
based perspectives. My population-based dropouts were calculated by the ratios
of occurrence rates of critical events. This was compatible with the case-detection
gaps which were commonly used for international comparison. However, since the
approach does not consider time lag between occurrence rates, the estimators are
biased by the annual decline rate of TB incidence. For example, given one year no-
tification delay and TB incidence declines annually by 5%, the case-detection gap
is less than 0% if dropout rates are smaller than 5%. My cohort-based dropouts
differ from conventional approaches to measure dropout cascades, which depend
on the proportional dropouts from cross-sectional survey data, e.g. Subbaraman et
al. [18]. My approach complemented the drawback of using cross-sectional data,
which does not consider temporal information. For example, in cross-sectional
data, I cannot identify if a patient will not be or has not been diagnosed as a TB
patient yet.
8.8.4 Mean-field model
The major tasks of mean-field modelling were capturing the transmission dynam-
ics and TB latency. To reflect the active TB progression from being infected, there
is a variety of parametrisations for capturing latency structure. The latency can
be modelled by a single latent state or multiple states. For multiple latent states,
the connections to them from the susceptible population can be parallel, the sus-
ceptible go to different latency by respective probabilities, or serial, the infected
go through every latency than being active TB, the progression rates for different
latent states can be identical or different. Some simulation methods allow progres-
sion rates to vary continuously by time-since-infection. Moreover, the flows among
latent states provide more potentials for TB modelling. In line with the empirical
observation that TB activation rate decreases after the incubation period, Menzies
et al. [19] reviewed 312 models, suggesting that the model with a single latent state
or model having a series of latent states ended with active TB performed poorly.
Ragonnet et al. [20] reviewed and examined the structures for modelling TB in
low TB burden settings. The study confirmed the structure using two latent states
with different rates of disease progression as an optimal structure. Accordingly, I
used two latent populations in my mean-field modelling. In my implementation,
I separated the second population with lower disease progression rate into slow
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latency (SL) and recovered (R) to differentiate the individuals treated before or
not, while I did not parameterise them differently. This approach was to provide a
potential for further investigations on the impact of previous TB treatment record
on the diagnostic process.
8.8.5 Hybrid modelling
My hybrid modelling is a novel approach in addressing the interaction between
TB patients and healthcare systems. To the best of my knowledge, it is the first
application projection care-seeking pathways in individual level to overall TB epi-
demiology.
The model architecture was synthesised multiple studies from the collection
of Chapter 3. I used the frameworks of Mielczarek and Zabawa [21] to populate
agents and injecting population dynamics. I employed the idea from Djanatliev
and German, 2013 [22], to design a coupling strategy, ensuring the information in
the ABM and EBM parts were well-synchronised. I took Leonenko et al. [23] as
an example to separate the infectious population and the others while keeping the
value of force of infections unbiased.
In the results, by comparing the simulations of MFM and HM, MFM suffi-
ciently represented the mean-field of HM, so I did not re-calibrated the HM but
used the posterior parameters directly from MFM. However, HM sometimes ren-
dered higher epidemics than MFM. I attributed this to a nature of stochasticity
models. HM has a chance to simulate casual outbreaks, and the chance positively
correlated to the prevalent cases.
8.8.6 Limitations
My model did not consider asymptomatic, extrapulmonary, and multiple drug-
resistant (MDR) TB cases. The asymptomatic TB have infectiousness, but they
have a lower chance of transmitting the pathogen through the air without cough-
ing. Thus, this simplification might lead to potential underestimation on TB epi-
demiology. As for extrapulmonary and MDR TBs, I ignored them and regarded
them as the other pulmonary TB. I decided due to its small share among all TB:
about 3% [24], and since the features were less relevant to my primary interest.
As extrapulmonary and MDR TB has more uncertainty around severity and infec-
tiousness, my decision of ignoring them were also due to robustness reasons.
Apart from the transmission parameters and the population dynamics, I did
not consider the other parameters as time-varying functions. The main reason was
that I did not identify validated evidence to support the trends. I have thought
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that the patient delay may reduce due to the implementation of active case finding
(X-ray vans for mountainous areas and contact investigation). However, given the
data I had (the IPPA results and the notification time-series), the trend of the
transmission parameter and the patient delay was not identifiable. Regarding the
trend of the transmission parameter implied the changes in social networks, the
intention of self-protection, and transportation behaviour, I preferred to model the
intrinsic temporal trend by the transmission parameter.
Although I used regional SES as predictors in parameter estimation for StSp,
I did not consider geographical information in HM. The health disparity and TB
clustering exist. Especially in the mountainous area in Eastern Taiwan, although
the TB clustering is always a focus of TB control of Taiwan CDC, the healthcare
accessibility is still below needed. Also the TB incidence and mortality were sig-
nificantly over the national average. The southern end of Taiwan showed similar
issues as well [24].
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Chapter 9
Analysis of interventions to
improve TB diagnostics assess
9.1 Introduction
As I reviewed in Chapter 2, TB epidemics can be intervened on by two groups of
SES-based approaches: Universal Health Coverage (UHC) and Social Protection.
UHC ensures people with TB-suggestive symptoms can assess healthcare facilities
which can treat TB. Social protection ensures that TB patients are able to complete
the treatment without socioeconomic threatenings on them or their families. After
searching for evidence on the impacts of Social protection and UHC on TB-related
outcomes, I have identified that ex-ante and ex-post evaluations around UHC are
both limited and that Social protection might act differently in different settings.
According to the results of Chapter 6 and Chapter 7, I identified that around
40% of patients started their care-seeking at the lowest level of hospitals (Level
A, general practice/clinic). However, only about 15% of those hospitals usually
cannot provide TB diagnostics. In Chapter 7, the results demonstrated that this
mismatch was associated with longer system delays and some SES determinants.
Considering the implementation of UHC, this chapter explores the interven-
tions that increase the coverage of TB diagnostics. Meanwhile, this chapter aims
at evaluating the impacts of the interventions on TB-related outcomes using the
model built, calibrated, and validated in Chapter 8.
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9.2 Methods
9.2.1 Increasing capacity of TB diagnostic services
This chapter considers interventions targeted at the time-to-diagnostics-available
(TTDA), the period from initial care-seeking to arriving at a hospital which can
provide TB diagnostics. To improve the capacity of hospitals of providing TB
diagnostics, I constructed interventions based on four rules. For each rule, I as-
signed a priority to each hospital that cannot provide TB-diagnostics and assigned
capacity from the highest priority under a targeted scaling up. After assigning
additional diagnostic capacity, I referred back the care-seeking pathways querying
their history of hospital visits. If a care-seeking pathway met a TB-diagnostics hos-
pital early, their TTDA and respective costs were shortened. Then, I parametrised
the shortened care-seeking pathways as StSp model in Section 8.2.
Referring back to Chapter 7, including Baseline scenario, I designed three
strategies to examine, Rule 1 and Rule 2 considered the results from Chapter 7
while Rule 3 is a nonstrategic approach, which is the theoretical less effective case.
Baseline, No intervention: this rule continues the parameters as before 2019.
The index of population ageing, which determines the transmission parameters (β)
follows the synthetic population built by Chapter 5. Except for β and population
dynamics, none time-varying components are used.
Rule 1, assigning TB diagnostic capacity by regional SES: the analysis in Chap-
ter 7 revealed that ill people with TB-suggestive symptoms living in the areas with
low hospital densities were more likely to seek-care at Level A hospitals (general
practice, clinics, usually without beds for in-patients). Therefore, this rule assigns
the capacity from the hospitals visited in any care-seeking pathways sorted by
their regional hospital densities from low to high, and to the other hospitals.
Rule 2, assigning TB diagnostic capacity by individual SES: the analysis in
Chapter 7 revealed that the employed (and self-employed) patients usually started
from lower-level hospitals and suffered from longer system delays. This rule sorts
the hospitals by the numbers of pathways for employed patients that have ever
visited the hospitals.
Rule 3, assigning TB diagnostic capacity without a strategy, shuffling: The last
rule gives all hospitals random orders. All hospitals have equal weights for the
randomisation.
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Figure 9.1 demonstrates the flow of the interventions. Starting from the list of
hospitals, I firstly filtered out the hospitals with TB diagnostic capacity already
and kept the rest for the intervention analysis. Then, select a prioritisation rule
and a scale of the intervention. It is worth noting that this chapter uses “Rule”
to indicates a type of intervention and “scenario” to indicate a “Rule” with a
certain scale. This chapter uses “X% scaling-up under Rule Y” to indicate that
sorting hospitals which had no capacity of providing TB diagnostics by Rule Y,
and assigning X% of them with the capacity according to the prioritisation. The
baseline scenario is always at zero % scaling-up.
Figure 9.1: The interventions on TB diagnostic capacity. Start with the list of all
hospitals. The initial step checks if the hospitals have the capacity for providing
TB diagnostics, keeping the hospitals without the capacity. The second step selects
a rule for prioritising the hospitals. Then, within the list of remained hospitals, the
intervention is simulated by assigning the capacity with a given level of scale-up.
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9.2.2 Measurements of effectiveness
Given a StSp with intervened agents, I inputted them to different model builds
for different aspects of TB-related outcomes. I evaluated the effectiveness of the
interventional scenarios from three perspectives.
Individual-level
From individual-level perspective, I evaluated the days of system delays averted
by the interventions. As Chapter 7, I used the Gini coefficients to investigate the
inequalities of costs of healthcare system cost, patient cost, and time cost (by the
number of visits) before any TB evaluation starts (see Appendix E for definitions).
I also considered the evaluation delay (the time difference between initial care-
seeking and evaluation initiation) as a measurement of time cost. For rules 1-3, I
increased the capacities of providing TB diagnostics, viewing the returns to scale-
ups from 10% to 50%.
Population-level, cohort perspectives
Using CSM (Section 8.4), I initialised 500 cohorts (for 500 posterior parameters
after calibration (see Section 8.6), simulated them for one year during 2035. Then,
I evaluated the changes in the proportions of dropouts. The cohorts were started
with 5,000 population at TB onset. I classified the dropouts as self-cure and death.
Population-level, population perspectives
Using the hybrid model constructed in Section 8.6, I simulated the full dynamics
from 2000 to 2035 and introduced interventions at the beginning of 2019. I eval-
uated the epidemiology indices of TB prevalence, incidence, and mortality (TB-
specific). I included an index of case detection gaps defined as the non-notified
cases divided by the incident cases. Also, I calculated the incidence and mor-
tality rates reduced by the interventions. I calculated the percentage reductions
using the results of the baseline. Explicitly, for each parameter set, I inputted the
simulations with different interventional scenarios. Then, I compared their re-




9.3.1 Individual effects on patients
Figure 9.2 demonstrates the costs and evaluation delay compared with the base-
line. Generally, Rule 1 and Rule 2 showed similar patterns of effectiveness in the
costs and evaluation delay, while Rule 3 usually showed two-thirds the effect of
Rule 1 and Rule 2. Conditioning on 50% scaling up, the reductions of the health-
care system and out-of-pocket costs under Rule 1 and Rule 2 will be 25% and 30%
respectively, while the visits and evaluation delays can reduce to 45% and 55% re-




































































Time Cost (number of visits) Evaluation Delay
Healthcare System Cost Out−Of−Pocket Cost

















Intervention ● ● ●Rule 1 Rule 2 Rule 3
Figure 9.2: Impacts of interventions on the reductions in costs and the length of
evaluation delay
Figure 9.3 shows the changes in inequality by Gini coefficients under interven-
tions. For Rule 1-3, the values and trends in the Gini coefficients were close. With
the interventions scaling up to 50%, the interventions decreased the inequalities
in the time cost of visits but increased in the healthcare system cost, out-of-pocket
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expense and evaluation delays.
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Figure 9.3: Impacts of intervention on the inequality in costs and the length of
evaluation delays
9.3.2 Population effects of dropouts from cohort perspectives
Table 9.1 shows the dropouts, death and self-cure, between initial care-seeking
and treatment initiation under interventions with 30% scale-up using the 2035
cohorts started with symptom onset. Under the baseline, the dropouts due to
death will be 1.1% (95% PI: 0.7%-1.7%) and 2.4% (95% PI: 2%-2.9%) for the 3rd
and 12th months respectively while the self-cured will be about three times as
deaths. Compared with the baseline, Rule 1 will prevent about 0.7% self-cured
and 0.2% before treatment initiation at the 12th month. The results of Rule 1 and
Rule 2 will be alike. For Rule 3, the results did not show improvement in dropouts
compared with the baseline.
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Table 9.1: Dropouts under interventions with 30% scaling-up in 2035 cohort
Dropout
3rd month 6th month 9th month 12th month
mean (95% PI) mean (95% PI) mean (95% PI) mean (95% PI)
Baseline
Self-cure 3% (2.1%, 4.2%) 5.1% (4.3%, 6.2%) 6.1% (5.3%, 7%) 6.6% (5.8%, 7.4%)
Death 1.1% (0.7%, 1.7%) 1.9% (1.4%, 2.5%) 2.3% (1.8%, 2.8%) 2.4% (2%, 2.9%)
Rule 1 (30%)
Self-cure 2.7% (1.9%, 3.8%) 4.6% (3.8%, 5.6%) 5.5% (4.7%, 6.3%) 5.9% (5.1%, 6.7%)
Death 1% (0.6%, 1.5%) 1.7% (1.3%, 2.2%) 2% (1.6%, 2.5%) 2.2% (1.8%, 2.6%)
Rule 2 (30%)
Self-cure 2.7% (1.9%, 3.8%) 4.7% (3.8%, 5.7%) 5.5% (4.8%, 6.4%) 5.9% (5.2%, 6.8%)
Death 1% (0.6%, 1.5%) 1.7% (1.3%, 2.2%) 2% (1.6%, 2.5%) 2.2% (1.8%, 2.6%)
Rule 3 (30%)
Self-cure 3% (2.1%, 4.2%) 5.2% (4.3%, 6.3%) 6.3% (5.4%, 7.3%) 6.8% (6%, 7.7%)
Death 1.1% (0.7%, 1.6%) 1.9% (1.5%, 2.5%) 2.3% (1.9%, 2.8%) 2.5% (2.1%, 3%)
PI: prediction interval
9.3.3 Population effects of TB epidemiology
From the viewpoint of population perspectives, Table 9.2 shows the trends of TB
incidence, prevalence, mortality, case-detection gaps. Up to 2035, the TB incidence
rates per 100,000 will be 18.8 (95% PI: 11.8-47.7), 18.3 (95% PI: 11.8-45.2), 18.4 (95%
PI: 11.8-45.1), and 19.1 (95% PI: 11.9-50) by the baseline and Rule 1-3 respectively;
the TB mortality rates per 100,000 will be 0.9 (95% PI: 0.4-2.4), 0.6 (95% PI: 0.2-1.4),
0.6 (95% PI: 0.3-1.6), and 0.7 (95% PI: 0.3-1.8) respectively. For the case detection
gaps in 2020, Rule 1 and Rule 2 showed lower rates of 7.7% (95% PI: 2.4%-14%)
and 7.8% (95% PI: 3.9%-12.9%) compared with the baseline, 10.8% (95% PI: 5.1%,
16.8%). However, the gaps will increase by 2035 to 13% (95% PI: 6.3%-20.1%) and
13% (95% PI: 9.3%-16.6%) since 2020, being close to the baseline, 14.1% (95% PI:
8.5%-20.3%).
Table 9.3 lays out the differences between interventions with 30% scale-up com-
pared with the results of the baseline. For Rule 1 and Rule 2, the differences in TB
incidence rates will increase with the calendar year from interval estimators over-
lapping with zero in 2020 and 2025 to 1.7% (95% PI: 0.25.6%) and 1.7% (95% PI:
0.2%-5.5%) for Rules 1 and 2 in 2035, respectively. However, Rule 3 will not cause
significant changes in TB incidence across the time frame. As for TB mortality,
Rule 1-3 will have reductions without time trends, which will be around 40% for
Rule 1 and Rule 2, 30% for Rule 3. The interval estimators showed that uncertainty
in the TB mortality reduction would be increasing with time for Rule 1 and Rule
2.
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Table 9.2: TB epidemiology under interventions with 30% scaling-up
Year
Incidence Prevalence Mortality Case detection gap
per 100,000 per 100,000 per 100,000 per cent
mean (95% PI) mean (95% PI) mean (95% PI) mean (95% PI)
Baseline
2020 42.2 (22.5, 135.8) 14 (6.2, 48.6) 2.2 (0.9, 7.6) 10.8 (5.1, 16.8)
2025 30.1 (16.5, 103.9) 9.9 (4.6, 37.6) 1.6 (0.6, 5.6) 12 (6.2, 17.6)
2030 22.8 (13.6, 72.1) 7.5 (3.9, 24.7) 1.2 (0.5, 4) 13.1 (6.7, 19.1)
2035 18.8 (11.8, 47.7) 6.1 (3.3, 15.6) 0.9 (0.4, 2.4) 14.1 (8.5, 20.3)
Rule 1 (30%)
2020 42.4 (22.6, 138) 13.4 (6.1, 47.4) 1.4 (0.5, 5) 7.7 (2.4, 14)
2025 29.7 (16.5, 101.1) 9.3 (4.3, 35.1) 0.9 (0.3, 3.8) 10.7 (4.6, 16.4)
2030 22.3 (13.5, 68.5) 6.9 (3.5, 22.4) 0.7 (0.2, 2.6) 12 (5.8, 18)
2035 18.3 (11.8, 45.2) 5.6 (3.2, 14.1) 0.6 (0.2, 1.4) 13 (6.3, 20.1)
Rule 2 (30%)
2020 42.3 (22.6, 136.8) 13.3 (6.2, 47.3) 1.4 (0.6, 5.1) 7.9 (4, 13)
2025 29.7 (16.5, 101.2) 9.3 (4.3, 35.2) 1 (0.4, 3.8) 10.6 (6.9, 14.5)
2030 22.3 (13.5, 68.5) 6.9 (3.6, 23.1) 0.7 (0.3, 2.6) 11.9 (7.9, 15.4)
2035 18.4 (11.8, 45.1) 5.6 (3.3, 14.4) 0.6 (0.3, 1.6) 13 (9.3, 16.6)
Rule 3 (30%)
2020 42.4 (22.6, 137.2) 14.3 (6.6, 49.9) 1.5 (0.6, 5.4) 11.9 (8.2, 16.9)
2025 30.5 (16.5, 106.1) 10.4 (4.8, 39.8) 1.1 (0.4, 4.3) 12.5 (8.7, 16.6)
2030 23.2 (13.6, 74.2) 7.8 (4, 26.4) 0.8 (0.4, 2.9) 14 (9.8, 17.7)
2035 19.1 (11.9, 50) 6.4 (3.6, 16.5) 0.7 (0.3, 1.8) 14.9 (11.1, 18.5)
PI: prediction interval
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Rule 1 (30%) - Baseline
2020 -0.3% (-2.1%, 1.5%) 36.6% (3.6%, 63.9%)
2025 1% (-0.4%, 3.5%) 38.9% (5.7%, 68.4%)
2030 1.6% (0.1%, 5%) 38.6% (-8.6%, 73.6%)
2035 1.7% (0.2%, 5.6%) 37.6% (-12%, 73.6%)
Rule 2 (30%) - Baseline
2020 -0.2% (-1.5%, 1.2%) 37% (14.8%, 56.9%)
2025 1.1% (-0.1%, 3.2%) 38.1% (10%, 59.6%)
2030 1.6% (0.2%, 4.6%) 38.3% (7.7%, 62.8%)
2035 1.7% (0.2%, 5.5%) 37.4% (0.4%, 63.2%)
Rule 3 (30%) - Baseline
2020 -0.2% (-1.6%, 1.1%) 32.8% (10.7%, 52.9%)
2025 -0.9% (-2.9%, 0.2%) 29.8% (1.9%, 53.4%)
2030 -1.1% (-3.6%, 0%) 28.5% (-8.5%, 52.6%)
2035 -1.1% (-3.8%, -0.1%) 28.4% (-7.8%, 55.9%)
PI: prediction interval,
reduction: (intervened− baseline)/baseline× 100%
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9.4 Discussion
Chapter 2 reviewed that most of SES-based TB interventions were social protection
for TB patients to improve their adherence to TB treatment. However, before TB
confirmation or treatment start, patients with TB were not yet TB patients, so those
interventions would not protect them for unfavourable outcomes. Therefore, this
chapter focused on increasing the coverage of TB diagnostics provision. I exam-
ined three rules of empowering hospitals to provide TB diagnostics. In summary,
based on the setting of Taiwan, the suggestions are as follows.
• Ranking the priority of hospitals to acquire TB diagnostics by TB patients’
healthcare visits, weighted by either the SES of patients or the regional SES
of hospitals, to effectively improve care-seeking processes.
• The interventions can reduce the costs before treatment, but might increase
the inequality in costs of the healthcare system and out-of-pocket expenses.
The reductions in costs will exhibit diminishing returns-to-scale for the in-
terventions
• Increasing TB diagnostics coverage will not have effects in the short run on
TB incidence but can have long term effects on it.
From a methodological viewpoint, this chapter demonstrated the use of hybrid
modelling with individual-level details. Specifically, my interventions were built
by matching of hospital details and aspects of the care-seeking history. It used
strong connections between data and models in intervention analysis rather than
just changing the values of parameters. Since the hybrid model preserved the
details of care-seeking processes and was able to project population interventions,
I can evaluate the impacts of interventions from multiple perspectives at different
scales. Also, since hybrid modelling efficiently used computational resources (see
Chapter 3), I could compute interval estimators using Monte Carlo experiments.
My analysis confirms the usefulness of hybrid modelling and encourages more
data-driven modelling approaches in intervention analysis.
I started the investigation of SES-based interventions with UHC approaches,
while there were other potential interventions can be considered according to the
results of Chapter 7. Considering the loss to follow-up (LTFU) during treatment,
the underprivileged patients were more likely to be LTFU. In fact, my analytic
framework can assess interventions to decrease LTFU by numerically switching
the LTFU rates of the underprivileged to that of the other patients. However,
I suggested investigating the intervention on adherence as future work after a
study surveying the reasons for LTFU.
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A modelling assessment highlighted the patient delay (pre-hospital care-seeking)
is a key for TB control in high burden settings [1]. The active case-finding (ACF)
and reducing the anxiety due to healthcare fee might improve the care-seeking.
However, my modelling results (Chapter 8) showed the importance of periods be-
tween initial care-seeking and treatment start, i.e. system delay. The interventions
on system delay remain underexplored. Based on the modelling, ill people were
willing to seek care, but they cannot immediately receive TB diagnostics after ini-
tial care-seeking. Competing diseases lies a difficulty. As Chapter 5 showed, 55%
of incident TB are aged 65 and above; one-third are male. The population fea-
tures overlap with many illnesses have TB-suggestive symptoms such as chronic
lung diseases and pneumonia. Considering other diseases may be more deadly,
physicians might not put TB as the top concern. Lower awareness due to lower
TB incidence is another difficulty in reducing system delay.
I considered the ACF which were routinely performed in Taiwan, such as
community-based ACF for the impoverished or remote areas and workspaces
as the background dynamics in my model. Therefore, it is difficult to consider
changes to these interventions using my model. In order to explore a new SES-
based ACF, further research could find an alternative parametrisation for patient
delays and system delays, allowing some ill people or asymptomatic TB to access
TB treatment under ACF.
I did not consider hospitals in relation to nearby hospitals. As I intervened on
the hospitals by their regional SES or that of their patients, hospitals which were
geographically near might receive similar priorities. Therefore, the demands of
TB services for some pathways might be double-counted. I suggest that further
investigation can introduce dynamic programming to sort the remaining hospitals
after each hospital acquires the capacity of diagnosing TB. That is, considering the
capacity among the nearby hospitals in the prioritisation.
In practice, to empower smaller-scale hospitals without expanding the scales,
the system needs to incorporate institutions with laboratories or larger hospitals.
The cost of this incorporation includes not only the cost of new tasks. As Datiko
and Lindtjørn [2] discussed, expanding healthcare services, such as sputum col-
lection, which were not the routine for a provider, the specimen might be in lower
quality. Moreover, the transportation infrastructure and cost required further in-
vestigation. For the same scale of each scenario, the cost would grow differently
due to their geographical distances. These extra-costs, which I cannot evaluate
with the data in this study, are the main reason why I did not conduct the cost-
effectiveness analysis for the interventions. Thankfully, the care-seeking processes
in my model was an individual approach; my model has the potential to deal with
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the spatial details if corresponding data are available.
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Tuberculosis has long been identified as a disease of poverty [1]. In the post-2015
era, tuberculosis control programmes have been widely calling for socioeconomic
actions and are targeting the elimination of catastrophic economic outcome [2–4].
Working within the context of Taiwan, this thesis departs from the empirical anal-
ysis of socioeconomic status (SES) and care-seeking, to bridge the evidence related
to tuberculosis epidemiology with simulation models, and to provide an innova-
tive approach for SES-based tuberculosis controls. In this chapter, I discuss the
existing gaps in the knowledge, the empirical/modelling inference I addressed,
and my methodological contributions as follows.
10.1 Knowledge and technical gaps before this thesis
While the association between TB and SES has been established in the existing
literature, the evidence of the relationship between care-seeking of TB patients
and socioeconomic determinants is somewhat disparate, as was seen in Chapter 2.
My review of assessments of two prominent forms of SES-based interventions for
TB control, UHC and social protection, found that most of the approaches were
focused on TB treatment adherence. Meanwhile, interventions for care-seeking
prior to treatment initiation remained largely unexplored.
Patient pathway analysis (PPA) [5] is an approach used to gain a better under-
standing of the alignment of TB services provision and healthcare visits. PPA has
been used to explore in numerous studies to assess the treatment of TB and has
been used to support efforts to improve treatment adherence. To the best of my
knowledge, PPA mainly utilises cross-sectional data, which does not include tem-
poral information. However, to fully understand the duration of untreated stages
and their impacts on TB epidemiology, a method that incorporates temporal pat-
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terns in PPA is much needed.
Care-seeking pathways are a combination of the decision making of patients
and healthcare providers. To enrich the inference on behaviour changes, I re-
viewed the approaches to the simulation of health-related behaviour in agent-
based models (ABMs) in Chapter 4. While ABMs that incorporate health be-
haviour demonstrated methods for driving agents using empirical data and be-
haviour theories, applications of care-seeking behaviours are limited.
Hybrid modelling presents a parsimonious way to model a system by using a
combination of agent-based models for the most complex features and equation-
based models for other supportive processes. Chapter 3 searched for health-
related applications of hybrid modelling and, while only a few examples were
found, they were largely heterogeneous. In terms of the technical aspects, syn-
chronising the equation-based parts and the agent-based parts as well as describ-
ing the communication among them remained a challenge.
10.2 Empirical findings and modelling inference
10.2.1 Demographic changes and TB burden (Chapter 5)
Based on the notification rates of TB in Taiwan, I forecasted that the age-specific
notification rates will have decreased by around 70% by 2035 for all age groups
apart from children. However, the higher rates of TB among the elderly may have
a detrimental effect on this decline. It is estimated that 76% of new TB cases will
be aged 65 and above in 2035. Furthermore, the results suggested that 39% of
the TB notifications in Taiwan in 2035 could be attributed to demographic change,
which highlights how the attendant policies should be more age-specific in terms
of the older age groups and their care needs.
10.2.2 Alignment between TB care provision and demand (Chapter 6)
Using the routine health insurance claim data in Taiwan, I found a general trend
for escalation in level of care for initial care-seeking, with 43% of patient path-
ways started at the lowest level hospitals (clinics or general practices) while only
a quarter of them (about 10% of all pathways) received treatments without being
referred to higher levels. Unfortunately, only around 15% of hospitals at that level
could provide TB diagnostics or treatment. The median delay between arriving
at the facility where they were treated, and treatment initiation was 6 days. As
for the delay to treatment, initiation was 41 days after initial care-seeking in the
median. These results highlighted two care-seeking barriers before TB treatment:
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availability of TB services at low-level hospitals and low attention to TB in the
hospitals which can handle TB.
I found huge heterogeneity in pathways driven by the interruption of evalua-
tion and re-evaluation: 10% patient pathways had system delays longer than 200
days, and about 75% of them encountered interrupted TB evaluations. Under-
standing the causes of interrupted evaluation should be a focus of further investi-
gation in Taiwan.
10.2.3 SES factors as risks of inefficient care-seeking (Chapter 7)
I analysed the associations of individual/regional SES and features of the TB care-
seeking pathways in Taiwan. Apart from age, which commonly led to extended
system delays, I identified some SES factors that affected the lengths of delays. I
found that unemployment and living in a more impoverished area or in a low-
income household were associated with initial care-seeking in higher-level hos-
pital levels and quicker evaluation processes. Although the underprivileged had
shortened the system delays, they had higher chances of unfavourable treatment
outcomes. I suggested two hypotheses. First, their shorter delays were due to
patients being “fast-tracked” through the care-seeking pathway due their presen-
tation in poorer states of health at their initial care-seeking, which is a result of
longer delays before seeking care. The second hypothesis was that they were
suffered from extreme costs other than healthcare fee, such as travelling costs or
income loss due to care-seeking.
there was less support available, other than healthcare provision and access,
for example removing financial barriers by granted income due to care-seeking or
create supportive communities through health education.
10.2.4 Inequality in care-seeking (Chapter 7)
Using the Lorenz curve [6] and the Gini coefficient [7], I assessed the inequality in
costs to the healthcare system, the out-of-pocket expenses of patients and the time
costs, which were measured by the number of visits. While the costs were diverse
among the patients; a small group of patients were faced with huge costs. For
the out-of-pocket expenses, 90% of the costs were attributed to 20% of the patients
with the highest out-of-pocket expenses. Meanwhile, I confirmed that the under-
privileged patients were protected from out-of-pocket expenses by the national
policy. However, this group were not protected from the time costs. Indeed, the
number of visits before treatment initiation was homogeneous across the social
groups, which implies that the costs of healthcare visits, such as travelling and
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time costs, of the underprivileged patients may not differ from the others.
10.2.5 Age-specific mortality estimation during treatment (Chapter 8)
According to the extracted patient pathways, I estimated the TB-specific death
rates by age-group. After adjusting for the crude death rates by age and sex for
every individual, the TB patients aged 65 and above were found to have a higher
TB-specific death rate (0.18 per person-year), with the rate potentially being higher
than that of the untreated. Following the onset of symptoms of TB, the chance of
being diagnosed increases due to care-seeking while the health status worsens.
According to the patient flows from outpatient to inpatients (Figure 6.4), about
40% of patients initiated TB treatment as inpatients, but there were about 15% of
inpatients at initial care-seeking. This suggested that the health status of patients
were decaying during care-seeking. This is also a vital issue to reduce delay to TB
treatment as early as possible.
10.2.6 Dropout cascade from cohort and population perspectives (Chap-
ter 8)
This thesis explored dropouts due to death and self-cure before treatment in Tai-
wan. Roughly speaking, 10% of the incident TB remained undiagnosed due to
death or self-curation. Especially for the old adults, the dropouts can reach as
high as 17% or over due to higher background death rates and the extended de-
lays to treatments. From the cohort perspective, I expect that the dropout profiles
of 2019 and 2035 would not reveal significant differences. Meanwhile, from a pop-
ulation perspective, the case-detection gap, which may be affected by the annual
decline in incidence rates, was found to be decreasing since 2005 but is expected
to start increasing again after 2020. This mismatch should be considered in setting
up the goals of NTPs, which generally use the population approach to identify
case-detection gaps.
10.2.7 The impact of providing TB-service capacity (Chapter 9)
I examined the impact of the interventions related to providing the capacity for
diagnosing TB for the hospitals that lacked it (most of them were lower level hos-
pitals). Increasing service provision at the hospitals where TB patients with ex-
tended delays were likely to initiate their care-seeking could decrease the dropout
rates before treatment and could have long-term impacts on the TB incidence and
mortality. Here, I illustrated the impact of specific decentralisation schemes re-
lated to the provision of TB diagnostics.
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10.3 Methodological contributions
10.3.1 Lee-Carter models in age-specific incidence forecasting (Chap-
ter 5)
I introduced LCMs [8], which were initially designed for mortality modelling, in
the modelling and forecasting of the age-specific TB notification rates. I argued
that the death rates and notification rates have similarities in terms of age-specific
patterns and time trends. The goodness of fit and the residual analysis also con-
firmed these arguments. In fact, while LCMs have been used for decades in popu-
lation modelling, to the best of my knowledge, this is the first time they had been
applying in infectious disease modelling. Moreover, I combined the notification
and population forecasts to analyse the age profile of future TB notification. This
method helped us to explore the future disease burden and the difficulty of TB
control due to the population ageing issue.
10.3.2 Individual patient pathway analysis (Chapter 6)
One key contribution of this thesis lies in developing the framework of the individ-
ual patient pathway analysis (IPPA). The IPPA is a patient-centred approach that
centres on the event history during care-seeking. The IPPA combines the concept
of patient pathway analysis and delays analysis in addressing the care-seeking
process of TB patients. Above all, it has the potential to the impacts of upstream
determinants, especially SES, and provide a rich source of new information for
locating the weaknesses of a given healthcare system.
The results I presented focussed on the healthcare system in Taiwan. How-
ever, the IPPA spans three dimensions of events: pre-evaluation, evaluation, and
treatment. This provides a systematic procedure for defining events from a com-
plicated space to generate specific patient pathways in the IPPA, which can be
adapted to different definitions in accordance with different settings and data
availability. I released the analysis package for general cases on a GitHub public
repository (see Appendix J).
10.3.3 Hybrid modelling with individual care-seeking processes and
population TB dynamics (Chapter 8)
I developed a hybrid simulation model that can capture nationwide TB epidemiol-
ogy in Taiwan with the details of the care-seeking process. The hybrid simulation
model synthesises the data related to TB service provision, demands and popu-
lation dynamics. Overall, it provides a platform for performing the intervention
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evaluation as a practice of prospective health technology assessment. The model
incorporates the advantages of data integration pertaining to ABMs and the re-
ductionism pertaining to EBMs. The simulation can be executed using a personal
computer or laptop with a tolerable computation time for each run.
10.3.4 Model-based dropout profile (Chapter 8)
This thesis provides a model-based dropout assessment. Going beyond the dropout
cascade that is entirely based on empirical data (e.g. Subbaraman et al. [9]), my
approach complemented the components that do not have proper supportive data.
For example, the period between the onset of TB symptoms and the initial care-
seeking can be surveyed in terms of TB patients’ pre-hospital care-seeking. How-
ever, starting a cohort with those who have not initiated their care-seeking is not
possible due to ethical issues. Given the care-seeking pathways, I used a dynamic
transmission model calibrated to the epidemiological data to infer the data-scarce
components. My model-based approach subsequently captured interrupted eval-
uations and LTFUs as well as their relative recurrence. Moreover, the modelling
approach can project the dropout cascade used in both population-based results
(e.g. Table 8.7) and cohort-based results (e.g. Figure 8.9). In short, it provided a
method for comparing dropout cascades in other settings with different types of
available data.
10.3.5 Analysis codes and packages
Along with compiling this thesis, I created four packages for the analyses and
the simulation modelling in addition to numerous related code repositories for
visualisation and presentations. I published the codes on Github. The full list of
codes and link to Github can be found in Appendix J.
For conducting an appropriate IPPA (see Chapter 6), I provided the requisite
full codes for it. Also, I published pseudo-data for testing the codes and for
guiding the data collection and management of further studies.
For profiling the age distribution of TB (see Chapter 5), I released the code for
statistically modelling and forecasting the age-specific TB incidence data under
the LCM [8]. Along with this package, I published a processed data set as an
example for investigating the impacts of population ageing on TB epidemiology.
For managing the parameter structure and the Bayesian modelling, I devel-
oped “PyEpiDAG”, which is a probabilistic modelling toolkit based on causal
diagrams [10]. This package can incorporate probability distributions, empirical
models from prior studies, and user-defined mathematical functions to support
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the parameterisation of simulation models. Furthermore, this package provides
the functions of modelling fitting in both Frequentist and Bayesian approaches.
The package uses the Python programming language, while a Java equivalent is
also available.
For the simulation modelling, I developed a package, “PyCx”, which is a simu-
lation modelling toolkit. This package can deal with agent-based, equation-based,
and hybrid modelling. The package is compatible with PyEpiDAG and can apply
the model-fitting functions provided by PyEpiDAG. All the simulation models in
this thesis were constructed using this package.
10.4 Limitations
10.4.1 Loss to follow up
Given the fact that the incidence of drug-resistant TB among all incident TB in
Taiwan accounted for approximately 1% or less, the 0.2 LTFU rate per person-
year from the IPPA results would appear not to make sense. In an unreported
result, I found that only 10% of the LTFUs were pathways completely lost in the
tracking, while the remaining 90% still had healthcare events with on-going TB
evaluation. I suggested three hypotheses for this mismatch. The first is related to
the competing priority in relation to other health conditions. As more than half
of TB patients in Taiwan were aged 65 and above, their health conditions were
likely to be more complex. Here, I expected that many treatments were temporar-
ily interrupted due to physiological reasons. Meanwhile, my second hypothesis
is that their treatments were started due to false positive results in the previous
assessments or because the patients were latent TB positive but were considered
as active TB patients (the NHI does not cover latent TB treatments). Finally, for
patients with special conditions, their treatments might be provided by the TCDC
but not the NHI. Thus, these cases were not necessarily LTFU; rather the NHI
database simply did not have them on record. As the TCDC supervises all the TB
patients once it is notified, the actual treatment outcome is always tracked. How-
ever, since my analysis did not link the TCDC database to the validated treatment
outcome data, I could not test these three hypotheses.
In the simulation modelling of this thesis, I did not pay a great deal of attention
to the outcomes of LTFU. In my dropout analyses, the TB patients were either
cured or had ultimately died, while the patients of LTFU will always have a chance
to seek care again. For simplicity, I did not assume that the patients with treatment
outcomes of LTFU have a rate of care-seeking that is different from those who have
not yet sought care. Further study is required for addressing the influence of LTFU
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with data of explicit health status.
In the reality, irregular use of anti-TB drugs may cause drug-resistance. I ar-
gue that the modelling did not significantly distort the reality because the drug-
resistant TB in Taiwan only shared around 1% of overall TB incidence.
10.4.2 Immigration
In my modelling, while I did consider the migration aspect, I only aimed to sim-
ulate the age-sex distributions compatible with the real data of population dy-
namics. I assumed the distributions of latency among the immigrants and the
emigrants were the same as the nationals of Taiwan. However, according to the
last-decade national statistics pertaining to Taiwan, around 60% of immigrants
were from China, while 20% were from Vet Nam, and 5% were from Indonesia.
Meanwhile, the latest TB incidence rates of these countries were estimated to be
approximately 1.5, 3, and 9 times that of Taiwan (38 per 100,000 as of 2018), re-
spectively.
10.4.3 Generalisability
In this thesis, I used the setting of Taiwan as an example for profiling care-seeking
and for constructing a hybrid model. I considered the models pertaining to
individual-level data and the epidemiology of TB. However, it may be challenging
to apply the study frameworks of this thesis to other settings.
In Taiwan, the public and private healthcare systems are fully integrated by
the NHI, which provide identical coverage of health services for both sectors. The
data of the NHI are also collected and encoded with the same standard for public
and private sectors. For the settings with data qualities and healthcare coverages
of private and public sectors were significantly different, standardising data before
conducting an IPPA is needed.
Moreover, the TB notifications system always synchronises with the anti-TB
drug prescriptions under the NHI. That is, the notification of TB happens imme-
diately after prescribing anti-TB drugs. According to that, throughout this thesis,
I assumed TB treatment initiation and TB notification were identical in timing.
However, for scarce resource setting, availability of the data as well as any notifi-
cation inefficiency should be considered.
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10.5 Future work
10.5.1 Combining patient cost surveys with IPPA
This thesis highlighted that the out-of-pocket expenses for patients was prevented
by the social welfare policy, the number of visits before treatment initiation for
the underprivileged was found not to be lower than that of the other groups. To
clarify the sources of costs incurred by patients, one could combine cost surveys
with my individual patient pathway analysis. In fact, a key target of the “End
TB strategy” [2] is to reduce the catastrophic costs related to TB care to zero on
TB-affected households.
10.5.2 Exploring innovative SES-based interventions
This thesis built a hybrid simulation model as a flexible environment for testing
intervention on care-seeking behaviours and for measuring the impacts from the
individual level to the population level. However, I only performed two types of
actions in my interventions analysis, while many other intervention implemen-
tations could have been considered. For example, with more detailed spatial in-
formation, I could experiment with community-based approaches such as Datiko
and Lindtjørn [11] to improve early diagnosis and to increase the risk perceptions
about TB. However, before evaluating more interventions, it is essential to have
further discussions with stakeholders in order to prioritise those most acceptable
and those most relevant to the policy.
10.5.3 Enhance the hybrid modelling and employ in healthcare mod-
elling beyond TB
It should be noted that my hybrid modelling extends a detailed view of the care-
seeking processes while incorporating transmission dynamics for projecting the
epidemiology at a national level. My approach combined the advantages of ABMs
and EBMs, and the simulation results stand somewhere between the reductionism
of EBMs and the resolution of ABMs. However, in going from a complex to a
simplified system, some information loss must be expected. I did not address pre-
cisely how much information and stochasticity was lost during the hybrid mod-
elling. If I consider the full ABM model to be on the right side of the spectrum
and the mean-field EBM to be on the left, the next step is to generate measure-
ments that will allow us to locate the hybrid model on the spectrum. This will
help inform the decision making based on hybrid models.
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Furthermore, although the hybrid modelling was developed for investigating
care-seeking related to TB, the frameworks were not actually TB-specific. For
example, pneumonia patients, who may share similar features of pulmonary TB,
may have care-seeking processes similar to those of patients with TB. In fact, this
is especially the case in Taiwan, where risk groups often tend to overlap as well.
Therefore, my model could be applied in terms of pneumonia, such that I could
address similar questions without major adaptations. This statement is also true
for some chronic lung diseases. Indeed, considering the difficulty in diagnosis
and the chronic features of TB (e.g. latent progression), it is worth noting that the
modelling scheme is applicable to other diseases that have complex progression
and diagnostic processes.
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A.1 Definitions and notations
In this appendix, the papers were grouped in terms of type of behaviour, and were
summarised with explicit behaviours they modelled, data type of behaviour variable in
model, critical function triggers final action, and function for collecting determinants.
The notations and definitions used for the critical functions and collection functions are
listed as follows.
Critical function: a function which triggers final action. Y indicates a final action (be-
haviour) of a model
Variable, Y← µ: an action is assigned directly by output of determinant collec-
tion.
Random variable, Y ∼ distribution(...): an action is sampled from a probability
density (mass) function and the parameters are sourced from determinant
collection. The distribution will be a specific distribution if possible. Other-
wise, distribution indicates a mixture distribution or other sampling rule.
Threshold, Y← ifµ > τ : an action is triggered when a variable reaches thresh-
old. The process can be replicated for vectorial cases.
Optimisation, Y← argmax(u): an action is a result of optimisation.
Game, Y← game(u): an action is the optimal option in a game with a pay-off
matrix. Pay-off matrix are summary of determinants.
Intermediate variable: a variable of summary by a collection function and it will be the
main input of a critical function.
Continuous value, µ: a continuous variable, usually the mean of an action.
Utility, u: a value of utility of a pay-off matrix.
Probability, p: a probability or a conditional probability table.
Collection function: a function which collects determinants of targeted behaviour. (X
indicates a set of upstream variables)
Regression or linear combination, u = Xβ, p = logit(Xβ), p = probit(Xβ), ...: determinants
are summarised by a linear combination function with determinants (covari-
ates) and effects (coefficients). Transformation can be applied (e.g. logit and
probit functions)
Mathematical function, µ = f(X): determinants are summarised with a or a se-
ries of mathematical function except for regression function.
A.1. Definitions and notations
Algorithmic function, µ = λ(X): determinants are summarised with an algorithm,
including query within a parameter table (e.g. reading probability in a condi-
tional probability table).
Diffusion, imitation, or Huff function, µ = ∆(X): behaviour is transmitted from
neighbours or agents imitate neighbour behaviour. Determinants are mainly
neighbour attributes.
A.2 List of the retrieved studies
A.2.1 Models of lifestyle
For lifestyle (Table A.1), we identified behaviours of food intake, Body mass index (BMI)
control, physical activity. 24 eligible models were selected.
Table A.1: Summary of models of lifestyle




Food choice Categorical Y← argmax(u) u = Xβ
Langellier [58] Food choice Categorical Y ∼ Multinomial(p) p = logit(Xβ)
Li et al. [62] Food choice Categorical Y ∼ Multinomial(p) p = ∆(x)
Li et al. [61] Food choice Categorical Y ∼ Multinomial(p) p = ∆(x)
Zhang et al. [105] Food choice Categorical Y ∼ Multinomial(p) p = logit(Xβ)
Choi et al. [28] Food consumption Continuous Y← µ µ = Xβ
Li et al. [60] Food consumption Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Beheshti et al.
[11]
Food planning Vectorial Y← ifµ > τ µ = λ(X)
Blok et al. [14] Food planning Vectorial Y← argmax(u) u = Xβ
Basu et al. [10] SSB intake Continuous Y ∼ Norm(µ, ε) µ = Xβ
Chen et al. [26] SSB intake Continuous Y← ifµ > τ µ = ∆(X)
Beheshti et al.
[12]
Weight control Binary Y← ifµ > τ µ = f(X)
Bruzzone et al.
[21]
Weight control Continuous Y ∼ Norm(µ, ε) µ = Xβ
Edwards and
Clarke [34]
Weight control Continuous Y ∼ Norm(µ, ε) µ = Xβ
Hammond and
Ornstein [46]
Weight control Continuous Y← µ µ = ∆(X)
Hennessy et al.
[48]
Weight control Continuous Y← µ µ = Xβ
Trogdon and
Allaire [91]
Weight control Continuous Y← argmax(u) u = f(X)
Wang et al. [96] Weight control Continuous Y← µ µ = f(X)
Orr et al. [75] Dieting Continuous Y← µ µ = f(X)
Orr et al. [76] Dieting Continuous Y← µ µ = f(X)
Blok et al. [13] Physical Activity TTE Y ∼ Exponential(...) µ = f(Xβ)
Yang et al. [103] Physical Activity Categorical Y← argmax(u) u = f(X)
Yang et al. [104] Physical Activity Categorical Y ∼ Multinomial(p) p = λ(X)
Yang et al. [102] Physical Activity Categorical Y ∼ Multinomial(p) p = logit(Xβ)
A.2. List of the retrieved studies
A.2.2 Models of substance use
For substance use (Table A.2), we identified behaviours of smoking, alcoholic drinking,
addictive drug abuse, and problem gambling. 32 eligible models were selected.
Table A.2: Summary of models of substance use
Article Behaviour Action Type Action rule Determinant collection
Adams and Schaefer [1] Smoking Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Chao et al. [25] Smoking Categorical Y← argmax(u) u = Xβ
Cherng et al. [27] Smoking Binary Y← µ µ = λ(X)
Schaefer et al. [84] Smoking Continuous Y ∼ Norm(µ, ε) µ = Xβ
Sun and Mendez [88] Smoking Binary Y ∼ Bernoulli(p) p = f(X)
Yang et al. [101] Smoking Binary Y ∼ Bernoulli(p) p = f(X)
Getsios et al. [42] Smoking cessation Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Igarashi et al. [51] Smoking cessation Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Xenakis et al. [98] Smoking cessation Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Atkinson et al. [5] Alcohol drinking Categorical Y← µ µ = λ(X)
Fitzpatrick et al. [37] Alcohol drinking Continuous Y ∼ Norm(µ, ε) µ = f(X)β
Fitzpatrick et al. [38] Alcohol drinking Continuous Y ∼ Norm(µ, ε) µ = f(X)β
François et al. [39] Alcohol drinking Continuous Y ∼ Norm(µ, ε) µ = Xβ
French et al. [40] Alcohol drinking Continuous Y← µ µ = f(X)
Giabbanelli and Crutzen
[43]
Alcohol drinking Binary Y← ifµ > τ µ = λ(X)
Gorman et al. [44] Alcohol drinking Binary Y← µ µ = ∆(X)
Millier et al. [71] Alcohol drinking Discrete Y ∼ distribution(µ) µ = Xβ
Purshouse et al. [78] Alcohol drinking Binary Y ∼ Bernoulli(p) p = probit(Xβ)
Rahhali et al. [79] Alcohol drinking Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Riva and Smith [80] Alcohol drinking Categorical Y ∼ Multinomial(p) p = logit(Xβ)
Scott et al. [85] Alcohol drinking Categorical Y← µ µ = λ(X)
Scott et al. [86] Alcohol drinking Continuous Y ∼ distribution(µ) µ = λ(X)
Zur and Zaric [109] Drinking level transition Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Bobashev et al. [15] Drug abuse Binary Y← ifµ > τ µ = λ(X)
Dray et al. [32] Drug abuse Binary Y ∼ Bernoulli(p) p = f(X)
Gutfraind et al. [45] Drug abuse Binary Y ∼ Bernoulli(p) constant p
Heard et al. [47] Drug abuse Categorical Y ∼ Multinomial(p) p = logit(Xβ)
Hoffer et al. [49] Drug abuse Categorical Y← µ µ = λ(X)
Lamy et al. [57] Drug abuse Binary Y← ifµ > τ µ = f(X)
Perez et al. [77] Drug abuse Binary Y← µ µ = ∆(X)
Xiong et al. [99] Drug abuse Binary Y ∼ Bernoulli(p) p = λ(X)
Markham et al. [67] Problem gambling Continuous Y← µ µ = ∆(X)
A.2.3 Models of preventive actions
For disease prevention (Table A.3), we identified behaviours of vaccination, self-protection,
having risky contact, and accessing screening. 35 eligible models were selected.
Table A.3: Summary of models of preventive actions
Article Behaviour Action Type Action rule Determinant collection
Andrews and Bauch [4] Self protection Binary Y← ifµ > τ µ = f(X)
Barrett et al. [8] Self protection Categorical Y← ifµ > τ µ = f(X)
Barrett et al. [9] Self protection Categorical Y← ifµ > τ µ = f(X)
Durham and Casman
[33]
Self protection Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Karimi et al. [53] Self protection Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Keane [55] Self protection Binary Y← game(u) u = f(X)
Keane [54] Self protection Binary Y← game(u) u = f(X)
Mao [65] Self protection Binary Y← µ µ = ∆(X)
Mao [66] Self protection Binary Y← µ µ = ∆(X)
Mei et al. [70] Self protection Categorical Y← µ µ = f(X)
Zhong [108] Self protection Binary Y ∼ Bernoulli(p) p = f(X)
Sahneh et al. [82] Self protection Binary Y ∼ Bernoulli(p) p = λ(X)
Buttenheim et al. [22] Vaccination Binary Y ∼ Bernoulli(p) p = f(X)
Collinson et al. [30] Vaccination Binary Y← µ µ = f(X)
Fu et al. [41] Vaccination Binary Y← game(u) u = f(X)
Iwamura et al. [52] Vaccination Binary Y← game(u) u = f(X)
Liu et al. [63] Vaccination Binary Y← game(u) u = f(X)
Salvarani and Turinici
[83]
Vaccination Binary Y ∼ Bernoulli(p) p = f(X)
Teoh Shian Li et al. [90] Vaccination Binary Y← game(u) u = f(X)
Xue et al. [100] Vaccination Binary Y ∼ Bernoulli(p) p = f(X)
Zhang Fa et al. [107] Vaccination Binary Y ∼ Bernoulli(p) p = f(X)
Nagoski et al. [74] Sexual risk taking Binary Y ∼ Bernoulli(p) p = λ(X)
Tully et al. [92] Sexual risk taking Continuous Y← game(u) u = f(X)
Tully et al. [93] Sexual risk taking Continuous Y← game(u) u = f(X)
White et al. [97] Sexual risk taking Binary Y ∼ Bernoulli(p) p = λ(X)
Bracher et al. [17] Condom use Binary Y ∼ Bernoulli(p) constant p
Hui et al. [50] Condom use Categorical Y ∼ Multinomial(p) p = λ(X)
Delaney et al. [31] Social distance change Binary Y← µ µ = f(X)
Epstein et al. [35] Social distance change Binary Y ∼ Bernoulli(p) p = f(X)
Brown et al. [20] Social group choice Binary Y← game(u) u = f(X)
Marquis and Buchanan
[68]
Insurance planning Categorical Y← argmax(u) u = f(X)
Sowa et al. [87] Insurance planning Continuous Y← argmax(u) u = f(X)
Suzuki et al. [89] Insurance planning Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Marshall et al. [69] Voluntary screening Binary Y ∼ Bernoulli(p) p = λ(X)
Turner et al. [94] Accepting screening Binary Y ∼ Bernoulli(p) p = λ(X)
A.2. List of the retrieved studies
A.2.4 Models of hospital access
For patient choice (Table A.4), we identified behaviours of seeking, care attendance,
treatment compliance, and taking seek leave. 18 eligible models were selected.
Table A.4: Summary of models of hospital access
Article Behaviour Action Type Action rule Determinant collection
Alibrahim and Wu
[2]
Care-seeking Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Anderson et al. [3] Care-seeking TTE Y ∼ Triangle(...) constant p
Carley et al. [23] Care-seeking Binary Y← ifµ > τ µ = f(X)
Macal et al. [64] Care-seeking Binary Y ∼ Bernoulli(p) constant p
Murata et al. [73] Care-seeking Categorical Y ∼ Multinomial(p) p = λ(X)
Turner et al. [95] Care-seeking Binary Y ∼ Bernoulli(p) constant p
Zhang et al. [106] Transportation for care-seeking Categorical Y ∼ Multinomial(p) p = λ(X)
Brailsford and
Schmidt [19]
Attendance Binary Y ∼ Bernoulli(p) p = f(X)
Brailsford et al.
[18]
Attendance Binary Y ∼ Bernoulli(p) p = logit(Xβ)
Ernecoff et al. [36] Attendance Binary Y← ifµ > τ µ = f(X)
Bowers et al. [16] Hospital choice Categorical Y← argmax(u) u = f(Xβ)
Chang et al. [24] Hospital choice Categorical Categorical Y ∼ Multinomial(p) p = f(X)
Knight et al. [56] Hospital choice Categorical Y← argmax(u) u = f(X)
Ciavarella et al.
[29]
Student absenteeism Binary Y← µ µ = λ(X)
Sadeghipour et al.
[81]
Dental visit Categorical Y← µ µ = λ(X)
Lewis et al. [59] Emergency calling Binary Y← ifµ > τ µ = f(X)
Balaban [7] Returning to work Binary Y← µ µ = λ(X)
Moro and
Pellizzari [72]
Sick leave taking Binary Y← µ µ = λ(X)
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Specifications of the Lee-Carter
approach
B.1 Notations and abbreviations
yage,year: number of events of age in year
nage,year: population size of age in year
αage: age-specific effect of age
βage: age-period adjustment term of age
κyear: period effect at year
E(.): expectation function
sign(.): sign function of a value, 1 for positive and -1 for negative.
`(.): log-likelihood function
ARIMA(p, d, q): Autoregressive integrated moving average with p number of time
lags of the autoregressive term, d order of differencing term, and q number
of time lags of the moving-average term.
B.2. Model structure and assumptions
B.2 Model structure and assumptions
Lee-Carter model [1] was defined as
log(E(yyear,age)) = αage + βageκyear + log(nyear,age) (B.1)
Two constraints are needed for ensuring identifiability:
∑
year
κyear = 0 (B.2)
∑
age
βage = 1 (B.3)
In implementation, we used a Poisson-regression-based approach [2] for the
Lee-Carter model
yyear,age ∼ Poisson(µyear,age) (B.4)
µyear,age = nyear,ageexp(αage + βageκyear) (B.5)
Thus, the log-likelihood function is
`(αage, βage, κyear|yyear,age, nyear,age) = −µyear,age + yyear,agelog(µyear,age)− log(yyear,age!)
(B.6)
= yyear,age(αage + βageκyear)− nyear,ageexp(αage + βageκyear) + constant
(B.7)
B.2.1 Comparator models
Two reduced models were considered as comparators:
Age-Period model assumed βage are the same for all age groups, so the model
reduced to
yyear,age ∼ Poisson(µyear,age) (B.8)
µyear,age = nyear,ageexp(αage + κyear) (B.9)
Age-Trend model assumed βage are the same for all age groups and a linear
period effect, so the model reduced to
yyear,age ∼ Poisson(µyear,age) (B.10)
µyear,age = nyear,ageexp(αage + year× κ) (B.11)
B.3 Model fitting
The maximum likelihood estimation of this model is to solve
argmax
αage,βage,κyear




κyear = 0 (B.13)
∑
age
βage = 1 (B.14)
We employed Newton methods as described in Brouhns et al. [2] to this task.
Our implementation used StMoMo::fit function from package StMoMo [3].
B.4 Modelling and forecasting
For period effects, κyear, we employed the Box-Jenkins method, which uses auto-
correlation function (ACF), partial autocorrelation function (PACF), and extended
ACF if necessary to specified a time-series model of κyear as a ARIMA(p, d, q)

















where φi and θi are coefficients of lag terms of κyear and previous random errors
ε i, c is the constant drift term, and L is the lag operator, shifting a variable to its
lag term, i.e. Liκyear = κyear−i
This specification and modelling were implemented using functions,TSA::acf,
TSA::pacf, and TSA::eacf from package TSA [4].
B.5. Bootstrap
B.5 Bootstrap
The bootstrap simulation employed the semi-parametric bootstrap by Renshaw
and Haberman [5]. Our implementation used StMoMo::simulation function from
package StMoMo [3]. In general, we generated 10,000 simulations for each pre-
sented result.
B.6 Measurements of goodness of fit
Since the likelihood-based LCM we applied is a special case of the ordinary Pois-
son regression [6], the measurements of goodness of fit of Poisson regression can
be directly applied.
Akaike information criterion (AIC): by definition,
2k− 2ˆ̀(α̂age, β̂age, κ̂year|yyear,age, nyear,age) (B.16)
where ˆ̀(.) is the log-likelihood function given estimated parameters, k is the num-
ber of parameters, which equals the sum of the numbers of α̂age, β̂age, κ̂year minus two
constraints.
Bayesian information criterion (BIC): by definition,
log(o)k− 2ˆ̀(α̂age, β̂age, κ̂year|yyear,age, nyear,age) (B.17)
where k is the number of parameters as above and o is number of observations.
Deviance residuals: We used the deviance residuals defined in Colin Cameron












[1] Lee RD, Carter LR. Modeling and Forecasting U. S. Mortality. J Am Stat Assoc.
1992;87(419):659–671.
[2] Brouhns N, Denuit M, Vermunt JK. A Poisson log-bilinear regression approach
to the construction of projected lifetables. Insur Math Econ. 2002 Dec;31(3):373–
393.
[3] Andres V, Millossovich P, Vladimir K. StMoMo: Stochastic Mortality Modeling
in R. J Stat Softw. 2018;84(3):1–38.
[4] Chan KS, Ripley B. TSA: Time Series Analysis; 2018.
[5] Renshaw AE, Haberman S. On simulation-based approaches to risk measure-
ment in mortality with specific reference to Poisson Lee–Carter modelling;
2008.







The aim of this document is to describe the construction of a synthetic population
of Taiwanese nationals as well as the basic population features based on the sim-
ulation of the model. The synthetic population will be used as an input of the TB
modelling.
The National Development Council, Taiwan (NDC), developed a synthetic
population for policy-making purposes and release a population projection report
annually [1]. However, the model did not capture the stochasticity in its subpro-
cesses and we required the lifespan between 0 and 100. Based on the assumptions
and model choices in the NDC model, we constructed a stochastic synthetic pop-
ulation model for use in the TB incidence modelling.
The main features of our synthetic population were as follows.
• Modelling lifespan from 0 to 100 (assumed deterministic deaths when reach-
ing aged 101).
• Being capable of generating stochastic population forecasts.
C.2. Notations and abbreviations
C.2 Notations and abbreviations
Data and demographic features
year: calender year
age: singe-year age
agp: five-year age group
sex: biological sex at birth
PFyear,age,sex: population size on 1st January of year
PMyear,age,sex: population size on 1st July of year
PEyear,age,sex: population size on 31st December of year
Dyear,age,sex: deaths during year
dyear,age,sex: death rate at year
Byear,sex: number of newborns during year
Fyear,agp,sex: number of newborns of sex during year, given agp of mothers
fyear,agp,sex: fertality rate of sex at year given agp of mothers
Myear,age,sex: number of net migrations during year
myear,age,sex: net migration rate at year
Lee-Carter components:
αage,sex: age-specific effect of (age, sex)
βage,sex: age-period adjustment term of (age, sex)
κyear,sex: period effect at year
E(.): the expectation of a random variable
ARIMA(p, d, q): Autoregressive integrated moving average with time lag p for
the autoregressive term, order d for the differencing term, and lag q for the
moving-average term.
C.3 Data
The demographic data were obtained from the Department of Statistics, the Min-
istry of the Interior, Taiwan. They were released publicly and available on the
internet. All the training data in this article were published by the Taiwan officials
and free access on the internet; the usage is licensed by the Open Government
Data License: [https://data.gov.tw/license].
End-year population estimates. The estimated population size on 31st December
of a year. These data were from 2004 to 2017 by sex, single-year age. We take them
as the equivalent of the start-year population estimates from 2005 to 2018.
Death counts. The number of deaths on registration of a year. These data were
from 2005 to 2017 by sex and single-year age.
Fertility counts. The number of births on registration of a year. These data were
from 2005 to 2017 by sex of newborns and five-year-age groups (15-19, ..., 45-49)
of mothers. We considered the childbearing ages of females from 15 to 49.
C.4 Modelling and forecasting
The synthetic population considers birth, death, ageing, and migration processes.
As the NDC model, we used cohort-component methods [2] to combine them and
drive the population dynamics. The essential model is:
PEyear,0,sex = Byear,sex + Myear,0,sex age = 0 (C.1)
PEyear,age,sex = PFyear,age,sex − Dyear,age,sex + Myear,age,sex age ∈ [1, 100] (C.2)
PFyear,0,sex = 0 age = 0 (C.3)
PFyear,age,sex = PEyear−1,age−1,sex age ∈ [1, 100] (C.4)
For all submodels, we generated 10,000 bootstrap simulations for considering
stochasticity with the time range from 2000 to 2017 for fitting and from 2018 to
2035 for forecasting.
C.4.1 Death process
We modelled the death rates of ages below 85 with the Lee-Carter model [3] and
above 85 with the Coale-Kisker method [4].
Aged 0-84 The Lee-Carter model (LCM) is a statistical model decomposing the
death rates into an age-specific baseline (αage,sex), age-specific trend terms with
resect to time effect (βage,sex), and an intrinsic time trend (κyear,sex), which is mod-
elled and forecasted using time-series methods. We applied the likelihood-based
implementation derived by Brouhns et al. [5] to model the death rates (dyear,age,sex),
where dyear,age,sex = Dyear,age,sex/PMyear,age,sex. Therefore,
C.4. Modelling and forecasting
log(E(Dyear,age,sex)) = αage,sex + βage,sexκyear,sex + log(PMyear,age,sex) (C.5)
We modelled κyear,sex using an ARIMA time-series model. Applying the Box–Jenkins
method [6], we identified κyear,male as a ARIMA(1, 0, 0) with drift and κyear, f emale
as a ARIMA(0, 1, 0) with drift. We then used the bootstrap method for LCM by
Renshaw and Haberman 2008 [7] to generate 10,000 simulations of deaths
Aged 85-100 In the extremely old population, the sample sizes of mortalities
might be small which usually leads to high uncertainty in statistical models. The
Coale-Kisker method [4] fits exponentially increasing mortalities with age.
Explicitly, our implementation follows the steps: 1) set up a final death rate
(dyear,100,sex) for each sex, 2) rescale dyear,84,sex and dyear,100,sex to a logarithmic scale,
3) linearly interpolate the log(dyear,age,sex) for age ∈ [85, 99], and 4) transform back
to the original scale.
We assumed final death rates at age 100 of males and females as 1 and 0.8 as
the NDC model to prevent the rates crossing over.
C.4.2 Birth process
As the LCM can can also be applied on fertility rates (e.g. Simpach [8] and Hynd-
man and Booth [9]), we modelled birth processes using the LCM. Considering the
number of newborns and availability of data, we aggregated the population size
of females to five-year age-groups (15-19, ... , 45-49). Using the same specification
of the method of the death process, we modelled fertility rates as
log(E( fyear,agp,sex)) = αagp,sex + βagp,sexκyear,sex + log(PMyear,agp, f emale) (C.6)
For deaths, we then used the bootstrap method to generate the numbers of





We did not use migration data directly, but used the residual method [10] to derive
the net migration instead. Under this method, the net migrations were calculated
from the difference between net flows in the population at an age and flows due
to birth and death:
Myear,0,sex = PEyear,0,sex − Byear,sex (C.8)
Myear,age,sex = PEyear,age,sex − (PFyear,age,sex − Dyear,age,sex) (C.9)
Then, the net migration rates are
myear,age,sex = Myear,age,sex/PMyear,age,sex (C.10)
In terms of forecasting, we took the arithmetic mean of net migration rate
for each single-year age, assuming the future migrations will be constant at a
given age. We sampled the number of net migration, Myear,age,sex, by the Poisson
distribution with mean myear,age,sex.
C.4.4 Simulation
After the parameter estimation procedures above, we simulated the population
dynamics as follows.
Step 1, Initialisation The first step starts with setting up the initial population
sizes of each (age, sex). For the population aged above one, the initial size is
from the end-year population estimates of the previous year. For the age zero
population, the initial size is zero.
Step 2, birth, death and migration For the zero aged populations by sex, add the
number of birth to the values. For each single-year age and sex, add the number
of net migration and subtract the number of deaths to the population.
Step 3, Ageing Remove the oldest population group (age = 100) and count them
as deaths. Then, shift the population upward by one year.
Step 4, Iteration Iterate through Step 1 to Step 3 until 2035.
Last, apply the procedure on every bootstrap sample to complete the simulation.
C.5. Notes
C.5 Notes
Software: The data manipulation, modelling, and forecasting in this document
were conducted using R 3.5.1 with packages of StMoMo and TSA [11–13].
Time inconsistency due to ageing process We did not use migration data di-
rectly because there is a time inconsistency due to ageing. The time inconsistency
of ageing and year progress commonly showed up in the dataset. For example, if
a newborn baby who has their birthday in August died in the March of the next
year, he/she would be counted in the zero-age death. However, if he/she died
in September of the next year, that would be a count in the one age death. The
same issue can be found in population and migration data. Therefore, the num-
bers are always unmatched by age structure. In order to fix this issue, we used
the residual method for the migration process, ensuring the other aspects of data
were balanced in every year.
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Residuals
Figure D.1: Residuals by age and by calender year.
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Figure D.2: Residuals by age and calender year.
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Fitted TB incidence rates
Figure D.3: Fitted TB incidence rates in logarithm to the base 10
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Model comparison
We modelled female and male TB incidence separately with the same parameteri-
sation. Apart from the likelihood-based Lee-Carter Model, two models were used
as comparators. Both models can be seen as reduced Lee-Carter Models:
Age-Trend: A Poisson regression model with categorical age effects and a linear
term of the calender year.
Age-Period: A Poisson regression model with categorical age effects and a dis-
cretised calender year.
Table D.1: Model comparison, female




No. parameters 16 28 42
Log(Likelihood) -852 -840 -811
AIC1 1737 1737 1706
BIC2 1790 1830 1847
Table D.2: Model comparison, male




No. parameters 16 28 42
Log(Likelihood) -1002 -979 -870
AIC 2036 2014 1825




TB diagnosis and medications
TB case: An individual having 1) TB-related diagnosis codes (ICD-9-CM: 010-
018) and 2) more than two anti-TB drugs prescribed for longer than 28 days or
two consecutive 14 days prescriptions.
Regular treatment: An individual having 1) TB-related diagnosis codes (ICD-9-
CM: 010-018) and 2) more than two anti-TB drugs prescribed for longer than 28
days (or two consecutive 14 days prescriptions).
First-line TB treatment: An individual having regular with a mixture of more
than two first-line drugs: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, and
Streptomycin.
Second-line TB treatment: An individual having regular with a more than two
types of anti-TB drugs apart from above first-line drugs. To be noted that, a mix-
ture of two first-line drugs and one second-line drug is a first-line TB treatment be
the definition.
Treatment completion: An individual having taken regular treatments for more
than 180 days.
Treatment initialisation, or empirical treatment: An individual having prescrip-
tions of more than any two anti-TB drugs for shorter than 14 days.
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Evaluation probably for TB: An individual having diagnostic or screening pro-
cedures that are specific to TB. The procedures are:
• Sputum culture test (Include Crystal, Parasite)
• Acid-fast culture
• Tuberculosis culture test
• Tuberculin Skin Test
• Chest X ray
• Chest computered tomography
Evaluation possibly for TB: An individual having medical procedures that can
are highly relevant to TB suspicions. The procedures are:
• Bronchoscopy
• Mycoplasma pneumonia antigen test
• Streptococcus pneumonia antigen-latex agglutination
• Chlamydia pneumoniae antigen
• Pneumococcus antigen (urine)
• Legionella pneumophila antigen (urine)
• Cryptococcus antigen
• Aspergillus antigen
• Influenza A cystic fibrosis Antibody
• Influenza B cystic fibrosis Antibody
• Pleural fluid analysis
TB-related illness:
Chronic lung condition, CLC: An individual having 1) respiratory diagnosis
codes (ICD-9-CM: 460-510) and 2) drugs for respiratory syndrome prescribed for
longer than 28 days.
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Acute respiratory disease, ARD: An individual having 1) respiratory diagnosis
codes (ICD-9-CM: 460-510) and 2) all drugs for respiratory syndrome prescribed
shorter than 28 days.
Nontuberculous mycobacteria, NTM: An individual having NTM diagnosis codes
(ICD-9-CM: 031)
Comorbidities
Chronic lung condition, CLC: An individual having 1) respiratory diagnosis
codes (ICD-9-CM: 460-510) and 2) drugs for respiratory syndrome prescribed for
longer than 28 days.
Diabetes Mellitus, DM: An individual having 1) DM diagnosis codes (ICD-9-
CM: 250, A181) and 2) DM control drugs prescribed for longer than 28 days. We
cannot differentiate type 1 and type 2 diabetes in the National Health Insurance
Research Database, NHIRD.
Human immunodeficiency virus, HIV: An individual having HIV related di-
agnosis codes (ICD-9-CM: 042, V08). We cannot differentiate HIV infection and
acquired immune deficiency syndrome from the NHIRD.
Appendix F
Data descriptions, NHIRD
This appendix lists the variables and their descriptions in the National Health
Insurance Research Database (NHIRD). The appendix only includes the tables
and columns used in this study. The full description can be downloaded from
Data description, Code book (Traditional Chinese only)
Healthcare facility (HOSP in the NHIRD)
The dataset stores all basic information the registered healthcare facilities, includ-
ing clinics, hospital, pharmacy, etc.
Table F.1: Hospital data
Variable Data type Description
HOSP_ID Character Primary key; Hospital ID; encoded
HOSP_CONT_TYPE Categorical Facility type, level, and public or private
AREA_NO_H Character, zip code Registered area
238
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Insured individuals (ID)
The dataset stores the sampled one million individuals.
• Age can be inferred from ID_BIRTHDAY
• INS_ID_TYPE indicates unemployment if the insured a dependant of an-
other
• UNIT_INS_TYPE implies job type and social group
Table F.2: List of variables, insured individuals
Variable Data type Description
ID Character Primary key; Hospital ID; encoded
ID_SEX Categorical Facility type, level, and public or private
ID_BIRTHDAY Date, YYYYMMDD Birthday
INS_ID_TYPE Categorical Dependent type
INS_ID_AMT Categorical Insurance amount∼Income
REG_ZIP_CODE Character, zip code Registered area
UNIT_INS_TYPE Categorical Insuring institution
ID_OUT_DATE Date, YYYYMMDD Leaving date
AREA_NO_H Character Area ID
240
Health facility visits (CD for outpatients, DD for inpatients)
The dataset stores the records of the visits happened.
Table F.3: List of variables
Variable Data type Description
SEQ_NO Character Primary key; sequence number
ID Character Foreign key, referring to insured individuals
HOSP_ID Character Foreign key, referring to hospitals
FUNC_TYPE Categorical Specialist type
T_AMT Number Total cost
PART_AMT Number Cost from out of pocket money of patients
Outpatient only











IN_DATE Date, YYYYMMDD Entering date
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Prescribed orders (OO for outpatients, DO for inpatients)
The dataset stores the records of the medications prescribed to patients.
• Age can be inferred from ID_BIRTHDAY
• For outpatients, total drug days = TOTAL_QTY ÷ DRUG_FRE
• For inpatients, total drug days is total hospitalised days
Table F.4: List of variables
Variable Data type Description
ORDER_SEQ_NO Character Primary key; sequence number of order
SEQ_NO Character Foreign key, referring to visit data
Outpatient only
DRUG_NO Character Order code
DRUG_FRE Number Drug use frequency
TOTAL_QTY Number Total drug quantity
Inpatient only








The objective of this appendix is to explain how to conduct an Individual Patient Pathway Analysis (IPPA) from 
individual healthcare data. This guidance is targeted for analysts to reason about  and to implement the IPPA 
in their intended setting. The IPPA was developed using the information on TB patients in the National Health 
Insurance Research Database, Taiwan, though this guidance will indicate options to adapt to different data.      
 
IPPA was designed to profile the efficacy of a healthcare system in responding to TB patients as well as to 
identify the obstacles of TB patients obtaining successful TB diagnosis and treatment. The IPPA approach was 
intended for use with passively and routinely collected healthcare utilisation data to inform the case seeking 
before patients being labelled as TB patients. Unfortunately, TB has many features overlapping with other 
respiratory diseases, such as pneumonia,  and chronic lung disease. The presence of many non-TB related 
data entries is to be expected. In addition, healthcare utilisation data includes the use of diagnostic procedures 
and treatment, but the respective outcomes are not always available. These issues are dealt with during the 
IPPA implementation by inferring the results from subsequent events.     
 
In general, the IPPA has two stages: patient pathways extraction and subsequent analysis of pathways. From 
the beginning, the data are usually collected with the perspective of healthcare providers in mind. The first 
stage of the IPPA translates the healthcare data to patient pathways, shifting information from provider-centred 
to patient-centred viewpoints. The extracted patient pathways are the first product of the IPPA. The second 
stage summarises and visualises the collected patient pathways.            
 
The guidance is formulated as follows: Section 1 lists the terminology used during the IPPA. Section 2 
prepares the IPPA ready data; Section 3 reads the data to a set of state-space dimensions; Section 4 trims the 
unnecessary information out and identifies care seeking episodes; Section 5 augments patient pathways by 
labelling stages of care seeking; Section 6 computes statistics from the patient pathways and Section 7 









Term Definition Example 
Record A healthcare record with 
variables of diagnosis, 
prescriptions, a visit time.   
 
The diagnosis in the IPPA is 
the suggestion but not the 
actual health status.   
 
  
Time Diagnosis Medication 
5 ARD* None 
10 ARD Fast-acid test 
20 TB anti-TB drugs 
 
ARD: acute respiratory disease 
Dimension A state-space time-series 
linking a group of relevant 
records to inform the transition 
of state. 
Related illness, capturing illness which can be initial 
consideration of a TB patient, or comorbidities with 
overlapped features of TB. 
 
Evaluation, capturing the prescriptions of screening or 
diagnostic tools to identify TB. 
 
Treatment, capturing the prescriptions of TB 
treatment   
Value in 
dimension 
A value reflects the information 
in the record given a 
dimension.  
 
Zero value indicates there is no 
relevant record during a period 
of time.  
In the Evaluation dimension, 
Zero: no ongoing evaluation 
Possible: diagnostic tools which might suggest TB 
Probable: diagnostic tools which can identify TB 
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Time-out The persistence of a healthcare 
record. The period will be 
extended if the next records 
contain similar information. 
 
Episode A collection of values of 
dimensions separated by 
periods with all dimensions 
equal to zero. 
 
Non-TB episode: episodes with 
any of dimensions is not zero 
while none of the records 
during the episodes met the 
definition of confirmed TB. 
 
Time Related illness Evaluation Treatment 
105 ARD* Zero Zero 
110 ARD Possible Zero 
120 ARD Possible First line 
... ... ... ... 
*ARD: acute respiratory disease 
Patient pathway An episode with a series of 
stages and the timing of 
progression.  
 
Stage, indicating the progress 
of a pathway of a patient  
● Waiting, the patient not 
received and TB related 
medication yet after 
initial care seeking.  
● Evaluating, the patient 
is under evaluation but 
possibly for TB 
● Detecting, the patient is 
being considered as a 
potential TB patient.  
● Treating, the patient 
has been identified as a 
TB patient and 
initialised TB treatment.  
 
State, specifying details of a 
stage. For example, the TB 
drug regimen 
 
Time Stage State 
0 Waiting Waiting 
10 Evaluating Evaluating 
70 Evaluating Interrupted Evaluation 
90 Evaluating Re-Evaluating 
100 Detecting Re-Detecting 
120 Treating First line treatment 
300 End Treatment completion 
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2. Preparing IPPA ready data  
The section guides how to manage data to which are ready to input to the IPPA. Three datasets (see figure), 
are required for the IPPA: patient information, healthcare facility information, and healthcare records. The 
patient information contains the basic variables of patients which are relevant to the decision making of either 
patients or healthcare providers. The healthcare facility information contains the type or the level of the 
facilities presented in the care-seeking records. The healthcare records, the most important dataset, contains 
the suggested clinical status (or diagnosis), prescriptions of diagnostic tools and medications, and keys 






Every patient entry requires a key for their identity (PID), linking to the healthcare records of the patient. 
Considering further analysis with the related variables,  basic information, such as age and sex, are 
suggested. Other variables, such as socioeconomic status and comorbidities, can be included if of interest and 
available.      
 
Healthcare facility (or hospital) information 
Every hospital entry requires a key for its identity (HID), linking to the healthcare records issued in the hospital. 
Level of hospitals is a necessary variable in this dataset. The capacity of TB services can be included if 
available as an external hospital dataset. Otherwise, the IPPA considers if a service has been used in as 
hospital to indicate capacity of the service. Area-specific information can be considered if spatial 
diversity/disparity is of interest. 
  
Healthcare records 
Healthcare records are the central elements of the IPPA. Apart from the foreign keys linking to the patient and 
hospital data, the records should contain timing, diagnosis, evaluations, and treatments. The diagnosis 
includes TB diagnosis and that of related illness, comorbidities and diseases which could potentially be TB. 
The evaluations of TB should be ordered data based on their capabilities to identify TB. Note that the 
sensitivity and specificity of diagnostic tools might be different from setting to setting, as may the order of use. 
The previous appendix of definitions, Appendix A, lists the related diseases and medications considered in our 






3. Transforming healthcare records into a three dimension system 
 
 
A patient pathway considers three dimension of information: related illness, evaluation, and treatment. First, 
Related illness captures the illness which can be initial consideration of a TB patient, or comorbidities with 
overlapped features of TB. Second, Evaluation captures the prescriptions of screening or diagnostic tools to 
identify TB. Last, Treatment captures the prescriptions of TB treatment. Every record contains information in 
different domains, and some records can inform multiple domains. Therefore, this step is designed to pass the 
information in each record to the intended dimensions.  
 
The IPPA builds three state-space dimensions based on the three domains. However, the data of healthcare 
utilisation might not contain the duration of state supported by each record. For example, TB culture can take 
several weeks to complete. The time to having the test result and following actions can be affected by the 
workload of the clinical laboratory as well as the schedule of the patient. As for anti-TB drug prescriptions, we 
can technically infer the duration through the number of drugs. However, how regularly the drugs are being 
taken depends on the implementation of DOTS and the schedule of patients to revisit hospitals. To correctly 
address the durations requires very detailed data. In such cases, the IPPA introduces a “Time-out” limit to 
presume the durations. In each domain, a specific value is set. As a default, we put 60 days for Related illness 
and Evaluation after visits and 30 days for Treatment after the drugs apparently ran out.     
 
Starting from Zero state of each dimension, IPPA scans records iteratively. For every record, each dimension 
checks whether the record is relevant to it or not. If it is relevant, the dimension will transition the respective 
state. Before that, if the record occurs later than the Time-out period since the last relevant record, the 
dimension will transition to Zero. After scanning all records, the IPPA will check the end of the dimensions, 
considering the end of the data timespan and death time if present. 
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4. Splitting Episodes and trimming unnecessary records off 
 
In the data used - all the healthcare records over given a period - many non-TB care-seeking records are to be 
expected. However, they are necessary for completing the IPPA because some of them may be early events 
in the diagnosis of TB. As the previous step has joined the records in the same domain to formulate the 
system of three dimensions, this step is going to join the non-zero states in different domains. 
 
Once the system of three dimensions aligned, we can locate the periods with all dimensions equal to zero. The 
step splits the three dimensions by these periods to specify episodes. For the separated episodes, we identify 
the episodes have confirmed TB (in our demonstration, ICD-9-CM codes for TB and more than two types of 
anti-TB drugs prescribed over 28 days), and drop the others. Each of the kept episodes will be formulated as 
patient pathways thereafter.   
 
This step allows construction of episodes that included records related to care-seeking prior to TB diagnosis as 
possible. Also, it trims the healthcare records which are not relevant to TB care off. To be noted that, whether 
an episode is TB related or not is affected by the length of the “Time-out” period. For a short “Time-out”, an 
episode will be fragmented as several episodes. The care-seeking before TB diagnosis will be ill-addressed. 









5. Finishing patient pathway construction 
 
A TB episode includes the dynamics of the three state space dimensions but not the meaning of them. This 
step concludes the three dimensions into a patient pathway. For every separated TB episodes, this step. The 
stages and states in patient pathways should summarise by not only the current states of the three dimensions 
but also the states before and after. For example, the “Re-Evaluating” state indicates (1) evaluations are going 
on, (2) previous evaluations were interrupted, and (3) TB treatment has not started yet. As in the following 
definition, this step labels care-seeking stages considering the states of the three dimensions.     
 
Waiting Stage 
In Waiting Stage, the patients have started their care-seeking at hospitals but are not considered as potential 
TB patients. Namely, they are “waiting” for TB-related evaluation. 
 
State Dimensions* Contexture Note 
Waiting R: non-zero 
E: Zero 
T: Zero 
Start with initial care-
seeking 
Waiting for the first TB-related evaluation or 
treatment. 




In the Evaluating Stage, physicians start to use evaluation techniques for the patients. TB might not be a 
consideration in the evaluation, but the techniques should be able to narrow the possibilities down until TB-
specific evaluations prescribed.   
 
State Dimensions* Contexture Note 
Evaluating E: Possibly 
T: Zero 
No IE before Under evaluations which can narrow the 






After a period with the 
evaluation dimension in 
a non-zero state 
The previous evaluation does not narrow the 
possibility down to TB which might be because 
of (1) comorbidity, (2) false negative, or (3) self-
referral.  
Re-Evaluating E: Possibly 
T: Zero 
Have IE before  
* R: related illness, E: evaluation, T: treatment 
TB Detecting Stage 
In TB Detecting Stage, the evaluation techniques which can identify TB if clinicians are well-trained. Apart from 
the techniques, anti-TB drugs with doses below regular regimens can be considered in this stage as well, 
namely, empirical treatment or treatment initialisation. 
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State Dimensions* Contexture Note 
TB-Detecting E: Probably 
T: not meet 1st 
line or 2nd line  
No IE before Being evaluated by procedures which can 







After period with the 
evaluation dimension in a 
non-zero state 
IE can be a state in Evaluating Stage or TB-
Detecting Stage. It depends on the most TB 
specific evaluation used before.  
Re-Detecting E: Probably 
T: Zero 
Have IE before Re-visiting TB-Detecting State after 
Interrupted Evaluation 




Once TB confirmed, Treating Stage will start. The stage captures the intensity of treatment used. 
 
State Dimensions* Contexture Note 
First-line 
treatment 
T: 1st line Between two periods with 
the treatment dimension in 
non-zero states 
Being treated with first-line TB regimen. 
Treatment 
change 




A zero treatment 
dimension between two 
periods of treatment 
dimension in non-zero 
states; or the timing when 
treatment intensity 
increases.  
Switching between two TB treatments or 





see contexture T: 1st line after Treatment 
change or T: 2nd line 
Being treated with second-line TB regimen or 







Treatment Outcomes are the end of patient pathways. The labels are totally customizable for different settings 
Datasets of treatment outcome and death registration outside healthcare records can be linked if available.   
 
In our demonstration setting, registering in the National Health Insurance programme in Taiwan is compulsory. 
We used leaving the programme as the indicator of death.       
 
Outcome Definition 
Treatment completed > 180 days of treatment period 
Censored Reach the end of data 
Dead Leaving the National Health Insurance 
programme.  




6. Statistics and indices of the Individual Patient Pathway Analysis 
 
Hospital-level of initial care-seeking features the places to start care-seeking for the patients with TB 
symptoms. The levels of hospitals or facilities are defined differently setting by setting. Our demonstration only 
presents four levels while it can be disaggregated by private and public sectors, by hospital divisions, or by 
counties. In Taiwan, the National Health Insurance covers both private and public sectors with the same 
services, so we did not separate them. 
 
Coverage of TB services denotes the percentage of hospitals have TB services available. The TB services 
are the evaluation tools with respect to the medications in Evaluating, TB Detecting, and Treating stage of 
patient pathways. The denominator is the number of hospitals has ever been visited in the collected patient 
pathways; the numerator is the number of hospitals has ever provided respective TB services during the data 
timespan. In the original IPPA, the index is measured by whether the hospitals can provide respective TB 
services. That might overestimate the values if the services are not considered in practice. On the contrary, 
our approach might underestimate the values in the case of the hospitals can provide the services but have 
not met the situations to use. We suggest reporting values from both approaches if possible as lower and 
upper bounds.     
 
Hospital-level of stages denotes the distributions of hospital levels at the starts of stages. The options are the 
same as Hospital-level of initial care-seeking.    
 
Hospital-level of notification features the places which notify TB cases to authorities. In the setting of 
Taiwan, and so our demonstration, the notification process and treatment prescribing are synchronised. The 
distribution was the same as Hospital-level of Treatment Stage, so we did not show them separately.   
 
Accessibility to TB services at initial care seeking denotes the percentage of patient pathways which have 
initial care seekings at a hospital which has TB services available (evaluations or treatments). With the 
individual hospital data identifiable, it is calculated by (1) linking initial care-seeking records to the availability of 
the corresponding hospitals, and (2) finding records can access to TB services within all initial care-seeking 
records. However, if the data does not support individual hospitals, applying the original approach in the PPA 
[1] is suggested.     
 
Time to arriving at a hospital with TB treatment denotes when is the first time seeking care at a hospital 
which can provide TB treatment. The period starts with the time of initial care-seeking. Again, the availability of 
TB treatment in our demonstration was based on whether the hospital has provided TB treatments or not 
during the timespan.  
 
Time to arriving at the hospital initialise TB treatment denotes when is the first time seeking care at the 
hospital which ultimately provides TB treatment to the patient.  
 
System Delay, time to treatment start, denotes the length of the period between the initial care-seeking and 
the start of regular TB treatment. This is the common output of care-seeking delay studies. However, the 
definitions may be different for different data sources.  
 
No System Delay indicates a patient pathway starts with regular TB treatment prescription at the initial care-
seeking. We suggested reporting this and System Delay and a proportion  
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Interrupted Evaluation indicates at least one Interrupted Evaluation in a patient pathway. The presence 
shows if the diagnosis has been put on hold, potentially in favour of other investigations. The percentage of 
Interrupted Evaluation quantifies the complexity of TB diagnosis in a healthcare system. Applying covariate 
analysis can identify the risk factors related to interruption. The presence of Interrupted Evaluation has multiple 
meanings. Firstly, comorbidities, especially chronic lung diseases, can mask the features of TB. As the 
respiratory symptoms of TB are not unique, the clinicians might not aware active TB from patients who have 
had those symptoms already. Secondly, there are competing diseases to be considered before diagnosing a 
patient as a TB patient. For example, in the Western Pacific region, TB is prevalent in the old population and is 
sometimes similar to pneumonia. Considering the higher fatality rate of pneumonia than TB, TB could be less 
urgent. Thirdly, the false negative of any TB test results and false positive of non-TB test results might happen. 
Either of them can cause interrupted evaluation.    
 
System cost, out-pocket cost, and healthcare contacts (optional) in each stage measure the burden for 
the perspectives of a healthcare system and patients. Using the records grouped by the stage when they 
occurred, these three indices are summarised. The number of healthcare contacts is a proxy of the time cost 
of a patient pathway during a stage. This should be available since it corresponds to the input of the IPPA, but 
the other two depend on availability. Additional costing survey is suggested to provide more precise measures 





The figure (as Fig 2A in the paper) is adapted from the original PPA. Seven columns are included in the 
diagram. The A-1 shows the places of initial care-seeking by hospital level. A-2.1 shows the coverages of 
evaluation services in proportions by hospital level. This is from the perspective of healthcare providers. A-2.2 
shows the accessibility at initial care-seeking. This is from the perspective of patients, measuring if the patients 
seek care at proper places (See Statistics and Indices). A-3 and A-4 replicate A-2 but targeted at Evaluations 






Figure 2 (as Fig 2B in the paper) shows an example of the referral flow diagram. The diagram is a Sankey 
diagram describing the progress in hospital levels during care-seeking. Four columns match the four stages of 
patient pathways: Waiting, Evaluating, TB Detecting, and Treating. The blocks in each column are the hospital 
levels in each stage. For a pathway, the hospital level in a stage is based on the hospital of the first care-
seeking in the stage. While some pathways do not have all four stages, the diagram uses the start of the next 
stage for the current stage. For example, a pathway started with TB-Detecting Stage at a Level B hospital. The 
hospital levels in Waiting and Evaluating Stages are Level B as well. The heights of the blocks are determined 
by the counts of the pathways. The ribbons between columns link the current hospital levels to the hospitals 
triggering the next stages.   





Figure 3 (as Fig 3 in the paper) features the gaps between treatment accessible and treatment start. Three 
checkpoints are considered. The first is when a patient arrived at a hospital with TB treatment. From this 
checkpoint, the patient starts having a chance to be under TB treatment. The second is when a patient arrived 
at the hospital which provides TB treatment for them ultimately. From this checkpoint, the inter-hospital referral 
has been completed in the pathway. The last is when TB treatment starts. The curves are the cumulative 
percentage of pathways that have reached the respective checkpoints. The difference between the first and 
the second checkpoints (and their curves) can be regarded as a care-seeking gap due to inter-hospital 
referrals. The difference between the second and the third checkpoints can be regarded as a gap due to intra-






Figure 4 visualise the patterns of patient pathways before and after treatment start. The pattern means the 
series of states in a pathway without considering their timings in the stages. For example, a pathway starting 
Waiting state at day 0, Evaluating state at day 30, Treating state at day 40 has the pre-treatment pattern of 
“Waiting-Evaluating-Treating”. In the figures, each horizontal bar represents a pattern; the height indicates the 
number of pathways having this pattern; the width indicates the proportion of time spent in each state on 
average. The tiny rectangles on the right indicate the last states of patterns while the widths are meaningless. 
The blink bar in the pre-treatment figure quantifies the pathways having treatment at initial care-seeking. The 
bars are sorted by the numbers of pathways in the respective patterns. The figures are used to highlight the 







Figure 5 visualises the distribution of states of patient pathways. Aligning patient pathways by the time of initial 
care-seeking, every column in the figure indicates state distribution in one day; the height in each block 
indicates the number of pathways in the state at the day; for the pathways ended before the day, the treatment 
outcomes are extended to the day. The figure is used to understand the time spent in each state and to know 
the accumulation of treatment outcomes. For our example, the Interrupted Evaluation formed a flat tail, which 
dying out slowly, in the figure.  
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In the individual patient pathway analysis (IPPA), a “time-out” system is ap-
plied to define whether two healthcare records is related or not. Here, we tested
the sensitivities of Time-out for Related illness domain (TOR) and Time-out for
Evaluation domain (TOE). We varied them from 30 days to 120 days by 30 days
and (TOR, TOE) = (60 days, 60 days) were used as a comparator.
Throughout the sensitivity analysis, we will use two types of diagrams to
demonstrate how the selected indices reflect on the time-out changes. The first
uses heatmaps, mapping the indices given different time-out values (i.e. Fig-
ure H.1). The second is barplot (or unordered tornado chart) which shows the
marginal changes of the indices while increasing or decreasing by 30 days (i.e.
Figure H.2). The changes were measured by
Difference Ntor,toe − N60,60 or
Change rate Ntor,toe−N60,60N60,60 × 100%,
depending on variable types.
H.1. Number of pathways
H.1 Number of pathways
This section assesses the number of pathways rendered by the IPPA with different
TOR and TOE. The changes were measured by the change rate. Figure H.1 shows
that the number of pathways is negative corrected with both TOR and TOE. The
changes were within 5%. Figure H.2 shows that increasing TOR and TOE caused
higher change rates than decreasing while the number of pathways is more sensi-
tive to TOE.
Figure H.1: Heatmap: Number of Pathways
Figure H.2: Marginal changes: Number of Pathways
H.2 Length
This section assesses the length of patient pathways.
• Number of Contacts, median: the length considering how many healthcare
contacts happened during the patient pathways started from initial care-
seeking to treatment end.
• System Delay, median: the duration from initial care-seeking to treatment
start.
• Pathway Length, median: the duration from initial care-seeking to treatment
end.
These indices were summarised by median, and the changes were measured by
change rate.
As Figure H.3 shows, the numbers of contact ranged from 16 to 25 while the
values were positively correlated to TOR and TOE. Figure H.4 addresses the sys-
tem delays, showing the values were sensitive to both TOR and TOE. When TOR
and TOE were both 120 days, the change is more than being doubled compared
with 60 days. Figure H.5 focuses on the pathway lengths. Figure H.6 summarises
the sensitivity of the length of pathways. The system delay was the most sensitive
to TOR and TOE, while the total pathway length was the last. TOR and TOE had
equal impacts on the number of contacts in this analysis. Increasing TOR and TOE
brought more changes than decreasing across these three indices. The high sen-
sitivity of the median system delay suggested an external validation with future
interview data in the same setting. A previous study, Chen et al. [1], estimated
the system delay in Taiwan was 29 days (interquartile range 5–73) with the same
database and TB definition as my study. Although their assessment did not con-
sider interrupted evaluations and patients having chronic lung conditions, and so
their estimates constitute a lower-bound for our approach. Comparing with other
settings, Sreeramareddy et al. [2] summarised 52 studies, finding the system de-
lays to TB treatments ranged from 2 to 87 days, finding that the low-income and
high-income settings did not have a significant difference. However, the retrieved
studies in their review showed an imbalance in that the studies with longitudinal
data were conducted in specific hospitals or sub-populations, while the studies
that covered the general population were cross-sectional. My study, which used
longitudinal data on the general population, therefore, cannot be compared with
them directly. Therefore, I suggest using a retrospective design with interview-
ing patients embedded in the longitudinal data. This approach can validate the
H.2. Length
lengths of patient pathways from the IPPA and highlight the difference from per-
spectives of patients and the health system.
Figure H.3: Heatmap: Number of contacts in median
Figure H.4: Heatmap: System delay in median
H.2. Length
Figure H.5: Heatmap: Length of Pathways in duration
Figure H.6: Marginal changes: Length of Pathways
H.3 Typology
This section assesses the typology of patient pathways.
• Initialised at Level A Hospital: whether the initial care-seeking of pathways
were in Level A hospitals.
• Interrupted Evaluation: if the pathways experienced interrupted evaluation.
• Zero Delay: indicates if the pathways started their treatment at the day of
initial care-seeking.
These indices were summarised by proportion, and the changes were measured
by difference.
As Figure H.7 shows, Initialised at Level A Hospital were no sensitive to
TOE while that and TOR were positively correlated. Figure H.8 highlights higher
TOR led more Interrupted Evaluation but TOE had negative influence. Zero De-
lay in Figure H.9 shows negative correlations with TOR and TOE while the two
Time-outs were equally contributed. Figure H.10 summarises the sensitivity of
the typology of pathways. The marginal changes were usually smaller than 5%.
However, Interrupted Evaluation was very sensitive to TOR and TOE compared
with the other two indices.
H.3. Typology
Figure H.7: Heatmap: Initialised at Level A hospital (%)
Figure H.8: Heatmap: Interrupted Evaluation (%)
H.3. Typology
Figure H.9: Heatmap: Zero Delay (%)
Figure H.10: Marginal changes: Typology
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Algorithm I.1 Patient pathway extraction: overview
Data: records: an array of healthcare records of an individual
TOR: Time-out of Related illness
TOE: Time-out of Evaluation
TOT : Time-out of Treatment
Result: Patient pathways of a TB patient
1 /* Initialise dimensions */;
2 rel← New Related illness dimension;
3 eva← New Evaluation dimension;
4 tre← New Treatment dimension;
5 /* Read all records in each dimension */;
6 rel.readRecords(TOR, records);
7 eva.readRecords(TOE, records);
8 tre.readRecords(TOT , records);
9 /* Collect dimensions and cut them into episodes */;
10 episodes← cutEpisodes(rel, eva, tre);
11 pathways← ∅ /* Initialise a empty set collecting pathways*/;
12 foreach episode ∈ episodes do
13 pathway ← formulatePathway(episode);
14 pathways.append(pathway)
15 return pathways;
See dim.readRecords(...) in Algorithm I.2
See cutEpisodes(...) in Algorithm I.3
See formulatePathway(...) in Algorithm I.4
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Algorithm I.2 Read records in each dimension (dim.readRecords(...))
Data: dim: dimension, rel, eva, or tre
timeout: timeout for the selected dimension
records: an array of healthcare records of an individual
Result: the transition history in the dimension
1 /* Initialise the dimension with a Null event */;
2 timecurr ← 0;
3 timewait ←∞ /* the end of waiting time */;
4 state← Null;
5 Initialise dim with state at timecurr;
6 foreach record ∈ records do
7 timecurr ← time of record;
8 if timecurr > timewait then
9 /* Reset state */;
10 timewait ←∞ /* the end of waiting time */;
11 state← Null;
12 dim transits to Null at timewait;
13 end
14 if record is relevant to dim then
15 timewait ← timecurr + timeout;
16 if record can progress state then
17 /* Progress */;
18 state← the matched state of record;




23 /* Close record reading */;
24 dim transits to Null at timewait;
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Algorithm I.3 Collect dimensions and cut them by periods without events
(cutEpisodes(...))
Data: rel: state history in related illness dimension
eva: state history in evaluation dimension
tre: state history in treatment dimension
Result: A set of care seeking episodes
1 ts← ∅ /* A collection storing state transition times */;
2 foreach dim ∈ [rel, eva, tre] do
3 forall State transition time t of dim do ts.add(t);
4 end
5 Remove duplicated time points in ts Sort ts (ascending);
6 episodes = ∅ /* A collection for storing episodes */;
7 foreach t ∈ ts do
8 if all[rel, eva, tre] are Null at t then
9 /* Separate state-transition history*/;
10 x← state history before t split from rel;
11 y ← state history before t split from eva;
12 z ← state history before t split from tre;
13 /* Join dimensions */;






Algorithm I.4 Patient pathway formulation ( f ormulatePathway(...))
Data: episode: an episode with state transition history in rel, eva, and tre
Result: A patient pathway
1 /* Identify key information */;
2 teva ← time of first evaluation possibly for TB;
3 tdet ← time of first evaluation probably for TB;
4 ttre ← time of the start of first regular TB treatment;
5 /* Group state transition history */;
6 historyeva ← history between teva and tdet;
7 historydet ← history between tdet and ttre;
8 historytre ← history after ttre;
9 /* Start to construct pathway */;
10 pathway ← ∅ /* Initialise patient pathway */;
11 state← initial state of episode;
12 put state into pathway ;
13 ie← False /* indicating had interrupted evaluation or not */;
14 /* Read state series in Evaluating Stage */;
15 foreach dimensions ∈ historyeva do
16 state← find an state in Evaluating Stage matched dimensions and ie;
17 if state is Interrupted Evaluation then ie← True;
18 put state into pathway ;
19 end
20 /* Read state series in TB Detecting Stage */;
21 foreach dimensions ∈ historydet do
22 state← find an state in TB Detecting Stage matched dimensions and
ie;
23 if state is Interrupted Evaluation then ie← True;
24 put state into pathway ;
25 end
26 /* Read state series in Treating Stage */;
27 state← find the initial treatment level in historytre[0];
28 put state into pathway ;
29 foreach dimensions ∈ historytre[0 :] do
30 state← find the treatment level in dimensions;
31 if treatment level increased then
32 put Treatment Change into pathway ;
33 end
34 put state into pathway ;
35 end
36 /* Finalise patient patient formulation*/;
37 state← find the treatment outcome ;
38 put state with the time of treatment end into pathway;
39 return pathway;
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Appendix J
List of analysis codes and data on
GitHub
Age-profile of incident TB cases (Chapter 5)
• AgeingTB:
Description: Source codes/ original data/ results for applying Lee-Carter
models in TB incidence forecasting
Language: R >= 3.5
URL: https://patientpathwayanalysis.github.io/
Individual patient pathway analysis (Chapter 6)
• Online demonstration of the methods:
URL: https://patientpathwayanalysis.github.io/
• Example data and output files:
URL: https://github.com/PatientPathwayAnalysis/IPPA-data
• Pathway extraction:
Description: Extracting patient pathways from individual data
Language: Python >= 3.6
URL: https://github.com/PatientPathwayAnalysis/IPPA-py
• Result visualisation (R):
Language: R >= 3.5
278
Chapter J. Analysis codes and data, GitHub 279
URL: https://github.com/PatientPathwayAnalysis/IPPA-vis
• Result visualisation (d3):
Language: D3.js v3
URL: https://github.com/PatientPathwayAnalysis/IPPA-d3
Simulation modelling (Chapter 8 & Chapter 9)
• PyEpiDAG:
Description: Parameter modelling and statistical model fitting based on
Direct Acyclic Graphs
Language: Python >= 3.6
URL: https://github.com/TimeWz667/PyEpiDAG
• PyComplexism:
Description: An dynamic modelling toolkit for agent-based models, equation-
based models, and hybrid models. The package is essentially designed
for epidemiologists and health economists.
Language: Python >= 3.6
URL: https://github.com/TimeWz667/PyComplexism
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